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Summary
Although chemotherapy provides a potentially systemic cure for cancer, 
its application is hampered by a lack of exploitable differences between tumour 
cells and those which make up normal tissue. Even cells within the same 
tumour exhibit differing sensitivities to cytotoxic drugs, depending on factors 
such as their location in the cell cycle or distance from a blood supply. A further 
problem is increasing resistance of tumour cells to anticancer drugs.
Chemotherapeutic drugs commonly target cell division but many of the 
common malignancies such as cancer of the breast, colon and lung are "solid" 
tumours containing a low proportion of dividing cells. Moreover, drugs which 
inhibit cell proliferation can cause many unpleasant side-effects by affecting 
normal regions of fast-dividing cells too.
The treatment of advanced malignant melanoma is one area where 
current chemotherapy affords very low success rates. Dacarbazine (i) is the 
current drug of choice, yet it only gives a positive response in 20% of patients.
O
In the search for new anti-melanoma compounds, efforts are being made to 
exploit features which distinguish melanoma cells from other cell types in the 
body. One such difference is that melanoma cells generally continue to 
synthesise the pigment melanin by enzymes contained within the melanosome 
organelle. A key enzyme in the melanin biosynthetic pathway is Tyrosinase 
which catalyses the conversion of tyrosine ( ii)  to dopa (iii) and then 
dopaquinone (iv).
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One approach towards achieving selective treatment of melanoma is to 
design phenolic prodrugs which could be selectively oxidised to quinones by 
Tyrosinase in melanoma cells. The quinone product could then cause cell death
by attacking essential thiol-containing enzymes. Phenol (v) was previously 
prepared and shown to possess interesting anti-melanoma activity. As little 
work had been done to optimise its activity, we started a programme to probe 
its structure-activity relationship in some detail.
We initially prepared a series of 37 related compounds, represented by the 
general structures (vi), (vii), (viii) and (ix). These were evaluated by Professor 
R.M. MacKie of the Department of Dermatology, University of Glasgow and Dr 
L.R. Kelland of the Institute of Cancer Research, Surrey. Compounds of type 
(viii) containing two methyl groups a -  to the nitrogen (R1, R2) and a bulky 
group at the acyl position (R3) were far more cytotoxic than the parent 
compound (v), although some toxicity towards non-melanoma cell lines was 
observed. Compounds without a phenol group did not cause significant 
cytotoxicity, apart from phenyl esters which are likely to have been converted 
into phenols by hydrolysis. The most promising compounds exhibited GI50  
values down to 5 pM for melanoma cell lines and showed some selectivity over 
non-melanoma cell types (e.g. GI50 > 40 pM for the SKOV-3 ovarian line).
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Another area of investigation was to prepare a series of compounds to 
evaluate the effects of replacing the amide group of (v) with other functional 
groups. Thioamides of the general structure (x) and the heterocyclic derivative 
(xi) showed the highest levels of toxicity during biologically evaluation by Dr 
Kelland and the Ares Serono Group.
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We evaluated the effects of constraining conformation by the preparation 
and testing of bicyclic derivatives such as (xii). Analogues of (v) with general 
structure (xiii) containing an inverted amide group were also prepared. Related 
compounds which do not contain a sulfide group, represented by general 
structure (xix), were prepared for comparison.
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In order to study the biological effects of varying the side-chain bridging 
group, a series of eleven compounds of general structure (xx) were prepared 
and compared in terms of lipophilicity, electronic properties, steric effects and 
biological activity. It was found that selenide analogues exhibited greater anti­
melanoma activity than their corresponding sulfides. This was attributed to 
greater lipophilicity on the basis of their measured partition coefficients.
R 1 r 2 O  ( X X )
H
X = S 0 2, C=0, S=0, CH2, Se, O, NH2 
R1,R 2, R3 = H, alkyl
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1
Cancer: Causes and Cures
1.1 The Cancer Problem
In the industrialised nations, cancer is arguably the most feared of 
diseases. Statistically there is good reason for this; around one third of people 
in the developed world will develop cancer; one fifth will die from it. To the 
public at large, cancer is often considered to be a single condition differing only 
in the part of the body it affects. More specifically, it is a complex class of 
around one hundred diseases which vary widely in the cell type from which they 
are derived.
As there are so many different types of cancer, progress towards our 
understanding of the condition has been slow. The search for its cure has 
proved to be hard but by no means hopeless; the many successes in cancer 
treatment include testicular cancer, certain ovarian cancers, Hodgkin's disease, 
Ewing's sarcoma and acute lymphocytic childhood leukaemia. Unfortunately, 
progress towards curative therapy of the more common cancers of the lung, 
breast, prostate and colon has been comparatively slow.
1.2 The Origin of Cancer
In 1914, Boveri suggested that the origin of cancer may be malfunction 
of the cell's genetic material. It is now understood that almost all cancers 
originate from the aberration of the DNA sequence of a single cell.1 Howevar, a 
single mutation is not sufficient to cause cancer; this will occur only in the 
combination of several rare biochemical accidents. The likelihood of these 
accidents occurring is determined by a variety of internal and external factors.
The generation of cancer (carcinogenesis) is closely correlated tc the 
induction of DNA changes (mutagenesis) in the following four classes of agents.
1.2.1 Chemical Mutagens
The evidence linking certain chemicals with cancer has teen 
accumulating since 1761, when John Hill noted the high incidence of nasal
- 1 -
cancer among snuff users. This was followed by numerous observations linking 
particular substances to specific types of cancer, often in an occupational 
environment where the effects of a particular agent could be seen throughout 
the workforce. Since the early twentieth century, animal testing has 
supplemented our knowledge of the structurally diverse chemicals which are 
known to give rise to DNA mutation. Some examples of mutagenic compounds, 
their type of exposure and typical sites of human cancer are shown in Table 1.2
Table 1 Selected Mutagenic Compounds
Chemical
Type of Exposure 
Occupational Medical Food Cancer Site
Aflatoxin X Liver
Benzene X Marrow
Benzidine X Bladder
Busulfan X Marrow
Chlornaphazine X Bladder
Cyclophosphamide X Bladder
Melphalan X Marrow
Mustard gas X Larynx, lung
Oxymetholone X Liver
Phenacetin X Kidney
Vinyl Chloride X Liver
The use of all hazardous chemicals in all types of employment is now 
strictly controlled by COSHH regulations and earlier government legislation. 
This has led to a reduction in occupational exposure to mutagens yet we are 
still at risk from other sources such as air pollution, cigarette smoke, certain 
prescribed drugs and even some types of food.
The mechanism of genetic mutation by chemicals commonly involves 
some form of simple change to the nucleotide sequence, often by alkylation of 
the nucleophilic sites of DNA bases. This mechanism is analogous to the action 
of the alkylating class of anticancer drugs; indeed many anticancer drugs are 
known to be carcinogens (vide infra). In many cases it is a daughter of an
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inactive parent compound which is the active mutagen, frequently resulting from 
metabolism by the cellular oxidase enzymes associated with cytochrome P-450. 
One such example is aflatoxin B1, a toxin from the mould Aspergillus flavus 
oryzae which grows on grain and nuts which have been stored under warm 
humid conditions. When contaminated food is eaten, metabolites of aflatoxin 
are involved in mutations to the p53 gene by the mechanism shown in Scheme 
1,3 This is thought to be an important contributing factor to the incidence of liver 
cancer in tropical regions.
Scheme 1 Metabolic Activation of Aflatoxin B1
Oxidases associated w ith 
Cytochrom e P-450
HoCO
Aflatoxin B1
DNA Aflatoxin B1-2,3-epoxide
HO
NH
NH
Carcinogen bound to DNA guanine
A sim ilar oxidation-alkylation mechanism is evident with certain 
polycyclic aromatic hydrocarbons (PAHs), for example benzo[a]pyrene 1. The 
metabolic activation of PAHs involves a series of oxidative reactions which 
result in the formation of diol epoxides such as 2. Jerina and Daly have 
postulated that a bay region adjacent to the epoxide is instrumental to the 
mutagenicity of these agents.4
Bay region
HO
OH
PAHs are known to result from incomplete fossil fuel combustion, making 
them an important constituent of air pollution. Their presence in whisky and 
barbecued food is more insidious, unlike their predominance in the deadly 
cocktail of over 50 carcinogens which are found in tobacco smoke.
1.2.2 Ionising Radiation
The harmful nature of X-rays was evident shortly after their discovery in 
1895 by Rontgen. The initial symptoms of skin blistering and reddening were 
followed, several years later, by relatively high incidence of skin cancers, 
leukaemia and brain tumours amongst radiologists. As with chemical 
carcinogens, debate still continues about the "safe" levels of exposure to the 
high-energy electromagnetic radiation of X-rays, y-rays and particles arising 
from radionuclei.
The high energy associated with ionising radiation causes widespread 
damage through bond-breaking processes within the cell. Absorption of 
dissipated energy by water is critically important in mutagenesis; ionisation 
ultimately leads to the generation of hydroxyl radicals, hydrogen radicals and 
solvated free electrons. On interaction with DNA, these cause single and double 
strand breaks together with base deletions and rearrangements.5 Genetic 
mutation can also arise when these forms of damage are improperly rectified by 
the error-prone DNA repair processes of the cell.
The different forms of ionising radiation vary in the way they dissipate 
energy on contact with tissue; the concept of linear energy transfer (LET) is 
used to measure this factor. High LET forms of radiation, such as a-particles 
and neutrons, rapidly release their energy over a short distance causing large 
amounts of DNA damage and cell death. Low LET radiation, including y-rays, 
and X-rays, is markedly less cytotoxic.
In common with mutagenic chemicals, the consequences of ionising 
radiation may not take effect until many years after exposure The estimated 
latent periods for lung, skin, brain, thyroid and intestinal cancers are all greater 
than twenty years.6
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1.2.3 U ltraviolet Radiation
The lower energy and low penetration of ultraviolet (UV) radiation 
accounts for the observation that its effects are limited to the skin. Initially, these 
effects appear to be quite pleasant; increased melanin formation is induced 
thus giving the sought-after "healthy-looking" bronzed complexion. 
Unfortunately, a side-effect of this can be the induction of skin cancers, the 
most rapidly increasing forms of cancer in the developed world.
UV radiation is grouped into three wavelength bands; UVA (>320 nm), 
UVB (290-320 nm) and UVC (200-290 nm). Of these, UVB is the most 
important in carcinogenesis and is also the band largely filtered out of solar 
radiation by the ozone layer. In contrast to high-energy ionising radiation, UV 
radiation is not thought to cause genetic mutation through widespread nucleic 
acid bond-breaking processes. Its activity appears to be associated with the 
generation of excited states in DNA bases which leads to mutagenic 
photochemical reactions, such as the dimerisation of pyrimidine bases as 
exemplified in Scheme 2.7 Thymine-cytosine and cytosine-cytosine dimers can 
form in a similar manner.
Scheme 2 Photodimerisation of Pyrim idines
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The role of UV radiation in the incidence of a deadly form of cancer 
known as malignant melanoma will be discussed in more detail in chapter 2.
1.2.4 V iruses8
Viruses are parasitic infective agents which require host cells for their 
survival and reproduction. Structurally, they consist of genetic material (DNA or 
RNA) encased in a protein capsid or membrane envelope which allows 
movement from one cell to another. On entry to a cell, viruses deposit their 
nucleic acid and utilise the host's biochemical machinery to create typically 
hundreds of progeny which can leave to infect other cells. In many cases, viral 
infection will cause the cell to burst open (lysis) thus accelerating further 
infection. Viruses are responsible for a large number of human diseases such 
as cold sores, chicken pox, the common cold and polio, yet their role in human 
carcinogenesis has proved to be more elusive.
Viral carcinogenesis can be mediated through both RNA- and DNA- 
containing viruses. RNA viruses infect cells and use reverse transcription to 
produce DNA which can then cause mutation by incorporation into the host's 
genome. This form of carcinogenesis is common in other animals but has little 
impact on human cancer where DNA-containing viruses predominate. To 
induce carcinogenesis, the latter viruses rely on the rare occurrence that their 
DNA does not replicate in the host, but is satisfactorily incorporated into the 
cell's chromosomes. If the inserted DNA somehow activates the host's 
machinery for replication, cancer can result.
Viruses are thought to be involved in about 15% of human cancers,9 
including forms of cervical cancer (papillomavirus), liver cancer (hepatitis-B 
virus) and Burkitt's lymphoma (Epstein-Barr virus). The study of animal tumour 
viruses has provided valuable clues to the mechanisms of cancer in general.
1,3 Cell Proliferation and Cancer
The process of cell proliferation is controlled by the cell cycle, a well- 
defined sequence of events which directs DNA duplication and mitosis (cell 
division). It was thought that cells continuously synthesise DNA between 
mitoses until the 1950s when it was found that the cell cycle has four distinct 
phases as shown in Figure 1.10 Firstly, cells enter Gi where RNA and proteins 
are synthesised and preparations are made to begin DNA synthesis. This is 
followed by the S phase, where DNA is replicated and DNA-packing proteins 
(histones) are synthesised. Thirdly, in G2 phase, the replicated DNA is 
complexed with protein and preparations are made for cell division. Finally, in M 
phase, the cell nucleus and cytoplasm divide in the process of mitosis. The two 
daughter cells can then begin the cycle, or in the absence of correct signals or 
nutrients, enter a resting Go phase. Checkpoints are present at sites around the
-  6 -
cell cycle to ensure that the tasks of one phase are complete before transition 
to the next. The time taken for one complete cycle, Tc , is usually within the 
range 15 to 120 hours; a notable exception is liver cells, which sometimes 
exhibit Tc values of over one year.11
Figure 1 The Cell Cycle
In itia tion of m itosis
G2 DNA 
damage ^  
checkpoint
START or 
restriction point
DNA synthesis 
com pletion
G^/S DNA damage 
checkpoint
Tumours were long considered to be masses of rapidly dividing cells and 
we would therefore expect the Tc of a cancer cell to be somewhat shorter than 
that of normal cells. In reality, tumour cells complete an average cell cycle in a 
slightly greater time than normal, implying that if Tc was the only factor, 
tumours would grow at a similar rate to surrounding tissue. However, cell 
replication is normally strictly controlled to replace lost cells in order to maintain 
a constant cell number. In tumours, these control mechanisms are lost so the 
net cell number does increase with the rate of increase being affected by the 
extent of cell kill mechanisms such as the immune system and apoptosis 
(programmed cell death).
In spite of the monocellular origin of cancer, tumours are only detectable 
once thay have matured to a late stage in their life. When palpable, they will 
contain over 109 cells and aberrant cells may have already metastasised by 
contamination of the lymphatic and circulatory systems. The growing tumour will 
be expanding in size, starving other tissue of nutrients and space thus causing 
damage to blood vessels and ultimately, the vital organs of the body. Once the
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disease has spread away from the primary tumour, the prognosis is generally 
very poor. Effective treatment of cancer therefore depends on early detection 
and rapid therapy. The various types of cancer treatment will be discussed in 
the following section.
1.4 Treatment of Cancer^
As soon as cancer is detected, a programme of therapy is rapidly 
implemented to maximise the chance of survival. If localised, the cancer is 
usually surgically removed and adjuvant therapy is given to kill residual tumour 
cells. Radiotherapy is commonly used to treat cancer cells which remain in the 
tissue which surrounded the excised tumour; however, the encasement of 
malignant cells inside a region of hypoxia (oxygen deficiency) can sometimes 
render them radioresistant. Moreover, radiotherapy is not effective against 
undetected metastases which may have developed in other parts of the body
Chemotherapy provides a potentially systemic cure for cancer; however 
its application is hampered by the lack of exploitable differences between 
tumour cells and those present in normal tissue. Even cells within the same 
tumour exhibit differing sensitivities to cytotoxic drugs, depending on factors 
such as their location in the cell cycle or distance from blood supply. A further 
problem is the increasing resistance of tumour cells to anticancer drugs, a 
situation which is being addressed by combined treatment with a cocktail of two 
or three agents. Chemotherapeutic drugs commonly target cell division but 
many of the common malignancies such as cancer of the breast, colon and lung 
are "solid" tumours with a low proportion of dividing cells; these cancers are 
less susceptible to treatment with anticancer agents.
Despite these problems, chemotherapy has achieved remarkable 
successes in certain types of cancer. The different types of anticancer drugs 
and their mechanisms of action will now be briefly surveyed.
1.5 Chemotherapeutic Agents^
Over the past fifty years, many thousands of compounds have been 
evaluated for potential as anticancer drugs; the fruits of this research are the 
forty chemotherapeutic agents which are in common use today. Hopes of 
discovering an across-the-board drug to combat all types of the disease have 
been all but abandoned with most effort now being directed towards the design 
of medicines for particular forms of cancer.
For our purposes, the compounds which are in current use can be 
conveniently categorised into five areas: alkylating agents, antimetabolites,
noncovalent DNA binding drugs, inhibitors of chromatin function and drugs 
affecting endocrine function. Each of these classes of agent will be discussed 
separately.
1.5.1 A lkylating Agents
The alkylating class of drug forms adducts with the nucleic acid bases 
thus interfering with DNA synthesis. Some of these compounds contain two 
reactive moieties which enable them to cross-link the complementary strands of 
DNA and thus prevent uncoiling of the strands during replication. Alkylating 
agents are the largest family of clinically used cancer drugs; three structural 
types are discussed here.
1.5.1.1 Nitrogen Mustards
The structure and activity of the archetype mustard mechlorethamine 3 
demonstrates the function of this type of agent (Scheme 3).14 Intramolecular 
reaction, with concomitant expulsion of chloride leads to an electrophilic 
aziridinium ion. On reaction with the nucleophilic sites of DNA such as the N-7 
of guanine, genetic mutation will result. Cross-linking occurs when the 
remaining chloroethyl group reacts with the complementary strand of DNA.
Scheme 3 Biological Action of Nitrogen Mustard
Mechlorethamine 3 now has only very limited application in modern 
chemotherapy. It is highly toxic, corrosive, acts for only a very short period of 
time and requires intravenous infusion. In order to alleviate these problems,
— N
— N Guanine
-► Cross-linking
Alkylated guanine
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chlorambucil 4 and melphalan 5 were developed by British scientists in the 
1950s. The electron-withdrawing effects of the aromatic ring of these agents 
has pronounced effects on the rate of aziridinium ion formation and alkylation 
thus extending the lifetime of the drug. This improves absorption of the drug 
and allows the compounds to be orally administered.
COoH
NH
Cyclophosphamide 6 was designed as a prodrug which would utilise the 
high concentrations of phosphoramidases at tumour sites to release the active 
drug at the required site of action. In practice, the drug was found not to be 
metabolised by tumour cells, actually undergoing initial metabolic activation by 
the liver. Further transformation affords an active phosphoramide drug and the 
side-product acrolein which is responsible for the bladder toxicity associated 
with cyclophosphamide chemotherapy. This compound remains to be an 
important drug, often used in combination with methotrexate and 5-fluorouracil 
for the treatment of a variety of cancers.
1.5.1.2 Nitrosoureas
Nitrosoureas, such as cyclohexylchloroethylnitrosourea (CCNU) 7, are a 
success resulting from the U.S. National Cancer Institute's drug development 
programme. They have widespread alkylating activity and are known to inhibit 
DNA polymerase thus preventing the repair of DNA strand breaks. In this class 
the drugs are lipophilic and are able to cross the blood-brain barrier which has 
allowed their successful application to cerebral cancers. The mechanism of 
their activity is not as clear as that of the nitrogen mustards but it is known that 
their action is mediated by both alkylation and carbamoylation. Interestingly, 
despite the presence of only one chloroethyl group in CCNU, this and other 
nitrosoureas are known to be potent DNA cross-linkers. The simplified 
mechanism shown in Scheme 4 accounts for this.15
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Scheme 4 Nitrosoureas: Mode of Action
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The major clinical application of nitrosoureas is in the treatment of 
lymphomas. The bone marrow toxicity associated with them has precluded their 
inclusion in combination chemotherapeutic regimes.
1.5.1.3 Platinum Compounds
In 1965 Rosenburg et al. serendipitously discovered that the electrolysis 
products from a platinum electrode caused inhibition of bacterial division.16 
Four years later, the same research group observed the anticancer activity of 
the square planar complex cisplatin 8,17 now a major cytotoxic drug which has 
found particular application against testicular and ovarian cancers. Many 
analogues have been prepared in the hope of producing compounds which lack 
the severe toxicity of cisplatin. Of these, carboplatin 9 is now in clinical use and 
offers reduced side-effects towards the kidneys and nervous system.
CL NH
O NHNH
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The action of cisplatin and its analogues is known to involve metallation 
of the bases of DNA nucleotides; a cis pair of labile ligands has been found to 
be essential. However, unlike the nitrogen mustards, the platinum anticancer 
drugs are thought to exert their effects by formation of crosslinks between 
bases on the same strand of DNA. This is thought to cause bending of the 
duplex towards the major groove resulting in inhibition of DNA replication.18
1.5.2 Antimetabolites
In preparation for mitosis, an accumulation of nucleic acid and protein is 
required to furnish the daughter cells. Antimetabolites are designed to interfere 
with this process by closely mimicking natural compounds thus causing enzyme 
inhibition or the accumulation of false components into nucleic acids. Two 
different types of inhibitor are discussed here.
1.5.2.1 Folate Inhibitors
Folic acid 10 is an essential nutrient which undergoes a two-step 
conversion by dihydrofolate reductase (DHFR) into 7,8-dihydrofolate and 
thence 5,6,7,8-tetrahydrofolate. The latter is required to generate several co­
factors which are essential to purine biosynthesis and the formation of 
thymidine monophosphate (dTMP). Methotrexate 11 potently inhibits DHFR 
thus causing depletion of cellular tetrahydrofolate; this blocks nucleoside 
formation leading to a halt in DNA synthesis.
HN
COoH
COoH
CH
COoHNH
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The administration of methotrexate is highly effective towards the 
treatment of choriocarcinoma. It has also found application in the treatment of 
acute leukaemia and many solid tumours.
1.5.2.2 Pyrim idine Antagonists
The development of this class of metabolite arose from an observation 
that rat hepatomas required increased quantities of the RNA pyrimidine base 
uracil 13 over normal liver cells. 5-Fluorouracil (5-FU) 12 was prepared and 
evaluated to test the theory that increased uracil uptake could be exploited to 
gain selectve chemotherapy.
5-FU is a close analogue of uracil 13 and thymidine 14, the 
corresponding base in DNA. It is known to act by several mechanisms; each of 
which can result in cytotoxicity.19
H N '7 r ^ F HN HN
5-FU can cause mutation from rapid metabolism and incorporation into 
DNA and RNA. Another important effect is due to its metabolite 5-fluoro-dUMP, 
which inhibits thymidylate synthase and thereby slows down DNA production by 
depletion of suitable thymine-containing precursors.20
5-FU is used to treat several solid tumours, principally those of the breast 
and gastrointestinal tract. Application is often dependent on combination 
treatment with other anticancer agents or with certain non-toxic agents which 
are known to potentiate its activity.
1.5.3 Noncovalent DNA Binding Drugs
Most examples of this class of anticancer drug are derived from natural 
sources and also exhibit antibiotic activity. Structurally, they all contain a planar 
polycyclic moiety which is thought to interact with DNA in a different fashion to 
the alkylating agents. Activity is mediated through intercalation of the 
complementary strands of DNA in addition to other cytotoxic effects. Two of the 
clinically used groups will be discussed in this section.
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1.5.3.1 Anthracycline Antib io tics
These antibiotics, typified by doxorubicin 15 and daunorubicin 16, were 
isolated in the 1960s from different strains of Streptomyces fungi. They are 
characterised by a tetracyclic structure linked to the aminosugar daunosamine 
via a glycosidic bond.
OH
OCHqO OH O
CH
15 R=OH
16 R=H
HO
NH
The mechanism of action of these agents has still not been fully 
elucidated but they are known to initiate their effects by tight intercalation 
between the strands of DNA. X-Ray crystallography of DNA adducts of 
anthracyclines has revealed that this is mediated through strong interaction 
between the hydrophobic planar faces of DNA bases and the tetracyclic core of 
the antibiotic. Once bound, the activity of these drugs involves inhibition of 
topoisomerase II,21 a group of enzymes which normally direct strand breakage, 
uncoiling and annealing during DNA replication (see section 1.5.4.1). Another 
significant mode of action appears to involve the formation of iron chelates 
which are able to produce free radical and active oxygen species within the cell; 
these too can initiate DNA strand breaks and thus contribute to the overall 
cytotoxicity of anthracycline antibiotics.
Daunorubicin was initially found to have good activity towards 
leukaemias. Doxorubicin is more versatile and is an effective drug for the 
treatment of a wide variety of solid tumours.
1.5.3.2 Anthracenediones
Mitozantrone 17 is the most important member of this class of synthetic 
anticancer drugs. Structurally, it bears resemblance to the anthracyclines (vide 
supra) but does not contain a sugar conjugate.
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The anthracenediones act by a similar mechanism to that of the 
anthracycline antibiotics; interference with DNA strand reunion by 
topoisomerase II inhibition is believed to be the principal response. In contrast 
to the antibiotics, mitozantrone does not initiate the formation of free radicals 
which accounts for its lower toxicity to the heart.
Clinically, the anthracenediones are employed to treat forms o t  
lymphoma, leukaemia and advanced breast cancer.
1.5.4 Inhib itors of Chromatin Function
Throughout the cell cycle, chromosomes are required to undergo a 
series of major conformational changes in order to facilitate DNA replication and 
mitosis. Various enzymes are involved in these changes, particularly in the 
function of chromatin, in which DNA is decondensed and complexed with 
packing proteins called histones prior to replication. Two groups of agent have 
been found to be cytotoxic to proliferating cells by interfering with the enzymic 
manipulation of chromosomes.
1.5.4.1 Topoisomerase Inhibitors
The two groups of topoisomerase enzymes (types I and II) are involved 
in the untwisting of DNA portions to make them available for vital functions such 
as transcription and replication. Of the commonly used drugs, cancer 
chemotherapy by inhibition of topoisomerase II is more common, although 
further agents are in development which are known to target the type-l 
enzymes. Important topoisomerase II inhibitors include the podophyllotoxin 
derivatives etoposide 18 and teniposide 19.
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The normal function of topoisomerase II involves initial non-covalent 
interaction with the two strands of DNA resulting in a non-cleavable complex, so 
called because dissociation of the enzyme-DNA complex at this stage would 
not result in strand breaks. After cleavage of the strands and covalent bonding 
to the free 5'-ends of the nucleic acid chains, a transient cleavable complex 
results. Figure 222 shows how etoposide inhibits topoisomerase II action by 
stabilising the cleavable complex thus preventing the completion of transcription 
or replication and the regeneration of the free enzyme and DNA.23 The drug- 
stabilised persistent cleavable complex may then be denatured, giving rise to a 
DNA strand break.
Figure 2 DNA Damage by Inhibition of Topoisomerase
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Another effect of these drugs appears to be the prevention of protein 
kinase p34 activation.24 This kinase is usually activated during the G2 phase of 
the cell cycle and has a pivotal role in the initiation of mitosis. The observation 
that etoposide treatment can confine cells to G2 corroborates this theory.25
Etoposide has proved to be particularly useful in the chemotherapy of 
lung cancer and testicular cancer; combinational therapy with cisplatin and 
bleomycin is now the standard treatment for the latter condition. Teniposide has 
found utility in the treatment of adult brain tumours and acute lymphocytic 
leukaemia.
1.5.4.2 M icrotubule Inhibitors
Microtubules are polymeric proteins which fulfil a variety of essential 
roles within the cell, predominantly in functions relating to cellular shape and 
movement. During mitosis, cellular microtubules form a spindle which directs 
the complex processes of chromosomal division which precede cytokinesis 
(cytoplasm cleavage). To function correctly, microtubules exist in a sensitive 
equilibrium with dimeric tubulin; by interfering with this balance, several natural 
products have been found to exert useful anticancer properties.
The vinca alkaloids vincristine 20 and vinbiastine 21 were isolated from 
the periwinkle Catharanthus rosea. They are potent drugs which act by 
specifically complexing free tubulin dimers thereby causing depletion of the 
polymeric microtubules which form essential components of the cell. The 
anticancer properties are predominantly due to the destruction of the mitotic 
spindle which prevents the completion of cell division.
OH
MeOoC
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Vincristine has been applied to conditions such as acute leukaemias, 
lymphomas and breast cancer but its use is hampered by side-effects towards
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the heart and nervous system. Vinblastine is comparatively less neurotoxic and 
has found application in lymphoma and cancers of the reproductive system.
The terpenoid derivative paclitaxel (Taxol®) 21 is a more recently 
discovered microtubule antagonist which has provoked much interest amongst 
cancer biologists and organic chemists; its total synthesis has been completed 
by the groups of Nicolaou,26 Holton27 and Danishefsky.28 The compound was 
originally isolated from the bark of the yew Taxus brevifolia but is now generally 
obtained by partial synthesis from 10-deacetyl baccatin III, obtained from the 
needles of a related plant.
OCOMe
OHOH
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In contrast to the vinca alkaloids, the mechanism of paclitaxel's activity 
stems from its ability to tilt the tubulin-microtubule balance in the favour of 
microtubule formation. This causes depletion of tubulin dimers, the construction 
of abnormal bundles of microtubules and the stabilisation of the microtubule- 
containing components of the cell.29
Paclitaxel is being used investigationally in the treatment of breast and 
ovarian cancers. Difficulties such as bone marrow depression and poor 
solubility have led to the search for more suitable analogues.
1.5.5 Drugs Affecting Endocrine Function30
Cell proliferation in sexually differentiated tissues such as the 
endometrium, prostate and breast can be strongly influenced by the levels of 
related hormones in the body. In order to utilise this observation in 
chemotherapy, we must understand how a type of cancer is affected by a 
particular hormone. Tumours are termed hormone-responsive if increased 
hormone concentration gives rise to increased proliferation, hormone- 
dependent if growth is inhibited. In this section, the use of drugs affecting 
endocrine function will be illustrated by their application to the treatment of 
prostate cancer.
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1.5.5.1 Prostate Cancer
Control of cell proliferation in the prostate is affected by the levels of 
testosterone in the body; this hormone-dependent response may therefore be 
exploited chemotherapeutically to control the growth of cancer within this organ. 
Treatment involves the combinational use of drugs to inhibit both testosterone 
synthesis and action.
Testosterone is secreted by the Leydig cells of the testes in a process 
controlled by gonadotrophin releasing hormone (GnRH) and leuteinising 
hormone (LH), as shown in Figure 3. Feedback inhibition by the sex hormones 
controls GnRH and LH production. Therefore administration of oestrogens such 
as diethylstilbestrol 23 to prostate cancer patients decreases GnRH and LH 
formation which leads to the required fall in testosterone levels. As abnormally 
high oestrogen concentrations cause several undesired effects to the male 
body, another strategy involves the use of GnRH agonists to block GnRH 
receptors in the anterior pituitary. This prevents the release of LH, and hence, 
secretion of testosterone. Leuprolide and goserelin are now used clinically to 
mimic the decapeptide GnRH; the drugs are also decapeptides and work by 
competitive inhibition of the GnRH receptors in the anterior pituitary.
Figure 3 Sex Hormone Regulation
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In addition to the inhibition of testosterone synthesis, adjuvant therapy is 
employed to block the effects of its active metabolite dihydrotestosterone. 
Flutamide 24 is a clinically employed antagonist which competitively inhibits 
androgenic receptors thus leading to a reduction in prostate growth.
Unfortunately, chemotherapy by androgen-suppression is never curative 
in cases of prostate cancer. However, in such a disease for which there is no 
particularly effective cytotoxic drug, hormone therapy can stabilise the condition 
thus providing a welcome relief from the symptoms of cancer.
A major success of hormonal anticancer therapy has been in the 
treatment of adenocarcinoma of the breast, a common cancer amongst 
European women. The drug of choice is the antioestrogen tamoxifen 25, which 
is employed in early breast cancer and in the treatment of metastatic disease in 
post-menopausal women. In comparison to classical anticancer agents, 
administration of tamoxifen is relatively free of side-effects yet gives a similar 
therapeutic response rate to ablative removal of the oestrogen source by 
ovariectomy.31
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1.6 The Search for New Anticancer Drugs
The preceding sections have provided an overview of cancer and its 
treatment, with particular emphasis on the anticancer drugs and their 
mechanisms of action. The discovery of these compounds has occurred by a 
variety of means such as screening of chemicals and natural products, targeted 
synthesis of designed drugs, analogue studies of active compounds and, of 
course, serendipity. In future, drugs are likely to arise from all these areas, 
although more emphasis will be placed on the rational design of drugs to exploit 
the subtleties of cancer cells which differentiate them from normal cells. As 
advances in molecular biology emerge, they are accompanied by often 
elaborate chemotherapeutic approaches towards selective toxicity against 
cancer cells. Recent developments have included the use of enzyme-antibody 
conjugates to target cancers and selectively convert inactive prodrugs into 
cytotoxic drugs at the tumour sites. This regime is known as antibody-directed 
catalysis (ADC)32 or antibody-directed prodrug therapy (ADEPT) and elegantly 
highlights the importance of progress towards better drug-delivery systems to 
compliment the discovery of new types of anticancer agent. In addition to 
chemotherapeutic advances, exciting developments have been made towards 
the search for a genetic cure for cancer through gene therapy. Ideally, this 
might involve the beneficial use of viruses to insert tumour suppressor genes 
into the DNA of cancer cells; proliferation could then give rise to cells which 
fight the cancer rather than propagate it.
It is hoped that in the 21st century, these and other sophisticated 
therapies will come to replace the harsh drugs which can make cancer 
chemotherapy such a traumatic experience. In the meantime, it must be borne 
in mind that epidemiologists estimate that 80% of cancers arise from 
preventable causes. It is even thought that certain foods can help prevent 
cancer; however, educating those most at risk to eat broccoli rather than deep- 
fried foods is not a simple task.
Chapter 2 details how the factors which differentiate malignant 
melanoma tumours from normal tissue may be exploited to generate selective 
chemotherapy towards that form of cancer. Chapters 3-6 describe the synthesis 
and properties of some new phenols which have been designed to utilise this 
strategy.
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Melanoma: The Search for a Cure
2.1 Introduction
The rational development of new anticancer agents is driven by the 
search for biochemical features which differentiate tumour cells from their 
normal healthy counterparts. In the case of malignant melanoma, one such 
feature is the highly pigmented nature of most tumours, a characteristic that 
arises due to their continued production of melanin. Efforts that have been 
made towards the use of the enzymes of the melanin biosynthetic pathway in 
melanoma chemotherapy are discussed in this chapter.32
2.1.1 Skin Cancer
The unique position of the skin at the interface between the body and the 
outside world makes this, the largest organ, also the most vulnerable to the 
harmful effects of UV radiation. Those races most at risk have been furnished 
with skin containing large quantities of melanin, a pigment that absorbs the 
energy of solar radiation thus preventing it from inducing the DNA mutations 
that can lead to skin tumours. However, with increasing foreign travel, 
emigration and the use of sun-beds, greater numbers of people are becoming 
exposed to UV radiation at levels unsuitable to their skin type. Preventative 
measures, such as the use of sunscreens, are often neglected in the pursuit of 
a "beautiful" bronzed complexion. An unfortunate consequence is the increased 
incidence of skin cancers in all white-skinned populations of the world.
Non-melanoma skin cancers, such as basal cell carcinoma and 
squamous cell carcinoma are normally restricted in growth and do not readily 
metastasise. In these conditions, which make up the vast majority of skin 
cancers, surgery is a highly effective cure and affords success rates of greater 
than 95%.33 This is in stark contrast to malignant melanoma of the skin, an 
extremely aggressive condition that is highly metastatic and difficult to treat 
satisfactorily.
- 22  -
2.1.2 The Melanoma Problem
Cutaneous malignant melanoma is a relatively rare condition, accounting 
for less than 3% of cancer cases in the industrialised nations.34 In common with 
other skin cancers, the incidence of melanoma is rising rapidly in all areas of 
the world from which accurate data are available. Independent statistics from 
Norway, Australia and Scotland show that the occurrence of the condition in 
these areas is doubling every decade.35 Mortality is also rising, albeit at a lower 
rate.
Efforts are being made to establish the genetic factors which can lead to 
the disease, but as yet, the root causes of melanoma are still to be confirmed. 
In common with the other types of skin cancer, much evidence points to UV 
radiation as the major preventable cause of melanoma. The following 
observations add weight to this hypothesis.
• Due to lower protection from the sun, melanoma is predominant amongst 
white-skinned people. For example, the incidence of melanoma in 
Queensland, Australia is 150 times that observed in Osaka, Japan.36
• Israeli orthodox Jews wear head coverings and dark clothing all year round 
which protects them from the sun and may explain their significantly lower 
rates of melanoma when compared to their non-orthodox counterparts.37
• Case control studies have revealed that instances of severe sunburn are a 
risk factor in the development of melanoma.38
• Women are five times more likely than men to develop melanoma on their 
legs, which may be due to clothing such as skirts and dresses providing 
inadequate protection from the sun. 38
• Pale-skinned individuals who have fair hair and tend to burn rather than 
generate a protective tan on sun exposure are at greatest risk from 
melanoma.39
Despite the significant evidence that UV radiation is a principal cause of 
melanoma, some puzzling observations suggest that other factors are important 
too. For example, the incidence of melanoma in non-exposed regions of the 
anatomy such as the oesophagus, genitalia and the soles of the feet would 
appear to rule out carcinogenesis mediated by solar radiation in these cases. 
However, speculation about other possible causes of melanoma such as dietary
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factors, fluorescent light, tobacco, arsenic and female reproductive factors have 
been met with controversy. 40
Current knowledge suggests that the initiation of melanoma only requires 
episodic exposure to high levels of UV radiation. Moreover, the likelihood of 
developing the cancer appears to be determined more by the presence of 
freckles or moles rather than any environmental factors. For example, the 
occurrence of greater than 100 facial freckles in an individual has been reported 
by Holman and Armstrong to be associated with a 20-fold increase in the risk of 
developing melanoma.41
In the search for the cause and cure of melanoma, it must be borne in 
mind that there are several pathological forms of this disease. The four principal 
types of melanoma and their distinguishing features are outlined in Table 2 42
Table 2 Clinical Features of Common Melanoma Types
C lin ic a l
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S iz e  of 
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2 .5  c m 1 -2  cm 4 -7  cm 3  cm
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2  p h a s e  
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1 p h a s e
V e rtic a l (fro m  o u ts e t)
2  p h a s e .
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V e rtic a l (W k s /M o n th s )
2  p h a s e .
R a d ia l ( 1 -1 0  yr) 
V e rtic a l (W k s /M o n th s )
Further study is needed to establish whether different causal factors are 
responsible for the different types of melanoma shown in Table 2. Clearly, 
lentigo maligna melanoma is more likely to be UV-dependent in origin than 
acral lentiginous melanoma which develops in sites generally protected from 
the sun. Despite the varying properties of these tumours, the prognosis in every 
case is dependent on one main factor; the degree of skin invasion.
Melanoma can be treated satisfactorily provided that metastasis to other 
tissues has not occurred. Spread of melanoma cells to other areas of the body 
arises by transport of aberrant cells through the lymphatic or circulatory 
systems. The likelihood of invasion to blood or lymphatic vessels, and hence 
the chance of survival from melanoma, is governed by the level to which
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melanoma cells have invaded through the skin. In order to assess the prognosis 
of an individual melanoma case, the distance between the overlying granular 
layer of the epidermis to the deepest identifiable tumour cell is measured as 
shown in Figure 4.43 This measurement, known as the Breslow thickness, is the 
principal factor used to postulate the likelihood of survival after surgical removal 
of the primary tumour.43 For example, a Breslow thickness of greater than 3 
mm implies a 5-year survival rate of less than 40%. In contrast, tumours 
possessing Breslow thicknesses of below 1 mm have good prognosis and are 
associated with 5-year survival rates of greater than 90%.44
Figure 4 Calculation of Tumour Thickness
Epidermal surface
Granular layer
Dermo-epidermal
junction
O
O  Q } O
^  o
o  o  D ,o o o o o
°0 aO o °0  o ° o ° o  
U O o Oo o o Oo  o
1
Epidermis
-  Breslow Thickness
Dermis
Deepest invasive 
malignant melanoma cells
2.1.3 Surgical Treatment
The extent of invasion and metastasis is used to classify melanoma 
cases into three clinical stages 45
Stage I No clinically detectable lymph node metastasis.
Stage II Clinically detectable lymph node metastasis.
Stage III Distant metastases.
Melanoma is initially treated by surgical removal of the primary tumour 
and 2-5 cm of surrounding tissue; the clinical stage is used to determine the 
quantity of healthy tissue that must be excised. Local lymph nodes, which can 
mediate metastasis, are also removed in clinical stages II and III where 
pathological examination reveal that these have been contaminated by tumour 
cells. Some surgeons also carry out lymphadenectomy on stage I patients as 
microscopic examination of excised lymph nodes is useful in confirming the
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prognosis. Even with appropriate surgery and additional therapy, the 5-year 
survival rate for stage III patients is almost 0%.45
Radiotherapy is usually limited to certain cases of the rarer lentigo 
maligna melanoma form of the disease. Occasionally, this can also be applied 
to tumours on the extremities which lie away from internal organs that could be 
harmed by the therapy. However, these applications account for only a small 
proportion of melanoma cases with surgery being the best available treatment 
for the vast majority of these cancers.46
2.1.4 Current Chemotherapy
The lack of an effective drug to treat disseminated melanoma severely 
hampers the management of this disease.47 All traditional cytotoxic agents 
afford low response rates, both as single agents or in combination. However, as 
there is no alternative, chemotherapeutic agents such as dacarbazine (DTIC) 
25 are employed in advanced melanoma therapy. DTIC gives a positive effect 
in 20% of patients, although very few long-term cures arise from treatment. 
Nevertheless, single-agent DTIC is superior to any other drug regime in the 
fight against melanoma.48
The anticancer activity of DTIC mainly arises by the mechanism shown 
in Scheme 5.49 Metabolism by cytochrome P-450 in the liver followed by loss of 
formaldehyde ultimately leads to expulsion of methyldiazonium ions which 
mutate DNA and RNA by methylating nucleophilic sites such as guanine N-7.
Scheme 5 DTIC Metabolism
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Of the newer anticancer agents, two compounds possess interesting 
activity against melanoma. In contrast to DTIC, temozolamide 26 can be 
administered orally and is not light sensitive. Stage II clinical trials have shown 
that this drug gives a comparable response rate to DTIC but offers greater 
convenience.50 As temozolamide is an analogue of the active metabolite of 
DTIC, hepatic oxidation is not required for biological action.
In the last few years fotemustine 27 has emerged as the most promising 
new anti-melanoma agent. In addition to its unique ability to treat melanoma 
metastases in the brain,51 this nitrosourea is as effective as DTIC in treating 
metastases in other areas. Phase III clinical trials may well lead to this 
compound being established as the drug of choice for the treatment of 
metastatic melanoma.
NH
2726
2.1.5 Immunotherapy
Interferons are naturally occurring proteins that are produced by the body 
to combat viruses and a variety of other foreign agents. Due to their potent 
effects on the immune system, interferons have been widely evaluated for 
antitumour activity.52-53 One subspecies, IFN-oc2, has been found to have 
useful properties against melanoma and was approved for this purpose by the 
United States F.D.A. in December 1995. Clinical trials revealed that its use in 
post-surgical therapy lead to a 42% improvement in relapse-free survival rate. 
Unfortunately, combination therapy employing IFN-oc2 in conjunction with 
cytotoxic drugs such as DTIC has yielded mixed results, a situation that needs 
to be addressed by more comprehensive trials. Further work is also required to 
optimise the method and time-scale of interferon administration in order to 
maximise its activity towards melanoma.
2.1.6 New Strategies
Genetic therapy is currently being investigated in the fight against 
melanoma and clinical applications may soon be available.48 Several strategies
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are currently being studied, such as the transfer of genes which may lead to 
increased expression of interferons.48
Nature's storehouse of biologically active organic compounds continues 
to provide new leads in the fight against cancer. The alkaloid (+)-camptothecin 
28 and its 9-nitro derivative have shown promising activity against melanoma 
cell lines.54 Further studies are underway to evaluate fully their activity in vivo.
OH O
Increased melanin synthesis is a major characteristic that differentiates 
melanoma cells from normal healthy tissue. Attempts are being made to exploit 
this trait by utilising certain enzymes of the melanin synthetic pathway to 
generate active drugs at melanoma sites selectively. In the remainder of this 
chapter this rationale is explained in more detail, beginning with a discussion of 
melanin biosynthesis.
2.2 Melanin Biosynthesis
2.2.1 The Melanocyte
Melanoma tumours arise by aberration of pigment-producing cells called 
melanocytes (Figure 5).55 These cells are associated with keratinocytes in the 
epidermis, a covering of epithelial tissue that forms the outermost layer of the 
skin. Melanin synthesis takes place by a complex series of reactions in the 
highly specialised melanosome organelle. As melanosomes are especially 
active in most melanoma cells, their unique biochemistry has been targeted as 
a strategy to exert cytotoxic effects selectively at these tumours.56 Such 
chemotherapy would be particularly useful in the treatment of inoperable or 
even undetectable secondary tumours.
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Figure 5 The Melanocyte
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2.2.2 B iosynthetic pathway
The different colours of hair and skin pigmentation result from the 
blending of phaeomelanins, trichochromes, eumelanins and oxymelanins. 
These complex polymers arise from a cascade of enzyme-catalysed and 
spontaneous reactions from dopaquinone 29. Scheme 657 shows how this 
substrate can undergo cyclisation to give cyclodopa 30 which affords, after 
further metabolism, the brown/black eumelanins and oxymelanins. Alternatively, 
dopaquinone can react with cysteine to give 5-S-cysdopa 31 and the minor 
product 2-S-cysdopa. These are then oxidised by dopaquinone to the 
corresponding cysdopaquinones (e.g. 32) which after further elaboration via the 
benzothiazinylalanines (e.g. 33), furnish the yellow/red phaeomelanins and 
trichochromes. The common substrate for all branches of melanin biosynthesis 
is tyrosine 34. It is converted into dopa 35 and thence into dopaquinone 29 by 
the copper enzyme Tyrosinase.
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Scheme 6 Early Stages of Melanin B iosynthesis
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2.2.3 Tyrosinase
As shown in Scheme 6, Tyrosinase fulfils a pivotal role in melanogenesis 
by its unique ability to act as both phenol ortho-oxidase and catechol 
dehydrogenase by the conversion of tyrosine and dopa 35 into dopaquinone. 
The latter step also participates in a tandem shuttling mechanism where 
dopaquinone oxidises its daughter metabolites cysdopa and cyclodopa. This
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reactivity of Tyrosinase towards phenols is akin to potassium nitrosodisulfonate 
(Fremy's salt), the stable radical compound that is widely used in the chemical 
laboratory to convert phenols into o/t/70-quinones.58
The enzyme is found exclusively in the melanosome thus making it an 
excellent biochemical marker for sites of melanin synthesis. Its essential role in 
melanogenesis, mediating an early sequence of conversions, ensures that high 
concentrations of the enzyme are always available. For this reason, Tyrosinase 
has attracted interest as a catalyst to aid the selective delivery of drugs to 
melanoma tumours. To achieve this goal, suitable Tyrosinase substrates must 
be designed which can be metabolised into powerful cytotoxic agents.
Scheme 6 showed how the Tyrosinase product dopaquinone is 
converted by endocyclisation, reaction with cysteine or reconversion into dopa. 
These processes help maintain low dopaquinone concentrations in order to 
suppress the toxicity that is associated with ortho-quinones.56 Furthermore, 
other mechanisms are employed by melanocytes to prevent damage by these 
species such as the compartmentalisation of melanin biosynthesis into the 
melanosome organelle. This segregates dopaquinone thus preventing it from 
interfering with the essential cellular processes that occur in the cytosol or other 
organelles. The tripeptide glutathione 36 augments this by "mopping-up" any 
dopaquinone that may escape from the melanosome. Its action relies on 
nucleophilic attack on the quinone by the thiol group of the peptide's cysteine 
residue in a process that is directly analogous to the formation of cysdopa 31 
(vide supra). In addition, the products from glutathione addition to dopaquinone 
undergo further conversion thus allowing them to rejoin melanin biosynthesis. 
This economical mechanism was long thought to be a major pathway to the 
synthesis of melanin. However, Karg et al. recently concluded that the role of 
glutathione is essentially protective, having little significance in normal 
melanogenesis.59
2.3 Drug
The search for a suitable Tyrosinase-catalysed drug regime for 
melanoma is aimed towards the selective generation of cytotoxic ortho- 
quinones at tumour sites. Dopaquinone is rapidly metabolised, therefore
h o 2c  N e N COoH
Design
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alternative substrates must be designed that will be transformed into more 
stable quinones which could percolate from the melanosome and exert their 
cytotoxicity by attacking vital cellular components. As phenols and catechols 
are both potential substrates for Tyrosinase, both have been investigated for 
anti-melanoma activity. However, as early studies revealed that catechols 
cause indiscriminate toxicity through non-enzymic auto-oxidation,60 most work 
in this area has been directed towards the synthesis and evaluation of phenols. 
Concurrently, studies have been made to reveal the toxic effects of resulting 
oz#?o-quinones. Scheme 757 illustrates how these are thought to be caused by 
the generation of active oxygen species and by alkylation of thiol-containing 
enzymes.
Scheme 7 Phenol Prodrugs: Mechanism of Action
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In order to utilise this rationale in selective anti-melanoma activity, the 
designed prodrug would ideally have the following properties.
• Low toxicity before bio-conversion.
• Selective oxidation, exclusively by Tyrosinase.
• Sufficient water solubility to facilitate distribution in the bloodstream.
• Appropriate lipophilicity to allow diffusion into melanocytes.
• Favourable enzyme kinetics towards Tyrosinase.
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Effective biological activity is also reliant on the evolved drug possessing 
the following characteristics.
Long lifetime.
• Capable of diffusion into the cytosol.
• High toxicity towards the cell
Three groups of tyrosine analogues have been prepared and evaluated 
towards meeting these criteria.57 The results obtained from each structural type 
are discussed in the following sections.
2.3.1 4-Aminophenols
The evaluation of 4-aminophenols as anti-melanoma agents stems from 
reports that susceptibility to oxidation by Tyrosinase is controlled by the 
electronic properties of the substrate, in addition to steric factors.61 Accordingly, 
the powerful electron-releasing amino group was incorporated into a range of 
tyrosine analogues in the hope that it would potentiate Tyrosinase activity. 
Studies by Kern et al.62 and Mascagna et al,63 have highlighted several active 
compounds such as A/-4-hydroxyphenylglycine 37, A/-4-hydroxyphenylornithine 
38 and A/-2-morphilinoethyl-4-aminophenol 39.
OH OH OH
NH
HN HN
COoH
37 38 39
Mascagna et al. showed that oxidation of 37 by Tyrosinase leads to the 
formation of muconic semialdehyde derivatives through cleavage of the 
intermediate ortho-quinone. Furthermore, the same study concluded that non- 
Tyrosinase mediated oxidation competes leading to the generation of free 
aminophenol and glyoxylic acid.64 The latter mechanism may account for the 
poor selectivity that is associated with these analogues.
-33  -
2.3.2 4-(A lkylth io)phenols and 4-(Alkyloxy)phenols
Research in this area continues to be based on simple hydroquinone 
derivatives such as 4-hydroxyanisole 40. Clinical trials showed that 40 was well- 
tolerated but its use was hampered by poor pharmacokinetics and non-selective 
activity.56 In order to address these problems, Naish-Byfield et al. studied 
analogues containing a longer ether side-chain, such as 41, and found that 
these exhibited different biological effects to 40.65 Furthermore, the observed 
toxicity of the compounds could not be satisfactorily correlated with the rate of 
oxidation by Tyrosinase.
OHOH
OCH
More recently, the same group elegantly employed pulse radiolysis to 
generate ortho-quinones rapidly from analogues of 40 in order to measure their 
reactivity towards thiols such as cysteine and glutathione.66 These studies 
confirmed that o/#?o-quinones derived from 4-(alkylthio)-phenols are 5-10 times 
more reactive towards thiols than those arising from 4-(alkyloxy)-phenols.67 
Quantitative Structure-Activity Relationship (QSAR) was used to forecast 
accurately the reactivity of oThoquinones towards selected thiols thus providing 
a useful numerical tool in the rational design of further analogues.68
The consequences of varying the bridging atom in simple 4- 
hydroxyanisole analogues were recently studied in more detail by Riley et al.69 
They confirmed that good biological activity depends on the presence of a 
heteroatom substituent such as sulfur, oxygen or selenium at the 4-position of 
the phenol.
2.3.3 Analogues of 4-S-Cysteaminylphenol
The potential of 4-S-cysteaminylphenol 42 in the chemotherapy of 
malignant melanoma was initially reported by Jimbow and co-workers.70 
Preliminary findings revealed that the drug effectively caused depigmentation of 
new hair growth in mice (80%)71 and significantly extended the life-span of 
melanoma-bearing mice.72 Promisingly, examination of non-melanotic tissue by
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electron microscopy showed no signs of damage, thus providing evidence for 
selectivity towards melanocytes.73 However, further evaluation revealed a 
significant primary toxicity which resulted in a low LD5o value. Independent 
studies by May and co-workers inferred that non-selective action may be due to 
the enzyme monoamine oxidase (MAO) .74 They showed that 42 is an excellent 
substrate for MAO leading to the formation of the toxic aldehyde 43, as shown 
in Scheme 8 .
Scheme 8
OHOH
MAO
43
NH
42
Herman et al. revealed that the major side-effect of 42 administration 
was antihypertensivity through interaction with dopamine (3-hydroxylase.75 
Although these problems have precluded clinical interest in 4-SCAP, its 
mechanism of depigmentation continues to attract attention. Novel biomimetic 
studies by Mascagna et al.76 provided evidence that it is oxidised by Tyrosinase 
to give a transient ortho -quinone 44. Scheme 9 shows how this is rapidly 
attacked intramolecularly to afford 45 which, after auto-oxidation, gives dihydro- 
4H-1,4-benzothiazine-6,7-dione 46 in a similar manner to the previously 
discussed endocyclisation of dopaquinone. Hasegawa et al. recently confirmed 
that 46 is the active metabolite of 42, providing evidence through reaction with 
thiol-containing peptides. Hence, 46 is likely to exert the cytotoxic effects of 42 
through alkylation of essential sulfhydryl-containing enzymes.77
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Scheme 9 4-S-CAP Metabolism 
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Alena et al. prepared several derivatives of 42 in order to prevent the 
troublesom e M AO -m ediated to x ic ity .7 8 Of th e se , A/-acetyl-4-S- 
cysteaminylphenol 47 proved to have the greatest de-pigmentation and anti­
melanoma activity. In addition, this new compound selectively reduces the size 
of melanoma tumours and leads to a reduction in the size of lung melanoma 
metastases in mice.78
OH
47
The biological activity of 47 analogues also involves formation of ortho- 
quinones, although endocyclisation is not possible due to the lack of a free 
amino group. As discussed in section 2.3.3, the melanocyte uses glutathione to 
prevent cellular damage by excess dopaquinone. As glutathione is non- 
selective in its action, it will also de-activate quinones derived from compounds 
such as 47. Therefore, 47 must be surmounting this response to generate its 
anticancer activity. Alena et al. provided further evidence of glutathione's 
protective role by observing that the effects of 47 were greatly increased by co­
treatment with D,L-buthionine-(S,/I?)-sulfoximine 48 .79 The latter compound 
blocks glutathione synthesis by inhibition of y-glutamyl cysteine synthetase and 
thus potentiates the activity of 47.
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Recent work by Thomas et al. has shown that 47 also elicits a non- 
Tyrosinase mediated cytotoxic effect through inhibition of poly-(ADP-ribose) 
po lym erase .80 As the evaluation of only a few analogues of 47 has been 
reported in the literature, there is an urgent need for a comprehensive 
chemistry-driven programme to examine the viability of melanoma treatment 
using this type of compound.
Chapters 4-7 constitute a study directed towards meeting that important 
goal through the design, synthesis and biological evaluation of over 70 target 
compounds. Most of the functionality present in 47 has been systematically 
manipulated in order to probe the structure-activity relationship of this type of 
agent. In Chapter 3 nucleophilic ring-opening reactions of oxazolines are 
discussed, a continuing theme throughout the thesis.
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3
The Wehrmeister Reaction
3.1 Introduction
Oxazolines are dihydro derivatives of the oxazole 49 heteroaromatic 
system. Three regioisomeric types are known: 2-oxazoline 50, 3-oxazoline 51 
and 4-oxazoline 52. Of these, only 2 -oxazolines (4,5-dihydro-oxazoles) have 
found useful application in organic chemistry.
5
W n o n 0
3 N 55- /  
2
N ^ / N ^ y H N >V
49 50 51 52
Substituted 2-oxazolines are particularly useful in their ability to act as 
latent or protected carboxyl or carbonyl groups. For example, carboxylic acids 
can be readily alkylated at the oc-position indirectly by the procedure shown in 
Scheme 10.81 The alkylation step utilises the base-stability of the heterocycle 
whereas the final deprotection step exploits its sensitivity to acid.
Scheme 10
OH
1. BuLi
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Pioneering work by Meyers and co-workers has led to the widespread 
use of 2-oxazolines in asymmetric synthesis. Readily available homochiral 
amino alcohols can be used to cause chiral induction after the formation of 
optically active auxiliaries. Andrews et al. used this methodology in the total 
synthesis of (-)-podophylleotoxin 55 (Scheme 11).82 The key step involved aryl 
addition to the chiral oxazoline 53 to furnish 54 in 92% diastereomeric excess.
Scheme 11
OMe
MeO OMe
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The numerous applications of 2-oxazolines and their methods of 
preparation have been comprehensively reviewed.83' 87 The purpose of this 
chapter is to focus on the use of this heterocycle in the synthesis of 
carboxamides through nucleophilic ring-opening reactions. This area of organic 
chemistry has developed from the initial observation by Goldberg and Kelly that 
treatment of benzoyl chloride with 2 -phenyl-2 -oxazoline in aqueous sodium 
bicarbonate affords amide 56 in good yield (Scheme 12).88
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Scheme 12
V aq. NaHCO
56
The mechanism of the reaction was studied by Fry89 and also more 
recently by Tomalia and Paige90 through the use of functionalised aromatic 
oxazolines and acid chlorides. It is known to progress through nucleophilic 
attack on the intermediate cation 57 by water.
57
Scheme 13 illustrates how similar cations 58 arise when oxazolines are 
treated with acidic substrates such as phenols or thiophenols. In principle, these 
ions can undergo nucleophilic attack at the 2-position to afford the oxazolidine 
60 or attack at the 5-position with concomitant ring-opening to give 
carboxamide 59.
Scheme 13
Nu
NuH
HN
HN
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60
The use of nucleophilic oxazoline ring-opening reactions in synthesis will 
be discussed in the following sections.
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3.2 Wehrmeister Reaction
In 1959, Jager first reported the use of phenols and thiophenols to effect 
ring-opening reactions of oxazolines.91 Several examples were given in the 
patent, including the high-yielding syntheses of amides 61, 62 and 63 (Scheme 
14).
Scheme 14
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OH
Ph
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Independently, Wehrmeister published similar findings in 1963 although 
studies were confined to the use of thiophenols.92 Perhaps unfairly, this method 
of preparing carboxamides has become known as the Wehrmeister reaction on 
the basis of this later work.
In a subsequent report Wehrmeister stated that isolation of the 
intermediate oxazoline was not necessary.93 The same study also extended the 
utility of the reaction to the preparation of amides with one extra carbon 
between the sulfur and nitrogen in the side chain. For example, 3-amino-1- 
propanol was treated with molar equivalent quantities of thiophenol and 
propanoic acid in toluene with azeotropic distillation of water to give amide 65 in 
a one pot procedure. Scheme 15 shows the course of the reaction, presumably 
via the 5,6-dihydro-oxazine 64. Evidence that a cyclic intermediate is involved 
was provided by the observation that 4-amino-1 -propanol does not react in a 
similar fashion 93
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Scheme 15
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In 1984, Saito et al. published a communication claiming to have 
discovered a new method of preparing carboxamides through the use of 2- 
oxazolines.94 The experimental procedure reported was essentially the same 
as that of Jager91 and Wehrmeister92 yet no citation to the earlier work was 
made. However, the paper of Saito et al.94 does complement the previous 
studies by establishing that selenophenols are also good substrates for the 
Wehrmeister reaction. Moreover, it was concluded that 2-oxazolines can 
successfully undergo nucleophilic ring-opening by azide or chloride ions 
through the use of azidotrimethylsilane or chlorotrimethylsilane, respectively. As 
an example, the 5,6-dihydro-oxazine 66 was used to prepare substituted azide 
67 in 74% yield as shown in Scheme 16. The product was required as a 
building block in the synthesis of kukoamine A.94
Scheme 16
^ 9
MeOH, 60 °C
67
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The Wehrmeister reaction has predominantly been employed in the area 
of medicinal chemistry. May and co-workers used a commercially available 
homochiral amino alcohol to prepare (S)-2,4-dim ethyl-2-oxazoline 68.95 
Treatm ent of this with thiophenol gave, after hydrolysis, the potent 
antihypertensive agent 69 as shown in Scheme 17. The (R) enantiomer of 69 
was prepared by a similar route and was found to have no antihypertensive 
activity due to its poor affinity for dopamine (3-monooxygenase.
Scheme 17
1. PhSH
2. aq. HCI
6968
Morgan and co-workers recently used the nucleophilic ring-opening of 2- 
ethyl-2-oxazoline by phenol 70 to synthesise novel antiarrhythmic agents such 
as 72 (Scheme 18).96-97 Acid hydrolysis of the amide from the Wehrmeister 
reaction furnished the required amine intermediate 71 in good yield.
Scheme 18
2. Hydrolysis
OH
70
NH
^ \ N H S 0 2Me
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72
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The Wehrmeister reaction has also been applied to polymerisation 
reactions through the use of bis-oxazolines and dithiols. Scheme 19 shows how 
Nishikubo et al. prepaped polyamide 75 in almost quantative yield by heating a 
mixture of co-monomers 73 and 74 in /V-methylpyrrolidine (NMP).98
Scheme 19
HS SH
74NMP
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3.3 Ring-Opening by Aromatic Amines
Treatment of 2-oxazolines with aromatic amines or their hydrochloride 
salts is known to give a mixture of products. Fazio reported that the treatment of 
aniline with an equimolar amount of 2-ethyl-2-oxazoline under acid catalysis 
gave a mixture of mono and bis(amidoethylated) compounds 76 and 77 in the 
ratios shown in Scheme 2 0 ."
Scheme 20 Product D istribution (by GC)
10% Ph-NH
/ \ PhNH2 (1 eq.) 87% P h-N 76
180 °C
3% P h-N 77
Seeliger et al. previously employed this reaction to prepare intermediates 
for the synthesis of substituted im idazolines.84 Scheme 21 shows how 
dihydroimidazole 78 was prepared in good yield by dehydration of carboxamide 
76 using phosphorus pentoxide.
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Scheme 21
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Treatment of oxazolines with aromatic amines has also been reported to 
generate alternative products by nucleophilic addition to the 2-position of the 
heterocycle. Kormendy et al. prepared amino-oxazolidine 79 by treatment of 
aniline hydrochloride with one equivalent of 2-phenyl-2-oxazoline under the 
conditions shown in Scheme 22.100
Scheme 22
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Studies by Hunig have revealed that am ino-oxazolidines and 
carboxamides are the kinetic and thermodynamic products, respectively, from 
the reaction of oxazolines with aromatic amines.101 However, the reversible 
nature of aminooxazolidine formation can, under the correct conditions, allow 
amides to be preferentially formed using this procedure. Nonetheless, 
Poindexter devised an alternative strategy to avoid this side-reaction whereby 
oxazolines were treated with anhydrous hydrogen chloride to prepare N- 
chloroethyl carboxamides.102 These were reacted with aromatic amines to give 
amides and (after hydrolysis) diamines in good yield. Scheme 23 shows how 
the process was exemplified by the preparation of aromatic diamine 80 thus 
offering an alternative to the use of highly-toxic aziridine, the classical reagent 
for ethanediamine synthesis.102
-45  -
Scheme 23
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3.4 New Methods
Despite the success of the above methodology in the synthesis of 
ethanediamines, a more convenient method for their preparation was recently 
disclosed by Poindexter et a/.103 It was found that phenols, thiophenols and 
aromatic amines could be effectively aminoethylated using 2-oxazolidinone 80 
and its A/-alkyl derivatives such as 81. Scheme 24 illustrates the application of 
this new strategy to the syntheses of amines 82 and 83.
Scheme 24
82
NHNH
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80 NH
83CHo Ph-NHCH
CH
Unlike ring-opening of oxazolines, this reaction could not be extended to 
the use of oxazolidinones bearing substituents on the ring carbon atoms.103
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Therefore both of these reaction types are of complementary value to the 
synthetic organic chemist.
The use of oxazoline ring-opening reactions in the synthesis of some 
new phenolic anticancer drugs will be described in the following chapters.
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4
Synthesis of New Phenolic Sulfides
4.1 Introduction
Our interest in the area of anti-melanoma drugs developed from 
discussions with Professor R.M. MacKie of Glasgow University's department of 
Dermatology. Her group required samples of 4-S-cysteaminylphenol 42 and N- 
acetyl-4-S-cysteaminylphenol 47 for their own studies and we were keen to 
assist by synthesising these drugs. As discussed in the previous chapter, these 
compounds have provoked much attention through their ability to mediate 
selective melanoma chemotherapy by targeting melanin biosynthesis. However, 
despite comprehensive biological studies of 47, our literature search revealed 
very little by way of medicinal chemistry in this area. Towards meeting this 
need, some preliminary work was carried out within our group as part of the 
Ph.D. studies of Paul McKeown.104 The interesting biological results obtained 
in that study provided the basis for the chemistry discussed in this chapter.
The phenol 47 was initially prepared by Padgette et al. for evaluation as 
an antihypertensive agent.105 By the use of the Wehrmeister reaction, 4- 
hydroxythiophenol was treated with 2-methyl-2-oxazoline to afford the desired 
amide in 92% yield (Scheme 25). The high yield reported demonstrates the high 
selectivity for thiophenols over phenols in the ring-opening reactions of 
oxazolines.
4.2 Synthesis of Compound 47
Scheme 25
OH OH
SH
92%
H
i. Neat, 120 °C, 2 h, N2. 47
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We began work in this area by preparing 47 in 87% yield by the 
procedure of Padgette et a/.105 Our spectroscopic data corresponded well with 
those reported in the literature.105 At this point we decided which structural 
changes would be required in order to probe the structure-activity relationship 
(SAR) of 47. As the drug is believed to act by mimicking tyrosine, we were 
particularly keen to justify structural features such as the amide and sulfide 
groups. These and other proposed areas of investigation are illustrated in 
Figure 6.
Figure 6 Structural Features of Compound 47
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4.3 The Phenol Group
As 4 7 is thought to exert its cytotoxic effects through oxidation by 
Tyrosinase, it seemed likely that the phenol group would be essential to anti­
melanoma activity. To help confirm this theory, a series of amides 84-87 were 
prepared by treatment of the appropriate thiophenols with 2-methyl-2-oxazoline 
(Scheme 26).
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Scheme 26
H
Product R Time (h.) Yield
84 H 2.0 82%
85 o c h 3 2.5 76%
86 c h 3 2.5 82%
87 Cl 2.0 64%
Two of the four products shown in Scheme 26 have been previously 
reported in the literature. Bewick et al. prepared sulfide 84 by a Wehrmeister 
reaction although different reaction conditions were used.106 By heating the two 
reagents together in refluxing acetonitrile with a catalytic amount of p- 
toluenesulfonic acid, they obtained an 85% yield of 84. Our own analytical data 
were in good accordance with those reported.106 McCormack and McElhinney 
prepared 86 by a multi-step route and gave a similar m.p. to that of our own 
sample.107 As no spectroscopic data were given, full data are presented in 
chapter 7.
In addition to analogues containing an amide group, we were also 
interested in preparing some analogues of 4-S-cysteaminylphenol 42. The 
parent compound 42 was prepared by the acid-catalysed hydrolysis of 47, as 
described by Padgette et a/.105 Known amines 88 and 89 were also prepared in 
a similar manner by hydrolysis of 84 and 87 (Scheme 27).
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Schem e 27
conc. aq. HCI
reflux 14 h
NHoCI
Product R Yield
OH 88%42
88
The biological evaluation of the products shown in Schemes 25-27 
revealed that only those compounds containing a phenol group were 
significantly active.108 Of course, this did not prove that the toxicity of 42 and 47 
was mediated through metabolism by Tyrosinase as some indiscriminate 
primary toxicity of phenols may have been responsible for the observed cell 
growth inhibition. However, on the basis of this result we decided to concentrate 
future work on phenols
We were also interested in functonalising the phenol moiety present in 
47 with the possibility that active drug would be released after metabolism in the 
body. To investigate this, the general procedure of Furniss et a/.109 was 
employed to prepare two ester derivatives 90 and 91 in good yield by treatment 
of 47 with the corresponding carboxylic anhydride (Scheme 28).
Scheme 28
OH
0 °C
Product R Yield
90 Me 52%
91 Et 62%
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The esters showed comparable in vitro activity to the parent phenol 47; 
therefore it seemed likely that hydrolysis was taking place within the cell. Within 
our group, McKeown exploited this observation by conjugating 47 to the 
polymer poly(ethylene glycol) via ester linkages.110 The resulting adduct 
showed excellent water-solubility and retained good anti-cancer activity.
4.4 Side-Chain Variations
Although the phenol group is the presumed pharmacophore of 47, we 
were keen to examine the effects of introducing variations to its side-chain. New 
analogues with different shape and lipophilicity to 47 would be expected to 
demonstrate variation in cytotoxicity and in kinetics towards Tyrosinase. Initially, 
we used 4-hydroxythiophenol and the commercially available 2,4,4-trimethyl-2- 
oxazoline to prepare 92 in 77% yield (Scheme 29).
Scheme 29
OH OH
130 °C
SH
Compared to 47, the in vitro evaluation of 92 revealed significantly 
higher anti-cancer activity and thus underlined the need for the synthesis of 
further analogues. It was decided to retain the new dimethyl functionality and 
examine the effects of varying the amide alkyl group. In order to synthesise that 
type of compound using a Wehrmeister reaction, samples of the corresponding 
2-oxazolines were required.
The classical method of oxazoline synthesis involves the cyclo- 
condensation of an amino alcohol with a carboxylic acid (Scheme 30). Removal 
of water by azeotropic distillation is required to afford good yields of product.
Scheme 30
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The success of this procedure is known to be dependent on a number of 
factors. As Dean and Stark conditions are used, volatile substrates are often 
removed from the reaction mixture before condensation has taken place. In a 
sim ilar way, volatile 2-oxazoline products sometimes co-distil with the 
hydrocarbon solvent once they have formed thus adding further complications. 
In addition, a major problem that arises when using this procedure is isolation of 
the intermediate amido alcohol (Scheme 30). For many substrates, this 
intermediate is not effectively dehydrated under the reaction conditions and a 
separate cyclisation step using thionyl chloride is often required to furnish the 
desired 2-oxazoline.
Barton et al. reported that the problem of amido-alcohol cyclisation could 
be circumvented by addition of boric acid to the reaction mixture.111 However, 
this method is only useful in the preparation of 2-oxazolines lacking labile 
functionality due to the harsh conditions involved. In particular, it has found 
value in the protection of carboxyl groups in steroid system s.112 The 
mechanism of boric acid catalysis suggested by Barton et al. is given in 
Scheme 31.111
S chem e 31
OHh 2o
B(OH) HBO
OH — O
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On moderate heating, HBO2 is generated which reacts with the amino 
alcohol and carboxylic acid to give 93. In this intermediate, the amine is suitably 
placed to interact with the now activated carbonyl group, leading to 94. This is 
converted through bicyclic intermediate 95 thus furnishing the desired oxazoline 
and re-generating HBO2 .
We employed this method to synthesise oxazolines 96-101 as shown in 
Scheme 32. Our analytical data for compounds 96-98 corresponded well with
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those reported in the literature.111,113-116 Novel 2-oxazolines 99-101 were fully 
characterised and gave the expected spectroscopic data.
Scheme 32
\
h 2n
r -c o 2h
OH cat. B(OH)3 
xylene
ref I. 2-3 d
Product R Time (d.) Yield
96 cyclo-C6H-,-| 2.0 75%
97 (CH2)6CH3 2.0 84%
98 (CH2)2-cyc/o-C6H11 2.0 58%
99 (CH2)3-cyc/o-C6H11 3.0 52%
100 (CH2)4-cyc/o-C6H-| -j 3.0 54%
101 cyclo-C5 Hg 3.0 62%
Witte and Seeliger first demonstrated the Lewis acid-catalysed synthesis 
of 2-oxazolines from nitriles and amino alcohols.117 The reported procedure is 
particularly convenient as no additional solvent is required when aliphatic 
nitriles are used. Moreover, the progress of reaction can be easily followed by 
monitoring the evolution of the by-product ammonia. This proved to be an 
extremely reliable method of oxazoline synthesis, limited only by the availability 
of nitrile substrates. A proposed mechanism of cadmium acetate-catalysed 
oxazoline formation from nitriles is given in Scheme 33.
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Two known 2-oxazolines, 102 and 103, were prepared using this 
methodology (Scheme 34). The spectroscopic data for these compounds were 
in good agreement with those reported in the l i t e r a t u r e . 1 15-116,118,119
S chem e 34
%  
HoN C
R-CN - A
OH cat. Cd(OAc)2
130 °C 3d.
-N
■o'
R
Product R Yield
102 Prn 60%
103 Pr1 76%
The oxazolines shown in Schemes 32 and 34 were used to prepare 
novel sulfides 104-111 by treatment with 4-hydroxythiophenol (Scheme 35).
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Scheme 35
130 °C
 )
No
Oxazoline Product R
96
97
98
99
100 
101 
102 
103
W  0
H
Time (h.) Yield
104 cyclo-C6Hu
105 (CH2)6CH3
106 (CH2)2-cyc/o-C6H11
107 (CH2)3-cyc/o-C6H11
108 (CH2)4-cyc/o-C6H11
109 cyclo- C5H9
110 Prn
111 Pr'
4.0
4.0
7.0
7.0
4.0
4.0
4.0
4.0
75%
74%
73%
65%
58%
72%
61%
69%
Padgette reported that the Wehrmeister reaction of 4-hydroxythiophenol 
with 2-methyl-2-oxazoline was essentially complete after a 2 hour reaction time 
at 120 °C. We found that for 2-oxazolines substituted at the 4-position, a 
combination of higher temperature and extended reaction time was required to 
give an acceptable yield of product.
Together with similar compounds prepared by McKeown,120 the eight 
products shown in Scheme 35 were evaluated in vitro by Dr L.R. Kelland of the 
Institute of Cancer Research, Surrey. Table 3 shows the growth inhibition data 
for compounds 104-111 and the parent compound 47. The G I 5 0  values quoted 
refer to the concentration of drug required to cause 50% growth inhibition in a 
96 hour sulforhodamine B (SRB) growth inhibition assay. Activities were 
evaluated against four melanoma cell lines (B0010, SK-Mel-24, SK-Mel-2 and 
G361) and for comparison the ovarian SKOV-3 line. Selective anti-melanoma 
activity would be expected to cause low G I 5 0  values for the melanoma lines 
together with high values for the ovarian cancer cell line.
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Table 3 Gl50 Values (pM) for 96H SRB Assay
Cell Line
Compound B0010 SK-Mel-24 SK-Mel-2 G361 SKOV-3
47 > 1 0 0 > 1 0 0 > 1 0 0 > 1 0 0 > 1 0 0
104 21 24 19 14 25
105 > 1 0 0 > 1 0 0 > 1 0 0 > 1 0 0 > 1 0 0
106 58 83 71 26 56
107 61 > 1 0 0 > 1 0 0 54 > 1 0 0
108 54 87 55 52 51
109 70 48 56 37 > 1 0 0
110 84 74 56 35 > 1 0 0
111 > 1 0 0 100 100 67 > 1 0 0
Several conclusions can be drawn from the in vitro test data given in 
Table 3. Firstly, most compounds are considerably more cytotoxic than the 
parent drug 47. Although promising, this is only of real value if selectivity is 
increased too. Compound 104  exhibited the greatest degree of growth 
inhibition, yet it appears to be toxic towards non-melanoma cells too. We initially 
thought this increased activity might be largely due to higher lipophilicity yet 
other compounds with large hydrophobic groups such as 105 gave high GI50 
values. Moreover, it was found that a reduction in growth inhibition resulted 
when we further decreased the polarity of 105 through addition of methylene 
groups to the amide alkyl group (compounds 106 - 108). Promisingly, sulfides 
109 and 110 showed good selectivity for the melanoma lines over SKOV-3 
which prompted us to design a further round of related compounds for 
screening.
Initially, we decided to prepare a bifunctional compound containing two 
phenolic moieties. By the procedure of Furuta ef a/.121 bis-oxazoline 112 was 
prepared in 70% yield and treated with two equivalents of 4-hydroxythiophenol 
(Scheme 36). A double Wehrmeister reaction afforded the novel dimeric 
compound 113 in 36% yield after column chromatography and recrystallisation. 
Due to its symmetry, the aliphatic region of 113 gave rise to 3 singlets in its 1PI 
NMR spectrum (Dg-DMSO). Similarly, the DEPT-edited 13C NMR spectra of 
113 showed nine peaks, as reported in section 7.2.2.
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Scheme 36
OH OH
112 113
i. p-HO-Ar-SH, neat, 130 °, 4 h.
Another area of investigation involved further changes to the alkyl region 
between the sulfur and nitrogen atoms in 47. As the introduction of methyl 
groups to this region had proved successful, analogues containing other 
functionality were required to define further the SAR of these agents. To this 
end, the general procedure of Witte and Seeliger117 was employed to prepare 
two new ethylated 2-oxazolines 114 and 115 (Scheme 37) as racemates for use 
as substrates in the Wehrmeister reaction.
Scheme 37
\  R-CN
/  \  ------------ ►
H2N OH cat. Cd(OAc)2
130 °C 3d.
T 0v«
Product R Yield
114 Et 79%
115 cyclo-C6H11 55%
The moderate yield of 115 was probably caused by steric factors 
impeding the reactivity of cyclohexanecarbonitrile. Complex 1H NMR spectra 
were obtained for both products, due to the stereogenic centre at the 4-position 
of the heterocycle. However, oxazoline formation was confirmed by the 
presence of a peak at ca. 5 170 in the 13C NMR spectra of the products. This 
was corroborated by the characteristic C=N stretching band at ca. 1665 cm '1 in 
the IR spectra of 114 and 115. Both of these oxazolines readily reacted with 4- 
hydroxythiophenol under the standard conditions to give the required novel 
sulfides 116 and 117 as shown in Scheme 38.
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Scheme 38
OH
SH
-N
*
•o'
R
130 °C 
4 h.
No
O x a z o l i n e  P r o d u c t  R  
114 116 Et
Y i e l d
79%
115 117 cyclo-CgH-,1 65%
In addition to lipophilic substituents, we were also keen to introduce polar 
groups in the side-chain. Known 2-oxazolines 118 and 119 were prepared as 
described by Wehrmeister.122 As only b.p. data for 118 are reported in the 
literature,122 this compound was characterised by the standard spectroscopic 
techniques. The m.p. and 1H NMR spectral data for 119 accorded well with 
those in the literature.122’122
OH OH
HO
119
Treatment of oxazolines 118 and 119 with 4-hydroxythiophenol under the 
standard conditions92 did not result in any detectable amide formation. As 
extended reaction times did not seem to resolve this problem, an alternative 
procedure was sought that would increase the rate of nucleophilic addition. In 
particular, it was thought that the use of polar aprotic solvents might enhance 
ring-opening by solvation of the troublesome hydroxymethyl group(s). 
Accordingly, required novel amides 120 and 121 were prepared in low yield 
through the use of DMF as reaction solvent (Scheme 39).
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Scheme 39
HOOH
OH
i. p - H O - A r - S H ,  DMF, 7 h., 130 °C, N
Y i e l d
Me 30% 
CHoOH 21%
O x a z o l i n e  P r o d u c t  R  
1 1 8  
1 1 9
120
121
The low yields encountered may be explained by further reaction of the 
products. For example, compound 1 2 0  may undergo dehydration to give the 
oxazoline 122 which could feasibly react with another thiophenol molecule to 
give the amide 1 2 3  (Scheme 40). This type of mechanism was suggested by 
Wehrmeister to account for a similar type of reaction,93 although Dean-Stark 
conditions were used in that case which would promote the initial dehydration 
step.
S c h e m e  4 0
OH
HO
OH120 N=<
p - H O - A r - S H 122
° = (
V NH
1 2 3
HO OH
If further hydroxymethylated analogues are required, attempts should be 
made to enhance ring-opening and to suppress product decomposition. As this 
would be difficult to achieve through control of reaction temperature and 
duration, the use of a protecting group may be more suitable. Meyers and 
Yamamoto123 have previously prepared acetals of dihydroxylated oxazolines
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such as 119. Such a protecting group could be removed under mild conditions 
after Wehrmeister reaction with 4-hydroxythiophenol.
In almost all cases, a rigorously pure sample of each 2-oxazoline was 
employed in our Wehrmeister reactions. Although only technical grade 4- 
hydroxythiophenol is commercially available, satisfactory yields of each 
carboxamide were produced in most cases. Nonetheless, we sometimes 
avoided oxazoline isolation in cases where substrates were expensive or in 
short supply.
As an example, amide 126 was required for testing in order to examine 
the effect of introducing a cycloalkyl group into the side-chain. We envisaged 
that this could be prepared from spirocyclic oxazoline 125 by the use of a 
Wehrmeister reaction. Due to the expense of commercially available amino 
alcohol 124, it was decided to prepare the required intermediate 125 and use it 
without any purification. Accordingly, cycloleucinol 124 was treated with 
propanonitrile and cadmium diacetate dihydrate as shown in Scheme 41. The 
progress of reaction was conveniently followed using 1H NMR spectroscopy by 
monitoring the appearance of a singlet at 5 4.00 arising from the protons on C-5 
(*) of the oxazoline 125. By comparison with the singlet at 5 3.37 arising from 
the analogous protons (*) in cycloleucinoi 124, integration was used to estimate 
the extent of reaction. After three days, formation of 125 was essentially 
complete, therefore one equivalent of 4-hydroxythiophenol was added before 
the mixture was heated for a further 5 h under nitrogen. Flash chromatography 
of the crude product mixture gave the required product 126 in 47% yield 
(Scheme 41).
Scheme 41
HO
OH
NH
124
126
125
i. PrnCN, cat. Cd(OAc)2, 3 d., 120 °C.
ii. p-HO-Ar-SH, 5 h., 130 °C, N2.
As preliminary testing had revealed that phenyl esters had anti­
melanoma activity, the acetate 127 was prepared from sulfide 92 in 92% yield
-  61 -
by a published general procedure.109 We required this ester to complete a set 
of compounds for in vitro biological evaluation.
127
The results from biological evaluation of the amides containing 
hydroxylated side chains shewed that these were poor growth inhibitors of each 
cell line tested. Treatment with a 25 pM solution of the compounds in ethanol 
resuited in the low percentage growth inhibition values shown in Table 4. These 
results are likely to be due to poor lipophilicity as much as any other factor. As 
120 only contains one hydroxymethyl group, the observation that this 
compound shows better growth inhibition data than its more polar analogue 121 
would appear to corroborate this.
Table 4 25|uM 96H SRB Assay. Growth Inhibition (%)
Cell Line
Compound
120
121
B0010
2.4
0
SK-Mel-24 SK-Mel-2 G361
20.4 0 19.7 
0 0 5.5
SKOV-3
2.9
1.1
Table 5 shows how in vitro evaluation of the less polar amides revealed 
low levels of cytotoxicity when compared to the preceding round of test data 
(Table 3). In particular, the bifunctional compound 113 and the diethylated 
compound 116 were surprisingly inactive. Phenol 117 showed promising levels 
of cytotoxicity with apparent selectivity for the melanoma lines but the IC50 
values for this compound were somewhat higher than those previously 
determined for its isomer 104. Compound 126 was synthesised to examine the 
effects of introducing a bulky cycloalkyl group into the central section of side 
chain. From the data in Tables 3 and 5, it would seem that the greatest activity 
results when this type of group is placed at the amide terminus of the 
compound.
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The prodrug 127 showed some activity, but we decided that the GI50 
values were too high to warrant further study of phenyl esters as potential anti­
melanoma agents.
Table 5 Gl50 Values (pM) for 96H SRB Assay
Cell Line
Compound B0010 SK-Mel-24 SK-Mel-2 G361 SKOV-3
113 > 1 0 0 > 1 0 0 > 1 0 0 > 1 0 0 > 1 0 0
116 > 1 0 0 > 1 0 0 > 1 0 0 > 1 0 0 > 1 0 0
117 70 54 52 44 91
126 n.d. > 1 0 0 62 96 > 1 0 0
127 > 1 0 0 57 72 40 > 1 0 0
n.d. = not determined
We believed that the wide spectrum of results obtained might have 
resulted from a combination of lipophilicity variations and the ability to act as 
substrates for Tyrosinase. Therefore, in order to gain further information we 
wished to determine whether these new compounds were substrates for the 
enzyme Tyrosinase. It was reasoned that selectivity for melanoma cell lines 
would be enhanced if good activity towards this enzyme was obtained. 
Therefore to investigate this, an established assay124 was employed to 
measure metabolism of the substituted phenols by commercially available 
mushroom Tyrosinase. It was envisaged that this would give a guide to 
corresponding activities towards human Tyrosinase, which is not readly 
available from suppliers. The rates of ortho-quinone formation were determined 
by UV spectroscopy and calculated as a percentage relative to that obtained for 
L-tyrosine. Observed activities for a representative selection of compounds are 
shown in Table 6 . Interestingly, the activity of compounds towards Tyrosinase 
appears to bear no correlation to their ability to inhibit cell growth. Compound 
109, for example, is a potent inhibitor of cell proliferation yet its activity towards 
mushroom Tyrosinase is very low. Conversely, phenol 119 is a good substrate 
for Tyrosinase but shows little toxicity to cells in vitro. As discussed earlier, the 
poor lipophilicity of compounds such as 119 may account for their poor 
biological activity.
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Table 6 Tyrosinase Activ ity Data
Compound Side Chain Structure % Relative A ctiv ity
100Tyr
NH
A r-S 10.5115
A r-S .47 9.7
OH OH
A r-S .119 5.6
A r-S .114 4.6
A r-S .
A r-S .109 < 0.2
From the results of the Tyrosinase assays we concluded that the growth- 
inhibiting properties of compounds such as 109 may be due to increased non- 
Tyrosinase mediated toxicity. Compounds containing a dimethyl group in the 
side-chain seemed to exhibit the lowest Tyrosinase activities and often high 
levels of indiscriminate cytotoxicity; therefore it was decided to exclude that 
structural feature from the following round of analogues.
4.5 Variations to the Amide Alkyl Group
In an attempt to increase Tyrosinase activity and explore the role of 
lipophilicity in this class of drug, we planned a series of compounds which
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would vary only in the structure of the amide alkyl group. In this way, lipophilic 
analogues of 47 could be prepared that might also show good activity towards 
Tyrosinase. To achieve this, a series of 2-oxazolines was required that would 
possess no substituents at the 4- or 5-positions of the ring. Early attempts at 
preparing these compounds using the boric acid catalysed conditions of Barton 
et a/.111 resulted in isolation of the intermediate amido alcohol, as exemplified 
by the formation of 128 rather than the desired oxazoline 129 (Scheme 42).
Scheme 42
C 0 2H NH2(CH2)2OH
cat. B(OH)3 
xylene
refl. 3 d.
128 129
Poindexter125 prepared 2-cyclohexyl-2-oxazoline 120 by a 3-step 
procedure involving initial formation of amido alcohol 128. He reported that 
treatment of this alcohol with thionyl chloride gave the corresponding alkyl 
chloride which could be cyclised using aqueous sodium hydroxide. However, for 
convenience it was decided to prepare 129 and several other 2-oxazolines ISO- 
134 from their corresponding nitriles by the general procedure of Witte and 
Seeliger117 (Scheme 43).
S chem e 43
R-CN N
— ► r  v rH2N OH cat. Cd(OAc)2 L  /
130°C 3d. U
Product R Yield
130 Et 65%
131 p ri 67%
132 Prn 50%
133 Bun 65%
134 Bu* 43%
129 cyclo-C6Hu 43%
Our characterisation data for oxazolines 129-134 accorded well with 
th o se  reported in the literature.117T25-131 anc| additional new data are provided
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in section 7.2.2. The new 13C NMR spectral data for these compounds and 2- 
methyl-2-oxazoline 135132 are presented in Table 7.
Table 7 13C NMR Spectroscopy of 2-Oxazolines
135 130 131 132
5 6
133 134 129
13C NMR Chemical Shifts (5)
Carbon Number
1 2 3 4 5 6 7
135 53.8 66.5 164.4 12.8
130 54.1 67.0 169.3 21.1 10.0
131 54.1 67.0 172.4 27.9 19.5
132 54.1 66.7 168.0 29.5 19.1 13.4
133 54.1 66.8 168.4 27.8 27.4 22.1 13.5
134 54.0 67.2 174.3 63.4 27.5
129 54.0 66.8 171.5 37.2 29.7 25.5 25.7
The Table shows that the chemical shifts of the two ring methylene 
groups are essentially unaffected by changes to the 2-alkyl substituent. 
Conversely, the resonant frequency of the imidate carbon is highly diagnostic 
and conveys valuable information. Due to inductive effects, a methyl or 
methylene group at the 2-position results in shifts of less than 5 170 for the 
imidate carbon and if a quaternary carbon is adjacent to the ring then the value 
is generally around 5 175. Intermediate values of approximately 5 172 result 
when a methine carbon is located at the same position.
The six oxazolines 129-134 were smoothly converted into the required 
sulfides 136-141 by treatment with 4-hydroxythiophenol (Scheme 44).
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Scheme 44
Oxazoline Product R Yield
130 136 Et 87%
131 137 p ri 72%
132 138 Prn 79%
133 139 Bun 74%
134 140 Bu1 64%
129 141 cyclo-CgH^ 81%
The novel sulfides 136-141 all gave the expected analytical and 
spectroscopic data. 1H NMR spectroscopy of the products at ~1 mol dm '3 
concentration in D6-DMSO revealed chemical shifts of about 5 9.9 for their 
phenolic protons thus indicating strong hydrogen bonding. Spin-spin coupling 
between the amide proton and the methylene protons of the adjacent carbon 
was also evident.
Salient features of the solid state IR spectra of the products were the 
strong amide I absorption at -1640 c n r1 and the slightly weaker amide II band 
at -1562 cm*1. The characteristic bands at -1600 cm-1, -1580 cm '1 and -1500 
cm-1, indicative of an aromatic system, were also identified. A weaker band at 
-820 c n r1 was assigned to the C-H out-of-plane deformation of protons in the 
para-disubstituted aromatic system.
The El mass spectra of these compounds show a relatively strong 
molecular ion peak and a base peak at m/z 152. The lack of any peaks between 
these two may reflect a propensity of these compounds to undergo McLafferty 
rearrangement resulting in cleavage between the amide nitrogen atom and the 
adjacent methylene group.
We were also interested in extending the series of compounds to include 
the formamide derivative 143. As before, this might be prepared by a 
Wehrmeister reaction of 4-hydroxythiophenol with 2-oxazoline 142 (Scheme 
45).
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Scheme 45
OHOH
T
SH
142
143
2-Oxazoline 142 is not commercially available but a 3-step procedure for 
its synthesis has been reported by Smith and Atigadda.133 As this would involve 
a total of four steps to prepare 143, we decided to explore a more convenient 
approach using the previously prepared amine 42 (section 3.3). Treatment of 42 
with a refluxing mixture of excess ethyl formate provided the required amide in 
64% yield after flash chromatography. As 42 is almost insoluble in ethyl 
formate, a small quantity of ethanol was added to the reaction mixture to aid 
dissolution (Scheme 46).
Scheme 46
OH OH
NH
42 143
i. HC 02Et, EtOH, 14 h, refl.
The structure of product 143 was confirmed by 1H NMR spectroscopy 
with the resonance at 5 8.06 being assigned to the formamide C-H proton. Its 
13C NMR spectrum in De-DMSO revealed a doubling of the amide quaternary 
carbon peak due to geometric isomerism, a phenomenon that was not apparent 
with the other analogues in the set. The possibility that this additional peak was 
caused by formylation of the phenol was ruled out on the basis of IR 
spectroscopy, UV spectroscopy, mass spectrometry and combustion analysis 
data.
In order to complete our desired set of compounds, we required a 
sample of the substituted benzamide 145. We initially considered preparing this
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by the Wehrmeister reaction; however the reaction of 4-hydroxythiophenol with 
2-aryl-2-oxazolines is reported to proceed in low yield under the forcing 
conditions required.134 This is possibly due to nucieophilic addition being 
hampered by delocalisation of the intermediate oxazolinium cation 144.
As an alternative, we prepared 146 in 51% yield over 2 steps from amine 
42. Standard Schotten-Baumann conditions135 were employed to generate 145 
in good yield before selective cleavage of the ester using butylamine.136 The 
second step was carried out according to the procedure of Bell,136 although the 
suggested solvent of benzene was replaced by THF. This method of ester 
deprotection under mild conditions is believed to be selective for phenolic 
esters. Its main disadvantage is the generation of a moiar equivalent of N- 
butylbenzamide as a by-product.
S c h e m e  47
OH
NH
42 145 146
i. B z C I ,  a q .  N a O H ,  5 min, r.t.
ii. B u n N H 2 , THF, 20 h, r.t.
Compound 146 gave the expected spectroscopic properties, and thus 
completed our desired set of 8 simple analogues of 47. In order to measure 
their lipophilicity, we now required the evaluation of their partition coefficients. 
This could allow us to highlight compounds which show increased activity due 
to factors other than lipid solubility. Naish-Byfield et al. employed hexadecane 
and pH 7.4 Phosphate Buffered Saline (PBS) as the two phases in their 
evaluation of the lipophilicity of a range of phenols.65 However, this system 
proved to be unsuitable for 47 and its analogues due to virtual insolubility in the
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non-polar phase. We found that more informative log P values could be 
obtained by the use of 1-octanol and PBS. Electronic spectroscopy was used to 
determine the relative concentrations of each phenol in the PBS layer before 
and after extraction by 1-octanol. The UV spectra of these compounds is 
typified by the spectrum of parent compound 47 in ethanol (Figure 7). The 
presence of para-disubstituted non-complementary auxochromes account for 
the absorption maxima at 228 nm (£9000) and 255 nm (e7300) from the 
benzene ring.
Figure 7
1 . 7 3 0  ,T ■ • ■
1 . 500
Abs.
1 . 0 0 0
0. 500i
190 . 0
Wavelength (nm)
The absorbance of the peak at -228 nm was used in the measurement 
of the partition coefficients P for compounds 47, 136-141, 143 and 146 (Table
8).
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Table 8 1-Octanol: PBS Partition Coefficients
Compound R P log P
143 H 3.96 0.60
47 Me 2.03 0.31
136 Et 1.99 0.30
137 p ri 5.63 0.75
138 Prn 3.60 0.56
139 Bun 3.02 0.48
140 Bu* 7.85 0.89
141 cyclo- CgH^ 7.18 0.86
146 Ph 13.47 1.13
Apart from the unexpectedly high log P value for formamide derivative 
143, the results broadly confirm that increasing the size of the alkyl group leads 
to greater lipophilicity. We were therefore keen to establish whether the in vitro 
growth inhibition data followed a similar trend. As before, the compounds were 
dissolved in ethanol and treated with a panel of human melanoma cell lines and 
the ovarian carcinoma line SKOV-3. The results, expressed as GI50 (pmol), are 
shown in Table 9.
Table 9 Gl50 Values (nM) for 96H SRB Assay
Cell Line
Cmpd B008 B0010 G361 HT144 SK-Mel-2 SK-Mel-■24 SKOV
143 >100 >100 >100 >100 >100 >100 >100
47 >100 >100 >100 >100 >100 >100 >100
136 >100 >100 >100 >100 >100 >100 >100
137 >100 >100 >100 >100 >100 >100 >100
138 82 >100 >100 >100 >100 >100 >100
139 47 >100 >100 >100 84 >100 >100
140 67 >100 >100 >100 >100 >100 >100
141 29 >100 77 >100 61 >100 >100
146 >100 >100 >100 52 >100 >100 >100
145 90 >100 >100 >100 76 >100 >100
These analogues obviously cause com paratively low levels of 
cytotoxicity to the cell types examined. However, certain compounds do show
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significantly higher activity than the lead compound 47. This is illustrated by 
comparing the percentage growth inhibition data of 47 with those of /7-butyl- 
substituted amide 139 and cyclohexyl-substituted amide 141 (Table 10).
Table 10 25|iM 96H SRB Assay. Growth Inhibition (%)
Cell Line
Cmpd B008 B0010 G361 HT144 SK-Mel-2 SK-Mel-24 SKOV-3
47 3.14 4.1 0.35 0 6.3 0 0
139 22.4 4.1 10.7 6.4 9.1 0.9 0.2
141 45.6 15.9 19.3 10.6 24.3 1.3 0.4
Not only does 141 have far greater activity than 47, it shows promising 
selectivity over the non-melanoma control (SKOV-3) too. In addition, good 
selectivity for Tyrosinase-containing cells is actually corroborated by the poor 
activity observed towards the SK-Mel-24 melanoma line. This cell type is non- 
melanotic and therefore does not contain the required biochemical machinery to 
generate o/tfro-quinones from these phenolic prodrugs.
Although some of the compounds discussed in section 3.4 showed 
greater cytotoxicity than 141, they showed little selectivity. Therefore 141 may 
be a suitable compromise that exhibits moderate activity together with greater 
selectivity for melanoma. Furthermore, the solubility of 141 in saline up to 100 
mM is an added advantage.
4.6 Extension of the Side-Chain
A two-atom linkage between sulfur and nitrogen atoms has been a 
feature of all the analogues previously discussed. In order to broaden our 
investigation, it was decided to prepare a series of compounds with a three- 
carbon linking unit for comparison. We postulated that the extended chain 
would further enhance lipophilicity and might also lead to better Tyrosinase 
activity by further separating the bulky amide group from the aromatic moiety. 
To this end, three 5,6-dihydro-oxazines 147-149 were highlighted as potential 
substrates for Wehrmeister reaction with 4-hydroxythiophenol. Compounds 147 
and 148 were prepared from acetonitrile and cyclohexanecarbonitrile, 
respectively, by the procedure of Witte and Seeliger117 (Scheme 48). Owing to 
its widespread use in the Meyers aldehyde synthesis,136-137 dihydro-oxazine 
149 is commercially available.
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Scheme 48
/ V  R-CN r ^ i  \  ^
I 1 -------------- *■ N ^. O
NH2 OH cat. Cd(OAc) 2 J  T  T
Product R Time Yield R
147 Me 2 d 59% 1 4 9
148 cyc/o-C6H-,i 4 d  32%
Our spectroscopic data for 5,6-dihydro-2-methyl-4H-1,3-oxazine 147 
corresponded well with those described by Toshimitsu et a/.138 Similar data 
were acquired for the hitherto unknown dihydro-oxazine 148. Its IR spectrum 
revealed a strong absorption at 1671 cm '1 due to C=N stretching. As this value 
is very close to the C=N stretching frequency in analogous 2-oxazolines, this 
technique cannot be satisfactorily used to differentiate dihydro-oxazines from 2- 
oxazoiines. In our experience, 13C NMR spectroscopy is more informative as 
the chemical shift of the imidate carbon resonance of 2-oxazolines is typically 
ca. 8 ppm greater than that of corresponding 5,6-dihydro-4H-1,3-oxazines.
Treatment of compounds 147-149 with 4-hydroxythiophenol under the 
standard conditions afforded the required novel sulfides 150-152 (Scheme 49).
Scheme 49
Substrate Product R1 R2 R3 R4 Yield
147 150 Me H H H 63%
148 151 cyclo-C6Hu H H H 58%
149 152 Me Me Me Me 75%
All three new products 150-152 were fully characterised and gave the 
expected analytical data. The presence of a stereogenic centre in the side- 
chain of 152 was clearly evident from its 1H NMR NMR spectrum. This revealed 
complex multiplicity due to the diastereotopic nature of the protons in the
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methylene group and separate singlets for the two methyl substituents on the 
carbon atom adjacent to its amide nitrogen atom.
Table 11 shows the results from the in vitro screening of phenols ISO- 
152 in terms of G I5 0  values (|iM).
Table 9 Gl50 Values (|iM) for 96H SRB Assay
Cell Line
Cmpd B008 B0010 G361 HT144 SK-Mel-2 SK-Mel-24 SKOV-3
150 60 >100 >100 >100 >100 >100 >100
151 5.3 34.5 11 70 11 >100 54
152 48 >100 90 >100 >100 >100 >100
The GI50  values for 150 and 152 show that the introduction of methyl 
groups to an extended side-chain appears to cause no significant changes in 
biological activity. However, compound 151 shows good activity towards all of 
the Tyrosinase-containing melanoma lines in addition to low toxicity towards the 
non-melanotic SK-Mel-24 melanoma cell type. Its moderate toxicity towards the 
ovarian carcinoma SKOV-3 line is rather disappointing. The increased activity of 
151 over the other compounds may be largely due to greater lipophilicity.
4.7 Further Biological Evaluation
The in vitro screening discussed in this chapter was performed at the 
Institute of Cancer Research by Dr L.R. Kelland and co-workers. These data 
enabled us to highlight compounds which warranted further investigation both in 
vitro and in vivo. As an example, the data in Table 3 showed that compound 
104 was highly cytotoxic towards the cell lines examined, exhibiting GI50 values 
as low as 15 mM. Further testing was required to give more information about 
the selectivity of this phenol at various concentrations. Professor R.M. MacKie 
kindly agreed to undergo these in vitro experiments, and the results for phenol 
104 are illustrated in Figure 8. The effects of the drug at six concentrations from 
10 '1° M to 10-5 M were measured against four cell types: B008 (melanoma), 
C8161 (melanoma), SK-Mel-23 (highly pigmented melanoma) and human 
fibroblasts (non-cancer).
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Figure 8 Further Evaluation of Compound 104
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For these assays, it is the change in cell number rather than the actual 
cell number that is important when comparing the graphs. We were particularly 
interested in the effects of 104 on the heavily pigmented SK-Mel-23 line, as this 
contains high levels of Tyrosinase and would therefore be expected to be 
particularly susceptible to these compounds. However, the data suggest that 
this cell line is actually more resistant to 104 than the other two melanoma lines. 
More importantly, high toxicity towards the non-tumour fibroblasts is observed 
at the micromolar concentrations required to kill melanoma cells. Therefore, we 
conclude from the combined in vitro experiments that there is a non-selective
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action associated with phenol 104, which may operate together with a 
Tyrosinase-mediated response.
Preliminary in vivo studies with 104 were carried out at the laboratories 
of Ares-Serono in Italy. Male mice were injected intraperitoneally with 245 (ig/kg 
of 104 in a mixed vehicle of water, ethanol and propylene glycol. This dose was 
selected to give approximate maximal drug concentrations of twenty times the 
active concentration in vitro (20 j l l M ) .  Major acute toxicity was observed together 
with undesired toxic effects towards the white blood cells. Further studies are 
needed to ascertain whether these effects are caused by a primary toxicity of 
phenols or by a mode of action specific to structures such as 104.
Initial screening of compounds such as 141 indicate that they are more 
selective than 104 towards melanoma cell lines. In order to confirm this 
observation, comprehensive in vitro assays are underway at the U.S. National 
Cancer Institute.
A concurrent study was aimed at determining the importance of the 
amide group present in 47 and its analogues. The results from this work are 
discussed in the following chapter.
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5
Amide Group Replacements
5.1 Introduction
The conclusion that the non-selective toxicity of 42 was due to oxidation 
by monoamine oxidase led to the synthesis and evaluation of the substituted 
acetamide 47 by Alena and co-workers.78 As hydrolysis of the amide group in 
47 is not essential for anti-melanoma activity, we wished to investigate the 
biological properties of analogues containing other groups at this position. A 
further aim was to determine whether inversion of the amide geometry would 
give rise to any changes in biological activity.
Our interest in isosteric replacements for the amide group in 47 stemmed 
from investigations into the reactivity of thiophenols towards 2-alkenyl-2- 
oxazolines, as discussed in the following section.
5.2 Wehrmeister Reaction - Further Studies
5.2.1 2-Alkenyl-2-oxazolines
In an attempt to prepare the olefinic 2-oxazoline 153 we heated allyl 
cyanide with 2-amino-2-methyl-1 -propanol and a catalytic quantity of cadmium 
diacetate, as shown in Scheme 50. Although fractional distillation of the viscous 
product mixture did not result in isolation of the desired product 153, a 26% 
yield of the isomeric oxazoline 154 was obtained.
Scheme 50
OH
CN 26%
154153
i. Cd(OAc)2 (cat.), neat, 130 °C, 2 d
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Our 1H NMR and IR spectroscopic data for 154 were in accordance with 
those reported by Alvhall ef a/.115They synthesised 154 in 44% yield by cyclo- 
condensation of A/-2-butenoyl-2-amino-2-methyl-1-propanol with thionyl 
chloride. Recently, Dahuront and Langlois reported an 88% yield of 154 through 
the use of phosphorus oxychloride as the dehydrating agent.139
The thermal isomerisation of [3y-unsaturated 2-alkenyl-2-oxazolines into 
a[3-unsaturated analogues was also discussed in the paper by Alvhall et a/.115 
They reported that (3y-unsaturated 2-alkenyl-2-oxazolines could not be purified 
by chromatography or distillation due to extensive decomposition. Moreover, 
they concluded that 2-alkenyl-2-oxazolines in general could not be satisfactorily 
prepared at elevated temperatures due to their propensity to undergo 
polymerisation. The high reactivity of ocp-unsaturated 2-alkenyl-2-oxazolines 
was recently exploited by Elliott and Kruiswijk in their stereocontrolled 
syntheses of substituted piperidines by aza-Diels-Alder reactions.140
We decided to use our sample of 154 to further our study of the 
Wehrmeister reaction. Due to the ambident nature of the oxazoline, we 
envisaged that treatment of 154 with 4-hydroxythiophenol could potentially lead 
to two different products. Conjugate addition to the alkene would yield oxazoline 
155 whereas nucleophiiic ring-opening would give rise to the amide 156 
(Scheme 51).
Scheme 51 OH
155
OH
154
156
Treatment of 154 with one equivalent of 4-hydroxythiophenol for 2 h at 
120 °C gave oxazoline 155 in 70% yield after chromatography (Scheme 52).
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The presence of the stereogenic centre in the product was confirmed by the 
non-identicai nature of the oxazoline methyl carbon atoms, as revealed by 
DEPT-edited 13C NMR spectroscopy. The solid state IR spectrum of 155 was 
dominated by a strong absorption at 1654 cm-1, likely to arise from oxazoline 
C=N stretching.
In order to determine whether 155 would be reactive towards an 
additional equivalent of thiophenol, oxazoline 154 was treated with two 
equivalents of 4-hydroxythiophenol. The amide product 157 was obtained in 
66% yield, presumably by Wehrmeister reaction of the intermediate product 155
(Scheme 52).
Scheme 52 OH
154 155
OH
OH
157
i. p-HO-Ar-SH (1 equiv.), neat, 120 °C, 2 h
ii. p-HO-Ar-SH (2 equiv.), neat, 120 °C, 2 h
These experiments illustrate the strong chemoselectivity of thiophenols 
towards Michael-type addition in preference to nucleophilic ring-opening. This is 
likely to be due to the more favourable energy stabilisation that is associated 
with such soft acid - soft base interactions.
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5.2.2 B io logical Evaluation
The in vitro biological screening of compounds 155 and 157 revealed 
high levels of cytotoxicity against every cell line tested (Table 10).
Table 10 G l50 Values (pM) for 96H SRB Assay
Cell Line
Cmpd B008 B0010 G361 HT144 SK-Mel-2 SK-Mel-24 SKOV-3
155 n.d. 7.2 12 n.d. 9.6 n.d. 21
157 3.2 18 7.7 13 17 20 31
n.d. = not determined
Although no evidence of selectivity for melanoma cells was obtained 
from our initial studies, we were prompted to evaluate 155 more 
comprehensively on the basis of its interesting structure and high toxicity. The 
effects of 155 against the highly pigmented SK-Mel-23 human melanoma line 
and the murine B16F1M2 and B16BL6 melanoma lines were measured by 
Professor R.M. MacKie. The cells were cultured for 4 days in the presence of 
six concentrations of 155 before harvesting and determination of total cell 
number. The variation in cell number for the three cell types at the six 
concentrations is illustrated in Figure 9.
Figure 9 Further Evaluation of Compound 155
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These data show that compound 155 causes no significant toxicity 
towards the three cell lines at sub-micromolar concentrations. In particular, 
cytotoxicity appears to be Tyrosinase-independent as the highly pigmented SK- 
Mel-23 line is no more susceptible to the drug than the other lines. This result 
corroborated the poor selectivity observed in our initial in vitro testing and 
prompted us to evaluate analogues of 47 containing other amide replacements. 
We initially focused on the synthesis of thioamides in order to increase 
lipophilicity without severely affecting molecular shape.
5.3 Thioamides
5.3.1 Synthesis of Thioamides
The classical method of preparing thioamides involves the thionation of 
carboxamides with phosphorus pentasulfide. However, the application of this 
procedure is often hampered by incompatibility with functional groups and an 
inability to suppress the decomposition of the products into nitriles and 
hydrogen sulfide.141 Although P4S10 is still frequently employed in the synthesis 
of thioamide-containing heterocycles, it has been superseded by Lawesson 
reagent 158 in most other thionation reactions.142
MeO OMe
158
We initially attempted to prepare thioamides such as 159 by treating 
thiophenol with 2-methyl-2-thiazoline (Scheme 53). No product formation was 
detected by the use of standard W ehrmeister reaction experimental 
conditions,92 even with extended heating times.
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Scheme 53
SH
158
159
From such simple experiments, it is not possible to conclude that 2- 
thiazolines do not react with thiophenols per se, but we can infer that reactivity 
is far lower than with 2-oxazolines. This difference can be rationalised on 
thermodynamic grounds by considering the bond-breaking and bond-forming 
processes that are involved. In both cases, formation of a new double bond is 
followed by cleavage of a carbon-nitrogen double bond and the feasibility of the 
process will be governed by the relative stability of the oxazolinium or 
thiazolimum anionic intermediate relative to the ring-opened product. Reactivity 
of 2-oxazolines with thiophenols involves cleavage of an imidate functionality to 
yield a stable amide product containing a resonance-stabilised p7i-p7t bonded 
carbonyl group. In contrast, with thiazolines a carbon-nitrogen double bond 
would have to be sacrificed in order to gain a relatively unstable pn-dju bonded 
carbon-sulfur double bond. This higher thermodynamic stability of multiple 
bonds between first row elements relative to those between first and second 
row elements is sometimes useful in synthesis. One example is the 
isomerisation of thionocarbamates which is usually effected thermally at 
temperatures of 200 °C or above or alternatively by microwave irradiation. 
Recently, Villemin et at. prepared thiophenols by hydrolysis of products such as 
161, obtained by isomerisation of thionocarbamate 160 (Scheme 54).U3
Scheme 54
Microwave Irradiation
10 min
161160
Scheibye et at. have studied the Lawesson reagent-mediated thionation 
of amides which also contain a phenol group.144 They reported that orly low to 
moderate yields of the corresponding thioamide were obtained by heating the
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substrates with 0.5 equivalents in HMPA. The low yields were attributed to a 
side-reaction between the phenol functional group and Lawesson Reagent, 
although the use of HMPA is thought to suppress this side-reaction by 
coordinating to the phenol. The ability of HMPA to form complexes with amino- 
and hydroxy-aromatics is well known.145
In analogy to the Wittig reaction, the driving force for these thionation 
reactions is the formation of strong phosphorus-oxygen bonds. Furthermore, it 
is thought that the active substrate is not actually Lawesson Reagent 158 itself, 
but a highly reactive dithiophosphine ylid 162. Such dipolar species have been 
detected by 31P NMR spectroscopy in solutions of Lawesson Reagent.146 The 
mechanism proposed by Lawesson and co-workers also involves the Wittig- 
type intermediate 163, as shown in Scheme 55.147
Scheme 55
MeO OMe
158
2 MeO
s o
162
MeO
MeO ►
163
We used the conditions described by Scheibye et a/.144 to prepare 164 
from the amide 92 in 31% yield (Scheme 56). Despite the poor yield of 164, it 
was readily separated from side-products by column chromatography due to its 
low polarity. Although the yield may have been improved by the use of a 
protective group for the phenol, we wished to find an alternative method of 
thionation to preclude use of the highly toxic HMPA solvent.
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Taylor et a/.148 recently reported a procedure for the preparation of 
thioamides from carboxamides using Lawesson reagent in DME at room 
temperature. We were therefore keen to establish whether these milder and 
less hazardous conditions could be applied to substrates containing a phenol 
group. To this end, a 58% yield of 165 was obtained by stirring 47 with 0.5 
equivalents of Lawesson Reagent, in accordance with the published 
conditions148 (Scheme 56).
On the basis of these two experiments it is not possible to conclude that 
DME is intrinsically a better solvent for these thionation reactions as different 
substrates and reaction temperatures were employed. The better yield obtained 
in the preparation of 165 may have been due the lower temperature enhancing 
the chemoselectivity of Lawesson reagent towards the amide group versus the 
phenol group. Another possibility is that DME coordinatively protects the phenol 
group more satisfactorily than HMPA.
Scheme 56
OH OH
Lawesson
Reagent,
HMPA
2 h, 100 °C 
31%
92 164
OH OH
Lawesson
Reagent,
DME
47 165
The IR spectra of 164 and 165 show, inter alia, absorption peaks at 
-1540 cm4 and -1270 cm '1. These are characteristic of thioamides and arise 
from the N-H bend and C=S stretching modes. Whilst the N-H bend (-1540 cnr 
1) is at a similar frequency to that recorded for analogous carboxamides, the 
thiocarbonyl stretching frequency (-1270 cm4 ) is considerably lower than the 
frequency of the amide I absorption in the parent carboxamides (1640 cm4 ). 
This difference can be explained by the relatively weak nature of the
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thiocarbonyl bond relative to the strongly p7t-p7i; bonded carbonyl group of the 
carboxamides.
Another major spectroscopic disparity between the thioamides and their 
parent amides is the chemical shift of the carbon atom in the (thio)carbonyl 
group, as revealed by 13C NMR spectroscopy. Due to poor orbital overlap, the 
7t-bonding electrons in thioamides groups are not as delocalised as those of 
amides, which causes deshielding of the thioamide sp2-hybridised carbon atom. 
This results in a 13C NMR chemical shift of ~5 200, some 30 ppm higher than 
that of the corresponding amide.
5.3.2 Biological Evaluation
GI50  values from the screening of thioamides 164 and 165 against the 
usual panel of cell lines are shown in Table 11. The results show that 164, 
which contains a branched side-chain, is considerably more cytotoxic than its 
parent amide. From the data obtained, it is not possible to conclude whether 
165 is a better cell growth inhibitor than its precursor 47.
Table 11 Gl50 Values (|iM) for 96H SRB Assay
Cell Line
Cmpd B008 B0010 G361 HT144 SK-Mel-2 SK-Mel-24 SKOV-3
92 29 >100 52 95 >100 79 >100
164 7.2 44 16.5 33.5 >100 22 67
47 n.d. >100 >100 n.d. >100 >100 >100
165 48 >100 >100 >100 >100 >100 >100
n.d. = not determined
Although 164 is clearly a very toxic compound, its effects are not 
significantly selective for the melanoma cell lines. Moreover, a high level of 
growth inhibition was measured against the melanoma line SK-Mel-24 which 
does not use Tyrosinase. Therefore, it is likely that the increased activity is 
simply due to the greater lipophilicity of the thioamide functional group. In order 
to quantify this increased lipid-solubility, we determined the 1-octanol:water 
partition coefficients of 164 and 165 and compared these with the value for 92 
(Table 12).
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Table 12 1-Octanol: Water Partition Coefficients
Compound P log P
\ /  °
92 A r ^ ^ X N A CH3
H
2.76 0.44
164 A r - ^ ^ X NX CH3
H
8.54 0.93
S
165
N CH3 
H
A 3.55 0.55
These data show that 165 is apparently more lipophilic than 92, yet its 
GI50 values are higher. This may indicate that the high toxicity of compounds 
with two methyl groups in the side-chain is due to factors other than greater lipid 
solubility. As discussed in Section 4.5, the cause of non-selectivity may arise 
due to low activity towards Tyrosinase.
An important feature of drugs with high lipophilicity is their poor solubility 
in saline. In contrast to amides such as 47 which are soluble in saline to 
concentrations of 100 (iM, the thioamides 164 and 165 are virtually insoluble. 
As the administration of such non-polar compounds would inevitably be 
problematic, we decided not to prepare any further thioamides for testing.
In the lead compound 47 and its analogues, the side-chain can rotate 
freely around the sulfide bridging group. As binding to the target enzyme 
Tyrosinase will require the adoption of a specific conformation, a drug that is 
locked in this conformation could be expected to exhibit higher activity. In order 
to prepare analogues of 47 with fewer degrees of freedom, several bicyclic 
compounds were prepared.
5.4.1 Derivatives of 1.5-benzothiazepin-5(4H)-one
2,3-Dihydro-7-hydroxy-2-methyl-1,5-benzothiazepin-5(4/-/)-one 166 and 
the isomeric system 167 were chosen as initial synthetic targets as they 
incorporate the structural features of 47 into a more rigid framework. A methyl 
group was included as, at the time, it was thought that cytotoxicity was 
increased by the presence of this group (see section 5.2.2).
5.4 Constriction of Conformation
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HOHO NH
166 167
The main literature synthetic routes to these heterocyclic systems are 
illustrated in Scheme 57 and include the following reaction types.
• Amide bond-forming cyclocondensation reactions.149-150
• Beckmann rearrangement of thiochroman-4-one oximes.151
• Schmidt reactions of thiochroman-4-ones.152
Scheme 57
NHCOoEt
COoMeNH
Cyclo-condensation
NH
Beckmann
Schmidt OH
As we needed to incorporate phenol and methyl groups, a ring- 
expansion reaction seemed to be the most convenient approach. We started by 
attempting to prepare the novel carboxylic acid 168 by a nucleophilic ring- 
opening of p-butyrolactone with 4-hydroxythiophenol. Initially we used sodium 
hydroxide as base, according to the literature procedure of Griesbeck and
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Seebach.153 Several products were detected by TLC, possibly due to side- 
reactions from deprotonation of the phenol in addition to the thiophenol. An 
alternative method by Clayton et a!,154 uses sodium hydride and would 
therefore be expected to be similarly non-selective.
In order to enhance selectivity, we modified the procedure of Griesbeck 
and Seebach153 by replacing sodium hydroxide with sodium carbonate and this 
furnished a 71% yield of 168 after recrystallisation (Scheme 58). The product 
gave the expected spectroscopic and analytical data, and was identical to a 
sample prepared by acid hydrolysis of 155 (Section 5.2).
Using the procedure of Robillard et a/.,155 compound 168 was smoothly 
converted into the novel thiochroman-4-one 169 by brief treatment with 
concentrated sulfuric acid (Scheme 58). This Friedel-Crafts cyclisation reaction 
gave 169 as a yellow powder in 64% yield.
Scheme 58
OHOHOH
64%NaHC03 
aq. IPA
73%
SH
168 169
The yellow coloration of 169 is a consequence of an absorption 
maximum at 381 nm (e2600), as determined by UV-visible spectroscopy. This 
arises due to the n-^7t* transition of the carbonyl group being shifted towards 
the visible region by the sulfide and phenol substituents of the benzene ring. 
The presence of the ketone group in 169 was confirmed by solid state IR 
spectroscopy which revealed an absorption band at 1662 cm-1, likely to arise 
from C =0 stretching. This compares to the analogous band at 1714 cm '1 for 
the carboxylic acid precursor 168.
Compound 169 was converted into the novel oxime 170 by treatment 
with hydroxylamine hydrochloride under standard conditions156 (Scheme 59). 
The product was isolated as a fawn powder and was found to contain only one 
oxime geometric isomer by the absence of any doubling of signals in its 13C 
NMR spectrum. Literature precedent156 suggests that (£)-oximes are 
preferentially formed by thiochroman-4-one oximes, hence 170 has been 
tentatively assigned to that geometry. It was intended that the structure of the 
amide product 167 after Beckmann rearrangement of 170 would be used to
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prove its structure. However, this conversion could not be performed 
satisfactorily due to the formation of many inseparable products after treatment 
with freshly prepared polyphosphoric acid (Scheme 59).
Scheme 59
OH OH OH
n h 2o h
NaOAc
EtOH
PPA
NH
ref I., 3 h 
79%
169 170 167
Concentrated sulfuric acid was similarly unsatisfactory in effecting the 
Beckmann rearrangement, therefore an alternative strategy was sought. As it 
seemed likely that the phenol group of 170 was causing side reactions, we 
initially considered protecting this group prior to the Beckmann rearrangement. 
However, as 170 and its regioisomer were required, we envisaged that a 
Schmidt reaction of thiochromanone 169 would effectively furnish both of these 
compounds in one reaction. When applied to ketones, this reaction uses 
hydrazoic acid to provide a method of inserting NH between the carbonyl group 
and one R group, as shown in Scheme 60.
Scheme 60
0
X  2 HN3
R1 R2
H+ O
X  -r2R1 N 
H
... ^
The mechanism166-167 is believed to proceed via initial formation of 
carbocation 171.  Nucleophilic attack by hydrazoic acid, followed by 
dehydration, migration of the R group and concomitant loss of nitrogen affords 
intermediate 172. Hydration and tautomerisation leads to the amide product, as 
shown in Scheme 61.166-167
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Scheme 61
OH HO N— N = NHN
171
js jh tautom.
t ---------
172
The migratory aptitude of the R group is obviously critical to the useful 
application of this reaction in synthesis. Generally, aliphatic ketones react more 
rapidly than those containing aromatic groups and with aryl alkyl ketones it is 
usually the aryl group that migrates to the nitrogen atom. However, the alkyl 
group is known to migrate preferentially in aryl alkyl ketones containing a bulky 
alkyl group or with cyclic aryl alkyl ketones containing electron-withdrawing 
groups in the ortho or para positions of the benzene ring.168
Due to its toxicity, hydrazoic acid is normally generated in situ by 
treatment of sodium azide with glacial acetic acid and sulfuric acid is typically 
added as a catalyst for the Schmidt reaction. Azidotrimethylsilane, in 
conjunction with trifluoroacetic acid (TFA), has also been developed as a non­
explosive azide source for the Schmidt reaction169 and this methodology was 
recently applied to thiochroman-4-ones by Kaye and Mphahele.170 They found 
that reaction of the parent system 173 led to the formation of 2,3-dihydro-1,5- 
benzothiazepin-4(5H)-one 174 in addition to the regioisomeric tetrazoles 175 
and 176 (Scheme 62).
Scheme 62
NH
=  N
176174 175173
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We applied the same conditions170 to thiochroman-4-one 169 and 
isolated the tetrazole 177 and the two regioisomeric benzothiazepinones 166 
and 167 from the product mixture by flash chromatography (Scheme 63). The 
other regioisomeric tetrazole was also formed in the reaction and co-eluted with 
177 during chromatography. However, a pure sample of the major isomer 177 
was obtained by crystallisation of the mixture.
OHScheme 63
OH
N -N
OH 177 13% OH3 d, r.t.
NH
169
NH
167 9%166 10%
The formation of tetrazoles such as 177 arises due to reaction of a late
cationic intermediate with an additional equivalent of hydrazoic acid rather than 
an equivalent of water171 (cf. Scheme 61). The product 177 was readily 
differentiated from the required products 166 and 167 by the lack of a amide 
carbonyl stretching band at -1650 cm-1 in its IR spectrum. In addition, 13C 
NMR spectroscopy (D6-DMSO) revealed that the imine-type carbon present in
177 resonated at 5 158, somewhat lower 5 than the corresponding amide 
carbon atoms present in 166 (5 171) and 167 (6 179).
The isolated tetrazole 177 was initially differentiated from its regioisomer
178  on the basis of 1H NMR spectroscopy. In the isolated product, the 
diastereotopic protons of the methylene group account for the doublet of 
doublets at 5 4.38 and the doublet of doublets at 8 4.83. According to literature 
data, chemical shifts for the analogous methylene group protons in 178 would 
be significantly (-1 ppm) lower and these were identified in the 1H NMR 
spectrum of the mixture of 177 and 178 before crystallisation.
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OH OH
N-N =  N
178177
In collaboration with McCormack,172 unequivocal proof of the structure of 
177 was provided by X-ray single crystal structural analysis which revealed that 
the compound crystallised into the monoclinic P2-|/c space group. The ORTEP 
diagrams (Figure 10) show important hydrogen bonding between the phenol 
group and a tetrazole nitrogen N(3) atom which was calculated to have a 2.09 A 
bond length and an O-H-N angle of 173.2 °.
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Figure 10 X-Ray Crystal Structure of Compound 177
N(3)
The two regioisom eric benzothiazepinones 166 and 167 were 
differentiated by 1H NMR spectroscopy, with coupling between the methylene 
group and the N-H group being used to identify 166.
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5.4.2 Biological Evaluation
The three products from the Schmidt reaction, thiochromanone 169, 
oxime 170 and the carboxylic acid 168 were all evaluated for anti-melanoma 
activity using the same cell lines and growth inhibition assay as before (Table 
13).
Table 13 Gl50 Values (jiM) for 96H SRB Assay
Cell Line
Cmpd B008 B0010 G361 HT144 SK-Mel-2 SK-Mel-24 SKOV-3
166 >100 >100 >100 >100 >100 >100 >100
167 >100 >100 88 >100 >100 >100 >100
177 >100 >100 >100 >100 >100 >100 >100
169 >100 >100 >100 >100 >100 >100 >100
170 >100 >100 72 >100 >100 >100 >100
168 >100 >100 >100 >100 >100 >100 >100
The test results for these compounds suggest that they are of very low 
toxicity and apparently have no potential in anticancer chemotherapy. However, 
due to their structural resemblance to the benzodiazepine class of anxiolytic 
drugs, the new benzothiazepinones prepared may have other biological activity. 
Therefore, it may prove useful to evaluate these compounds for effects towards 
the central nervous system.
On the basis of the low cytotoxicity of these compounds, we decided to 
examine the effects of inverting the amide group present in the lead compound 
47. The results of this work are discussed in the following section.
5.5 Inversion of the Amide Group
The anti-melanoma effects of 47 have been attributed to its structural 
similarity to tyrosine, which enables it to be oxidised by Tyrosinase to an active 
quinone drug. As regioisomeric analogues such as 179 have apparently not 
been evaluated for anti-melanoma activity, we were eager to prepare some of 
these compounds for testing.
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5.5.1 Derivatives of Phloretic Acid
It was presumed that 1 7 9  could be synthesised by amination of the 
carboxylic acid 1 8 0 ,  provided that competing reactivity by the phenol was 
minimal. In order to develop an effective preparative procedure, we decided to 
utilise the commercially available phloretic acid 1 8 1  as a model system for the 
amide-forming reactions. As 1 8 1  does not possess a sulfide group, we 
envisaged that the products formed would also be worthy of biological 
evauation on the basis of their tyrosine-like structure.
OH OH
OH
1 8 0 1 8 1
Direct aminations of 1 8 1  using DCC have been previously reported in the 
literature. For example, Herbert and Kattah treated 1 8 1  with an equivalent of 
tyramine 1 8 2  and excess DCC to afford the product 1 8 3  in 48% yield (Scheme 
64).173 However, we found that this method could not be applied to the 
synthesis of simpler analogues of phloretic acid due to rapid precipitation of the 
salt arising from protonation of the amines by the acid.
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Scheme 64
OH OHOH
D C C
C H C U - M e O H
OH
NH
1 8 1 1 8 2 1 8 3
Prompted by a preparation of the para -nitrophenyl ester of 1 8 1  by 
Williams and Salvadori,174 we implemented a one-pot procedure whereby this 
labile ester was generated in situ by DCC coupling, prior to treatment by an 
amine. This method proved to be an effective method of derivatising 1 8 1 ,  and 
was found to be amenable to the coupling of both primary and secondary 
amines.
The mechanism of the acylation of amines by esters requires two 
molecules of amine in the rate determining step, as shown in Scheme 65.175' 
177 Although this additional catalytic quantity of base is often provided by the 
use of additional amine substrate, an alternative is to use a non-nucleophilic 
base such as DBU.178 With para-nitrophenyl esters, the acidic para-nitrophenol 
by-product effectively removes one equivalent of base by salt formation. 
Therefore, in that case the reaction is base-promoted rather than base- 
catalysed and means that two full equivalents of amine are required, of which 
one equivalent may be provided by DBU.
Scheme 65
OR 1 ? R 
*- R1—C -N H R
slow
R — C N -H
R —C~NHR OR
Our one-pot procedure involved the initial treatment of 1 8 1  with para- 
nitrophenol and DCC in ethyl acetate solution. After stirring the mixture for 1 h 
at room temperature or 0 °C, the amine and DBU were added before stirring for
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a further 14 h at room temperature. The required novel products 1 8 4 - 1 8 7  were 
isolated in yields of 39-65% after work-up and flash chromatography (Scheme
66).
Scheme 66
OH
i.,
.c o 2h
OH
\ ^ C 0 2H
i. D C C ,  p - H 0 - A r - N 0 2, E t O A c ,  1 h, 0 °C
ii. N H 2 R , D B U ,  14 h, r.t.
OH
i., ii.
O
P r o d u c t  R  Y i e l d
1 8 4  Me 49%
1 8 5  Prn 43%
NHR
i. D C C ,  p - H 0 - A r - N 0 2, E t O A c ,  1 h, r.t./ 0 °C.
ii. P i p e r i d i n e / M o r p h o l i n e ,  D B U ,  14 h, r.t.
P r o d u c t  X  Y i e l d
1 8 6  CH2 65%
1 8 7  O 39%
All four products gave the expected analytical and spectroscopic data. 
For the tertiary amides, complex 1H and 13C NMR spectra were recorded due 
to the lack of rotation about the amide carbon-nitrogen bond which results in 
chemical (and magnetic) inequivalence between the ring methylene group 
protons of 1 8 6  and 1 8 7 .
5.5.2 Sulfide-containing analogues
Although only moderate yields were obtained, the successful preparation 
of these compounds prompted us to prepare the analogous sulfur-containing 
products by the same method. For this, a sample of the carboxylic acid 1 8 0  was 
needed and we initially planned to prepare this by hydrolysis of nitrile 1 8 8 .
We prepared 1 8 8  by treatment of 4-hydroxythiophenol with acrylonitrile, 
by a slightly modified literature procedure (Scheme 64).179 Our product gave a 
similar m.p. to that reported by Inoue et al,,179 and as no other analytical or 
spectroscopic information were reported in the literature, 1H NMR, 13C NMR,
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MS, IR and microanalytical data are presented in section 7.3. As attempted 
base-mediated hydrolysis of 1 8 8  failed (Scheme 67), possibly due to cleavage 
of the sulfide group, an alternative route to 1 8 0  was sought.
Scheme 67
OHOH^ C N  
N a H C O r  
E t O H  '
OH
aq. NaOH
ref I., 3 h
68%
SH CN
1 8 8 1 8 0
Although carboxylic acid 1 8 0  has not been reported in the literature 
covered by Chemical Abstracts for over 25 years, it was mentioned in three 
earlier publications.180-182 Akagi and Aoki prepared 1 8 0  by reaction of 4- 
hydroxythiophenol with 3-bromopropanoic acid.180-18i However, Buck and 
Sehring used a different approach by fusing 4-hydroxythioanisole with 
chloroacetic acid to furnish a 67% yield of the required acid 1 8 0 . 182
We prepared 1 8 0  in 53% yield by treatment of 4-hydroxythiophenol with 
acrylic acid, according to a general procedure reported by Hogeveen and 
Montanari.183 The product was subjected to the same one-pot procedure as 
before to afford the required amides ( 1 7 9 ,  1 8 9 - 1 9 1 )  in yields of 47-65% 
(Scheme 68).
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Scheme 68
OH OH
i . ,  i i .
C 0 2H
1 8 0
i. D C C ,  p - H 0 - A r - N 0 2, E t O A c ,  1 h, r.t..
ii. N H 2 R ,  D B U ,  14 h, r.t.
OH OH
c o 2h
1 8 0
i. D C C ,  p - H 0 - A r - N 0 2, E t O A c ,  1 h, r.t./ 0 °C.
ii. P i p e r i d i n e / M o r p h o l i n e ,  D B U ,  14 h, r.t.
O
N
O
P r o d u c t  R  Y i e l d
1 7 9  Me 61%
1 8 9  Prn 60%
R
P r o d u c t  X
1 9 0
1 9 1
Y i e l d
CH2 65% 
O 47%
All four amides are new compounds, and they were fully characterised 
by the usual range of analytical and spectroscopic techniques. A major 
difference between the amides derived from phloretic acid and those containing 
a sulfide group was evident from their partition coefficients. As expected, the 
log Rvalues (Table 14) show that the compounds containing a piperidine group 
are more lipophobic than those with a morpholine ring and those with an N- 
methyl group are more lipophobic than analogues with an A/-propyl substituent. 
As compounds 1 7 9  and 1 8 9 - 1 9 1  are simply the phloretic acid derivatives 1 8 4  - 
187 with a sulfur atom inserted into the side chain, these data also illustrate that 
the addition of the sulfide group has large effects in terms of lipophilicity. This, 
coupled with the vastly different electronic effects towards the benzene ring 
imposed by a sulfide group versus a methylene group, and different steric 
effects, would all be expected to cause much variation in cytotoxic activity. Also 
of interest is the observation that compound 1 8 9  is apparently more lipophilic 
than its regioisomer 4 7  (log P =0.31, Table 14), on the basis of the 1- 
octanol:PBS (pH 7.4 phosphate buffered saline) partition coefficients.
-99  -
Table 14 1-Octanol: PBS Partition Coefficients
Phloretic Acid Derivatives Sulfides
Compound P log P Compound P log P
184 2.67 0.43 179 5.57 0.75
185 3.87 0.59 189 14.4 1.2
186 20.4 1.3 190 9.53 0.98
187 2.28 0.36 191 5.67 0.75
5.5.3 Biological Evaluation
The four amides 184-187 were evaluated for anti-melanoma activity 
against the usual panel of cell lines (Table 15).
Table 15 Gl50 Values ( \ i M )  for 96H SRB Assay
Cell Line
Cmpd B008 B0010 G361 HT144 SK-Mel-2 SK-Mel-24 SKOV-3
47 >100 >100 >100 >100 >100 >100 >100
184 >100 >100 >100 >100 >100 >100 >100
185 >100 >100 >100 >100 >100 >100 >100
186 >100 >100 >100 >100 >100 >100 >100
187 >100 >100 >100 >100 >100 >100 >100
These data show that all of the phloretic acid derivatives exhibit low 
levels of cytotoxicity towards all of the cell lines tested. The final compounds 
179, 189-191 essentially comprise these phloretic acid derivatives with a sulfur 
atom inserted at the benzene ring bridging position. Although these sulfides 
have been submitted to the Institute of Cancer Research for evaluation, the 
results were not available at the time of thesis submission.
The sulfide group of 47  undoubtedly has large effects on polarity, 
conformation, Tyrosinase binding and drug oxidation. Therefore, in order to 
examine the biological effects of introducing other groups to this bridging 
position, a further round of analogues was prepared for testing. The results 
from that study are discussed in the following chapter.
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6
Sulfide Group Replacements
6.1 Introduction
Passi and Nazzaro-Porro61 concluded that the susceptibility of simple 
phenols to undergo oxidation by Tyrosinase is a function of the electron- 
releasing properties of the bridging atom. However, if this was the only factor 
controlling Tyrosinase oxidation, the natural substrate tyrosine would show little 
activity towards the enzyme. Other considerations such as bond angle, steric 
hindrance, lipophilicity and hydrogen-bonding ability are also critical.
In order to examine whether the sulfur atom of 47 is essential to its 
biological activity, we planned to make the series of compounds 192-198 shown 
in Figure 11.
Figure 11 Planned Sulfide Replacements
OH
A
T
47
Compound X
192 S=0
193 S 0 2
194 0
195 Se
196 c h 2
197 C=0
198 NH
Although the compounds 192-198 are of similar structure, diverse 
procedures are required for their syntheses. For simplicity, we began work by 
preparing analogues with an oxidised sulfur atom, as discussed in the following 
section. The results from the biological evaluation of all the compounds covered 
in this chapter will be discussed in section 6.8.
-  101 -
6.2 Sulfoxide / Sulfone
We envisaged that the introduction of a sulfoxide group to the bridging 
position of 47 would create a compound of lower activity due to decreased 
lipophilicity and deactivation of the benzene ring. However, the compound was 
required to confirm this hypothesis and was readily available by oxidation of the 
parent sulfide 47.
In selecting a suitable oxidising agent to be used in the preparation of 
192, we needed a reagent that would selectively oxidise the sulfide without 
further oxidising the product or affecting the other functionality present. 
Although there are several reagents such as sodium permanganate184 which 
oxidise sulfoxides in preference to sulfides, many more reagents further oxidise 
sulfoxide products sufficiently slowly to permit their isolation in high yield.
Accordingly, sodium periodate was employed to oxidise 47 to the 
required 192 in 69% yield (Scheme 69), according to the general procedure of 
Hiskey and Harpold.185 This method was found to be particularly effective as 
the sodium iodate by-product conveniently precipitated from the ethanol 
reaction solvent.
Scheme 69
OH OH
19247
i. aq. N a l04 (1.1 eq.), EtOH, 15 h, 0 °C - > r.t.
If the biological activity of 192 was governed mainly by polarity rather 
than the electronic or steric effects of the sulfoxide group, we envisaged that 
increasing lipophilicity would give rise to active compounds. Therefore, more 
lipophilic sulfoxides 199 and 200 were prepared by oxidation of sulfides 92 and 
105 by the same procedure185 (Scheme 70).
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Scheme 70
OH OH
Product R Yield
199 Me 72%
O 200 (CH2)6CH3 73%
na r
H
i. aq. N a l04 (1.1 eq.), EtOH, 15 h, 0 °C -> r.t.
Although sodium periodate is occasionally used to prepare sulfones from 
su lfides,65 the second oxidation step is sometimes troublesome. In an 
attempted preparation of 193, sulfide 47 was treated with two equivalents of 
sodium periodate under standard conditions.185 However, sulfoxide 192 was 
the only product detected by TLC after 24 hours stirring at room temperature. 
Rather than attempt to drive the reaction by increased temperatures, we 
decided to seek an alternative oxidising agent.
Trost and Curran186 developed the use of potassium peroxymonosulfate 
(Oxone®) as a convenient crystalline reagent for the preparation of sulfones 
from either sulfides or sulfoxides. By use of the original general procedure,186 
sulfoxide 200 was treated with an excess of Oxone® to furnish the required 
sulfone 193 in 69% yield after flash chromatography (Scheme 71).
Scheme 71
OH OH
200 193
i. Oxone (1.5 eq.), MeOH, 2 h, 0
The structure of product 193 was confirmed by 1H NMR spectroscopy 
which revealed a far simpler spectrum than that of its chiral precursor 200 , as a 
consequence of removing the sulfoxide stereogenic centre. The IR spectrum 
(KBr disc) of 200 showed an absorption at 1024 cm '1, likely to arise from 
sulfoxide S-0 stretching. A peak at tihis frequency was not observed in the IR
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spectrum of 193. However, it did reveal absorptions at 1304 and 1140 cm-1 
which are typical values for sulfone S=0 stretching modes.
6.3 Ethers
Our interest in the preparation of ether analogue 194 stemmed from a 
paper by Cooksey et al.67 which reported that ortho-quinones with alkylthio 
substituents were oxidised approximately 5-10 times faster than analogous 
compounds bearing alkoxy substituents. Therefore, coupled with the lower 
lipophilicity of ethers, we would expect 194 to exhibit lower anti-melanoma 
activity than 47. We wished to confirm this theory by preparing 194 in order to 
compare its biological activity with that of 47.
Most literature methods for the preparation of substituted acetamides 
such as 194 are generally less convenient than the simple oxazoline ring- 
opening procedure known as the Wehrmeister reaction (Section 3.2). One such 
example is the formation of 201 by reaction of phenyl acetate with aziridine, as 
reported by Funahashi187 (Scheme 72).
Scheme 72
pyridine (cat.
20%
201
As this method requires the use of the highly toxic aziridine, autoclave 
conditions and affords a low yield of product, we decided to evaluate other 
procedures to prepare the ethers 201 and 194. We were particularly intrigued 
by the only literature synthesis of 194, as reported by Howe et a/.188 (Scheme 
73). This method is further hampered by the three additional steps needed to 
prepare the precursor 202 from hydroquinone
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Scheme 73
OHOBnOBn
►
NH
194202 203
ii. H2, Pd-C, AcOH, 60 °C.
As the patent of Jager91 reported that oxazoline ring-opening could be 
effected by phenols, we wished to determine whether this method could be 
employed to prepare 194 and 201. In several trial experiments, it became 
apparent that more forcing conditions were required, compared to the 
analogous reaction with thiophenols. As these harsher conditions seemed to 
cause some decomposition, driving the reactions to completion led to severe 
problems in product isolation. Therefore, compromise conditions were 
employed to give a low yield of product with easier isolation (Scheme 74).
Scheme 74
135 °C
24 h
OH
Product X 
201 
194
Yield
30% 
OH 24%
Although the yields are rather disappointing, they are greater than those 
reported from the literature procedures shown in Schemes 72 and 73. In 
addition, the oxazoline method is more convenient and less hazardous. In the 
case of 194, an increased yield could be obtained by using a mono-protected 
hydroquinone for the Wehrmeister reaction. However, cleanly protecting only 
one hydroxyl group of hydroquinone in high yield would not be easy on the 
basis of chemoselectivity. For example, Stoddart and co-workers prepared the
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monobenzyl ether of hydroquinone in 63% yield by treatment with benzyl 
chloride.189
The products 194 and 201 gave spectroscopic data in accordance with 
those previously reported187’188 and additional data are presented in Section
7.4.
6.4 Ketone
Replacing the sulfide group of 47  with a carbonyl group to give 
compound 197  would be expected to cause wholesale changes to the 
electronic and steric properties of the molecule. In particular, the ketone group 
is likely to adopt co-planarity with the aromatic system which would have major 
effects on the molecular conformation.
In planning a retrosynthesis of compound 197, we envisaged that the 
best disconnection would be between the benzene ring and carbonyl group with 
the aromatic group as the nucleophilic component (Scheme 75).
Scheme 75 OH
OH
197
Although this disconnection would normally suggest a Friedel-Crafts 
acylation process, the presence of the para-hydroxyl group makes the Fries 
rearrangement an option. Such an approach would require the preparation of 
205 for use as the substrate ester. In principle, this could be achieved by 
condensing A/-acetyl-(3-alanine 204 with phenol using DCC as the coupling 
agent (Scheme 76).
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Scheme 76
PhOH, DCC o
HO
204
205
The amide 204 was prepared in 77% yield by the general procedure of 
Black and Boscacci,190 and gave m.p.191 and NMR spectroscopic data192 
similar to those reported in the literature. Due to the insolubility of 204 in many 
organic solvents, DCC coupling with phenol was attempted in a mixture of ethyl 
acetate : pyridine (5:1 v/v) at 0 °C. Although product formation was detected by 
TLC, complete removal of phenol was not obtained. Analysis of the product 
mixture by 1H NMR spectroscopy revealed the presence of the required 
product 205 and unreacted phenol. Curiously, the peaks corresponding to the 
methylene and methyl groups of 205 seemed to have shifted position. It 
became apparent that 204 had undergone a known190 dehydrative cyclisation 
to give 2-methyl-5,6-dihydro-4H-1,3-oxazin-6-one 206 (Scheme 77).
Scheme 77
rrDCC -►
OH
204 206
It was found that with increased reaction temperatures, this side-product 
206 is able to react with the residual phenol in the reaction mixture to give the 
required product. Hence, treatment of 204 with phenol in refluxing ethyl acetate 
- pyridine afforded ester 205 in moderate yield (Scheme 78).
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Scheme 78
HO
205204
i. PhOH, EtOAc-py (5:1), DCC, 0 °C, 4 h.
ii. Reflux, 4 h.
In a similar manner, the novel ester 210 was prepared from carboxylic 
acid 209, as shown in Scheme 79. The procedure of Eugster et a/.193 was 
employed to prepare 209 via a Ritter reaction of 207 with acetonitrile and 
subsequent hydrolysis of the ester intermediate 208.
Scheme 79
O MeCN, conc. H2S 0 4 O . , O
OE, ------------ '  A X AN
H
OEt
207
aq. NaOH
i., O
OH 65%
208
o  w  o
a a a
H
209 210
i. PhOH, EtOAc-py (9:1), DCC, 0 °C, 4 h.
ii. Reflux, 2 h.
The Lewis acid catalysed Fries Reaction offers an excellent method for 
preparing phenolic ketones, provided that the regiochemistry of the migration 
can be controlled. Generally, the reaction under aluminium chloride catalysis is 
believed to proceed via the mechanism shown in Scheme 80.194 Initially, the 
Lewis acid attacks the ester bridging oxygen which promotes acylium ion 
release. The phenol group then directs acylium ion electrophilic attack towards 
the ortho or para positions of the aromatic system. As the liberated phenoxy 
group remains associated with aluminium until the quench, at least one molar 
equivalent of 'catalyst' is required for the reaction.
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Scheme 80
CloAl
R -C  = 0
OH
As the ortho-para product ratio is dependent on the solvent, temperature, 
amount of aluminium chloride used and the nature of the alkyl residue, it is 
often possible to obtain the required isomer by optimising the first three 
variables. For example, increasing the reaction temperature generally increases 
the percentage of ortho isomer produced.194
We decided to employ the general protocol of Harwood and co­
workers,195 which involved the use of nitromethane196 as the reaction solvent, 
a large excess of aluminium chloride and a low reaction temperature. Under 
these conditions, esters 205 and 210 were converted into the ketones 197 and 
211 in low yield after flash chromatography (Scheme 81).
Scheme 81
o
o  R  R  O
XXX
OH
N
H i., n.
R  R  O
O-O C X
i. AICI3 (5 equiv.), MeN02, 0 °C -> r.t., 20 min., ii. 40 °C.
Substrate R Product Time (h.) Yield
205 H 197 24 32%
210 Me 211 4 42%
-  109 -
Although a low yield of 211 was obtained under the shorter reaction time, 
no ortho product was detected which simplified product isolation. This para 
selectivity is likely to be due to steric effects caused by the bulk of the side- 
chain dimethyl substituents. In contrast, a separation of 197 from its ortho 
isomer was required after the extended reaction time. Attempts to improve this 
selectivity through the use of lower temperatures were unsuccessful due to the 
consequent reduction in reaction rate.
Both novel products 197 and 211 were fully characterised by the usual 
range of analytical techniques, with 1H NMR spectroscopy proving to be 
particularly useful in determining the aromatic substitution pattern.
6.5 Methylene
Although the Tyrosinase-mediated oxidation of phenols is potentiated by 
electron-withdrawing substituents para to the hydroxyl group,61 we wished to 
evaluate the effects of introducing a methyiene group to ihat position in order to 
produce a more tyrosine-like analogue of 47. We envisaged that the greater 
structural similarity of 196 might increase drug selectivity through better activity 
towards Tyrosinase.
A synthesis of compound 196 has been previously reported by Eckardt 
et a/.197 (Scheme 82). They hydrogenated 3-(4-hydroxyphenyl)propionitrile 212 
to give the corresponding amine 213 which was acetylated to afford 196 in 23% 
yield over two steps.
Scheme 82
OH OHOH
H2 100 atm. 
cat., 140 °C
48%
CN
NH
212 196213
Rather than follow this procedure, we decided to prepare 196 by 
reduction of ketone 197. This conversion was achieved in high yield by catalytic 
hydrogenation using palladium on carbon, as shown in Scheme 83. Progress of 
the reaction was conveniently followed by TLC, which revealed rapid
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conversion into the alcohol followed by a slower second reduction step to give 
final product 196.
Scheme 83
OHOH
H2, Pd-C 
MeOH, 4 h, r.t.
196197
The product 196 gave a similar m.p. to the literature197 value and as no 
spectroscopic data were reported by Eckardt et a/.,197 additional analytical data 
are presented in Section 7.4. The functional group conversion was clearly 
evident by comparing the 13C NMR chemical shifts of the side-chain bridging 
carbon atom of 197 (5 197) and 198 (5 33). Spectroscopic proof that complete 
reduction had been effected was provided by the DEPT-edited 13C NMR 
spectrum of 196 which revealed three methylene carbon atoms.
6.6 Selenide
According to a recent study by Riley et al.,69 the simple selenides 216 
and 217 are oxidised in vitro by Tyrosinase significantly faster than their 
analogous sulfides 214 and 215 (Figure 12).
Figure 12
OH OHX A
V V
s . Se
R R
Sulfide R COR Selenide R COR
214 Me 0.47 216 Me 0.64
215 Prn 0.83 217 Prn 1.66
COR = Comparative Rate of Oxidation by Tyrosinase,
relative to 4-hydroxyanisole. Riley et a l69
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Moreover, as the lipophilicity of selenides is generally greater than 
analogous sulfides, we could anticipate an increase in anti-melanoma activity 
for selenide 195 relative to the lead compound 47. In order to evaluate this 
theory, the synthesis of novel selenide 195 (Figure 11) was planned.
As discussed in Section 3.2, Saito et a l94 reported that the Wehrmeister 
Reaction could be extended to oxazoline ring-opening by selenophenols. 
Although only one example was given (employing commercially available 
selenophenol), we envisaged that the reaction could be used to prepare the 
required compound 195. To this end, the procedure of Riley et al.69 was 
employed to prepare the diselenide 219 from 4-bromophenol via treatment of 
Grignard reagent 218 with elemental selenium (Scheme 84). Although the 
problem of mono- and poly-selenide formation is discussed in the paper,69 no 
attempt was made to isolate the required diselenide from the crude product 
mixture. We found that flash chromatography was partly effective in purifying 
diselenide 219, although separation of the monoselenide by-product 220 could 
not be achieved using this technique. This difficu lty in separating 
monoselenides from diselenides using standard separation methods is well 
known198 and is a major disadvantage of this synthetic method. In the coupling 
of the Grignard reagent derived from 218 with selenium, we estimated the ratio 
of products 219 : 220 (Scheme 84) by 1 H NMR spectroscopy.
Scheme 84 OTBS
OTBS
OTBSOH
Sei
Se
Se
218
OTBS
OTBS
i TBSCI, Imidazole, DMF, r.t., 2 
ii. Mg, DBE, Et20 , ref I., 5 h. 219 220
61% 20%
Monoselenides are often separated from diselenides by treatment with 
sodium borohydride. This converts diselenides into their corresponding selenols 
which can be removed by extraction using alkali. However, Riley et al.69 treated 
a crude mixture containing 219 with sodium borohydride, followed by a large
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excess of methyl iodide to give 216 after deprotection; the analogous selenide 
217 was prepared in a similar fashion.
By including an acidification in the work-up of the reduction, we modified 
this procedure to liberate the required selenophenol 221 in crude form. The 
impure mixture of 221 and selenide 220 was extracted into ether, rapidly dried 
under nitrogen and evaporated to dryness. The residue was immediately 
treated with a 2-oxazoline in order to facilitate a Wehrmeister reaction. By this 
protocol, selenides 222 and 223 were prepared using 2-methyl-2-oxazoline and 
2-tert-butyl-2-oxazoline, respectively (Scheme 85). Extremely careful practical 
work was found to be essential in order to protect the selenol intermediate from 
air oxidation and to prevent its release into the laboratory (harmful and stench 
hazards).
Scheme 85
TBSO—f ~ \ - S e  S e - ^ ~ V - O T B S  
219
and monoselenide impurity 220
i. NaBH4, EtOH, 0 °C - » r.t., 30 min.
ii. aq. HCI.
r ~ \o
R
OTBS
R Product Yield
Me 222 48%
Bu1 223 52%
After purification by column chromatography, novel products 222 and 
223 were fully characterised by the usual range of spectroscopic techniques. 
Although the acetamide derivative 222 was isolated as an oil, the tert-butyl 
substituted amide 223 was found to be a solid of m.p. 75-76 °C. Both 
compounds were readily deprotected using TBAF in THF to afford the required 
phenols 195 and 224, as shown in Scheme 86.
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Scheme 86
OHOTBS
TBAF, THF, r.t., 2.5 h. 
 ►
Se,Se,
Product Yield
87% 
86%
Me 197 
Bu* 224
The novel compounds 197 and 224 gave very similar 1H and 13C NMR 
and iR spectral data to their respective sulfide analogues 47 and 140, Indeed, 
the IR spectra were virtually identical. However, their elemental composition 
was confirmed by high resolution mass spectrometry and combustion analysis.
6.7 Amine
Our main reasons for replacing the sulfide group of 47 with an amine 
group were two-fold. Firstly, we believed that compounds with an amine group 
para to the phenol group would be rapidly oxidised by Tyrosinase. Secondly, 
the amine functionality opens up the possibility of producing water soluble 
hydrochloride salt derivatives.
We envisaged that compound 198 could be prepared by ring-opening of 
2-methyl-2-oxazoline by a primary aromatic amine. However, as discussed in 
section 3.3, the reactivity of oxazolines towards amines is completely different 
to that towards phenols, selenides or thiols. The reactivity of oxazolines towards 
arylamine hydrochlorides is similarly complex, with amino-oxazolidines and 
carboxamides being reported as products. As Kormendy et a/.100 claimed that 
amino-oxazolidines could be prepared in good yield by treatment of oxazolines 
with arylamine hydrochlorides (Scheme 22), we started work in this area by 
evaluating their published protocol. To this end, 4-hydroxyaniline hydrochloride 
225 was treated with 2-methyl-2-oxazoline under the conditions shown in 
Scheme 87. After stirring the reaction mixture overnight, off-white crystals were 
filtered off and analysed. Interestingly, on the basis of its IR spectrum, it 
became apparent that the solid was not the expected amino-oxazolidine 226. A 
strong absorption was recorded at 1646 cm-1, suggesting a multiple bonded 
structure; possibly a carbon-nitrogen double bond.
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Another theory was that reaction had proceeded via a Wehrmeister-type 
ring cleavage to afford the carboxamide 198 as its hydrochloride salt. However, 
this option was ruled out by 13C NMR spectroscopy by the absence of an 
amide carbonyl peak in the region 5180-170. Moreover, the 1H and 13C NMR 
spectra of the precipitate indicated that two compounds were present. However 
the two components seemed to be geometric isomers from the pairing of peaks. 
When the IR and NMR spectroscopic data were combined with comfirmation of 
molecular mass by CI-MS, it seemed likely that the observed product was an 
amidine salt. This could result from spontaneous cleavage of initially formed 
oxazolidine 226, potentially giving rise to four isomeric amidine salts 227 - 230 
(Scheme 87).
OHScheme 87 OH
H2^ @ /  
HN C225
EtOH, r.t., 18 h.
226
OH OH
OH
HN
OH
227 228
OH
OH
HO
229 230
2 of these 4 geometric isomers 
detected in product mixture
By simple molecular modelling, it seems that the compounds 227 and 
228 would contain greatest steric repulsions in a thermodynamically favourable 
conformation where the aromatic ring and the amidine group are co-planar. 
Therefore, we may tentatively assign the product mixture to be composed of
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229 and 2 3 0 . By integration of the 1H NMR methyl group singlets, 
approximately equal amounts of the two isomers were formed in the reaction.
Although a 55% yield of product was recovered from the reaction 
mixture, this was only the material which crystallised out of solution during the 
experiment. This could mean that the true yield of the reaction is higher, and 
this may indeed be a good synthetic method for the preparation of amidine 
salts. However, we must bear in mind that the crystallisation of amidine salt 
from the reaction mixture may have led to a series of equilibria being driven 
towards the formation of that particular product, and that this solubility 
difference may not be generally applicable. It is likely that cleavage of the 
presumed oxazolidine intermediate 226 could lead to either amidine salts such 
as 229 and 230 or the imidate 231. A high yield of amidine salts may require 
the crystallisation of the required product from the reaction mixture together 
with an equilibrium process converting isomeric imidates 231 and 232 back into 
the oxazolidine intermediate 226. This process is illustrated in Scheme 88.
Scheme 88 OH
OH
NH
HN
226
OH
OH
HO
NH
229/230
231 / 232
Our conclusions from the reaction between oxazolines and arylamine 
hydrochlorides appears to cast doubt on the earlier observations by Kormendy 
et a/.100 that amino-oxazolidines were the main product from the reaction. 
However, as our attempts to reproduce their original procedure using aniline
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hydrochloride and 2-phenyl-2-oxazo!ine have been unsuccessful, further work 
is needed to confirm this.
Towards preparing compound 198, we treated 4-aminophenol 225 with 
the commercially available A/-(2-chloroethyl)acetamide according to the 
published general procedure of Poindexter.102 However, a complex mixture of 
products resulted and we reasoned that this may have been due to 
deprotonation and consequent alkylation of the phenol group of 225. To prevent 
this, we protected 4-aminophenol 225 as its ter/butyldimethylsilyl ether 233 
using the procedure of Swenton et a/.199 (Scheme 89). Compound 233 was 
then alkylated by the literature102 general conditions to afford secondary amine 
234 in 41% yield, as shown in Scheme 89. We believe that this low yield may 
have been due to fu rthe r a lkyla tion of product ,2 3  4 by N-(2- 
chloroethyl)acetamide. In addition, some /V-(2-chloroethyl)acetamide may have 
been removed by base-mediated elimination to give its corresponding alkene.
Scheme 89
OTBSOH OTBSTBSCI
Imidazole, THF 
 ►
Na,COo, MeCN
reflux, 10 h. 
41% HNNH NH
225 233 234
In an attempt to prepare 198 as its free base, we attempted to deprotect
234 using TBAF. Although the reaction seemed to proceed cleanly by TLC, 
extensive decomposition was encountered during purification. We envisaged 
that this may have been due to air oxidation of 198 to give para-aminoquinone
235 (Scheme 90). Such a process would be auto-catalysed through 
deprotonation of the phenol by the amine group.
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Scheme 90
OH
HN
235198
In order to suppress this process, it seemed sensible to prepare 198 
directly as its hydrochloride salt. We achieved this by deprotecting 234 using 
ethanolic hydrogen chloride. After stirring at room temperature overnight, the 
reaction mixture was simply evaporated to dryness, leaving a solid residue. 
Crystallisation furnished the required hydrochloride salt 198 in good yield 
(Scheme 91).
Scheme 91
OHOTBS
conc. HCI(aq), EtOH
77% 0C IHN
234 198
Novel compound 198 was characterised by the usual range of 
spectroscopic techniques. Although it showed good stabilty in water, 
decomposition was evident in alkaline solutions. For example, after dissolving 
the compound at 100 pM concentration in pH 7.4 phosphate buffer, the colour 
of the resulting solution changed from pale pink to light brown over 24 hours. 
Monitoring of this decomposition by UV spectroscopy revealed the appearance 
of a new absorption maximum at 372 nm, which may be due to formation of the 
aminoquinone 235 by the process shown in Scheme 90.
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6.8 Partition Coefficients / Biological Evaluation
6.8.1 UV Spectroscopy and Partition Coefficients
The UV spectroscopy of para-substituted phenols was discussed in 
Section 3.5. It was stated that the absorption frequency of the principal 
wavelength maximum depended on the electronic nature of the substituent. If 
the substituent is electron withdrawing relative to the electron releasing phenol, 
then the absorption will take place at longer wavelength. This trend is illustrated 
by the UV spectra of the compounds prepared in this chapter with principal 
absorption maxima ranging from 280 nm for the para-hydroxy aromatic ketone 
197 to 225 nm for the para-hydroxy aromatic ether 194. As before (Section 3.5), 
these absorption maxima were used quantitatively to evaluate partition 
coefficients for the compounds 192 - 198, thus allowing us to compare their 
lipophilicities relative to the lead compound 47. The calculated partition 
coefficients for the 1-octanoi : phophate buffered saline (pH 7.4) system are 
given in Table 16.
Table 16 1-Octanol: PBS Partition Coefficients
H 0 ~ O “ X^ N ^
H
Compound R P log P
192 SO 0.205 -0.69
193 s o 2 0.362 -0.44
198 0 n h 2 0.978 -0.01
194 0 1.24 0.09
197 c = o 1.70 0.23
47 s 2.03 0.31
196 c h 2 2.09 0.32
195 Se 3.42 0.53
6.8.2 Biological Evaluation
The data presented in Table 16 clearly show that the nature of the side- 
chain bridging group has a major impact on the overall lipophilicity of the 
compound. However, for a drug to be available to the cells in a physiological 
system, we still require appreciable water solubility. Therefore, we may expect
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compounds with a "compromise" lipophilicity to be the most successful as these 
could be soluble in saline and be readily absorbed through cell membranes.
In the context of this type of anti-melanoma prodrug, other factors are 
important too. Clearly, the compounds must be substrates for Tyrosinase to 
permit their bio-conversion into active orf/70 -quinones. Moreover, an electron- 
releasing group such as an ether at the bridging position helps facilitate this 
process. However, this type of group is polar and hence lowers lipophilicity 
which can reduce uptake into cells!
These observations can help us predict that certain compounds are not 
likely to be successful anti-melanoma drugs. For example, the sulfoxide 192 is 
very polar and will therefore not be readily taken up by cells. In addition, its 
bridging group is electronegative which is likely to deactivate the compound 
from Tyrosinase-mediated oxidation. Considering these two factors, it is unlikely 
that 192 will exhibit significant anti-melanoma activity.
All of the phenols discussed in Sections 6.2-6.6 were evaluated in vitro 
against the usual panel of cell lines by Dr L.R. Kelland, Institute of Cancer 
Research. The results, expressed in terms of GI50 values, are given in Table 
17.
Table 17 Gl50 Values (jliM) for 96H SRB Assay
Cell Line
Cmpd B008
Sulfoxide
B0010 G361 HT144 SK-Mel-2 SK-Mel-24 SKOV-
192 >100 >100 >100 >100 >100 >100 >100
199 >100 >100 >100 >100 >100 >100 >100
200 >100 
Sulfone
>100 >100 >100 >100 >100 >100
193 >100 
Ether
>100 >100 >100 >100 >100 >100
194 >100 
Sulfide
>100 >100 >100 >100 >100 >100
47 >100 
Ketone
>100 >100 >100 >100 >100 >100
197 >100 >100 >100 >100 >100 >100 >100
211 >100 
Methylene
>100 >100 >100 >100 >100 >100
196 >100 
Selenide
>100 >100 >100 >100 >100 >100
195 >100 >100 >100 >100 >100 >100 >100
224 48 >100 80 >100 >100 >100 >100
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These data show that all of these compounds have relatively low toxicity 
towards the cell lines tested, when compared to the more lipophilic phenols 
discussed in Chapter 4. The only compound with GI50 values below 1 0 0 pM was 
the terf-butyl substituted selenide 224. From the partition coefficient 
measurements discussed in Section 8.6.1, selenides have greater lipophilicity. 
This is a likely explanation for its greater cytotoxicity of 224 relative to sulfide 
analogue 140, as shown by the more informative percentage cell survival data 
at 100 pM (Table 18).
Table 18 Cell Survival (%Control) at 1 OOjllM in 96h SRB assay
0  x
140 S
224 Se
Cell Line
Cmpd B008 B0010 G361 HT144 SK-Mel-2 SK-Mel-24 SKOV-3
140 37.7 80.1 56.9 8 6 . 8 66.7 89.1 89.2
224 17.3 62.9 44.3 75.6 60.1 101.3 85.9
The observation that compounds such as 224 show cytotoxicity towards 
the pigmented melanoma cell lines and inactivity towards the non-pigmented 
line SK-Mel-24 may indicate toxicity via Tyrosinase-mediated oxidation. 
However, as toxicity is evident towards the ovarian cell line SKOV-3 too, these 
compounds clearly exert some non-specific biological effects.
6.9 Final Comments and Future Work
Although we have not prepared compounds which specifically focus their 
effects on melanoma, it must be borne in mind that the currently used drugs for 
this condition afford only low success rates. Further work is therefore required 
to determine whether the goal of Tyrosinase-mediated drug delivery at tumour 
sites can be achieved.
In order to gain a better picture of the selectivity and potential of the new 
compounds prepared in the course of this research, 36 have been accepted for 
evaluation by the U.S. National Cancer Institute. The results will be useful in 
planning where further research efforts are best directed.
During the course of this work, some interesting observations have been 
made in the area of 2-oxazoline chemistry. Further work is required to study the 
reactivity of oxazolines towards aromatic amines and their salts in order to 
clarify and extend the small amount of literature in this area.
-  121 -
The Wehrmeister reaction has been extensively used throughout this 
work. An example was given (Section 6.3) where a 5 step literature procedure 
was reduced to one step through the use of this technique. Another area of 
future work could be to extend this reaction to more complex 2 -oxazolines or 
other nucleophilic species.
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7
Experimental to Chapters 4-6
7.1 General
Reagents were purchased from Aldrich Chemical Company (Gillingham, /  
UK) or Lancaster Synthesis (UK) and were used without further purification. 
Light petroleum refers to the fraction with boiling range 40-60 °C. Melting points 
(m.p.) were determined in open capillaries using a Gallenkamp apparatus and 
are uncorrected. 1H and 13C NMR spectra were obtained on a Bruker AM200- 
SY spectrometer operating at 200 MHz and 50 MHz respectively, or where 
stated, at 360 MHz and 90 MHz respectively on a Bruker AM 360 spectrometer.
J Values are given in Hz. 13C NMR spectra were assigned with the aid of 
D istortionless Enhancement by Polarisation Transfer (DEPT)-edited 
spectra.The numbering schemes shown are used for ease of assigning the 
NMR spectra and do not refer to the system of nomenclature. Mass spectra 
(MS) were recorded on AEI MS12 or MS902 spectrometers; percentage figures 
refer to relative intensity as a percentage of the base peak. MS were obtained 
using electron-impact ionisation (El) mode or, if stated, chemical ionisation (Cl) 
mode. Infra-red (IR) spectra were obtained on a Perkin Elmer PU 9800 FT-IR 
spectrophotometer. Ultra-violet (UV) spectra were recorded on a Shimadzu UV- 
1601 spectrophotometer. Combustion analysis was carried out on a Carlo-Erba 
1106 elemental analyser. Retention factors (Rf) were obtained by analytical 
Thin Layer Chromatography (TLC) on Merck aluminium-backed silica plates of 
0.25 mm thickness; chromatograms were visualised using UV conditions at 254 
nm or by staining with iodine. Flash chromatography and dry-column flash 
chromatography refer to the procedures described by Still et al.200 and 
Harwood,201 respectively. All column chromatography was carried out on silica 
gel (particle size 70-230 mesh).
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7.2 Experimental to Chapters 4
7.2.1 General Procedures for the preparation of oxazolines
General Procedure 1, as reported by Barton et a/ .111
The carboxylic acid (1 equivalent), the amino alcohol (2 equivalents) and boric 
acid (0.05 equivalents) were heated in refluxing xylene for 2-3 d. After 
concentration of the product mixture under reduced pressure, fractional 
distillation afforded the 4,5-dihydro-oxazine as a colourless oil.
General Procedure 2, as reported by Witte and Seeliger.117
The nitrile (1 equivalent) was heated with the amino alcohol (1 equivalent) and 
cadmium diacetate dihydrate (0.025 equivalents) at 130 °C for 1-3 d. Distillation 
of the product mixture gave the 4,5-dihydro-oxazine as a colourless oil.
7.2.2 Experimental Data
2-[(4-Hydroxyphenyl)thio]ethylamine hydrochloride (42)
OH
S
The title compound was prepared in 8 8 % yield on a 10 mmol scale by the 
procedure of Padgette et al.74 and gave m.p. 128-129 °C (from EtOAc-MeOH), 
(lit . , 74  128-129 °C). The 1H NMR, IR and MS spectral data were in good 
agreement with those reported.74
New data: 5C (D20) 156.7 (C-1), 135.3 (C-3), 123.1 (C-4), 117.3 (C-2 ), 39.9 (C- 
6 ) and 33.4 (C-5).
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A/-[2-[(4-Hydroxyphenyl)thio]ethyl]ethanamide (47)
OH
The title compound was prepared in 87% yield by the method of Padgette et 
al.74 and gave m.p. 124-125 °C (from EtOAc), (lit. ,74 1 23-125 °C). The 1H NMR, 
13C NMR, IR and MS spectral data were in good agreement with those reported 
by McKeown .202
A/-[2-(Phenylthio)ethyl]ethanamide (84)
A mixture of thiophenol (3.30 g, 30.0 mmol) and 4.5-dihydro-2-methyloxazole 
(2.55 g, 30.0 mmol) was stirred under N2 for 2  h at 120 °C. Cooling to r.t. gave 
a white precipitate which was recrystallised to afford sulfide 84 (4.81 g, 82%) as 
white crystals, m.p. 90-92 °C (from EtOAc), (lit. ,203 89-91 °C). The 1H NMR, 13C 
NMR, IR and MS spectral data were in good agreement with those reported in 
the literature.106
New data: Rf 0.40 (EtOAc); (Found: C, 61.55; H, 6.69; N, 7.11%. C i0H13NOS 
requires C, 61.51; H, 6.71; N, 7.17%).
H
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A/-[2-[(4-Methoxyphenyl)thio]ethyl]ethanamide (85)
A mixture of 4-methoxythiophenol (2.35 g, 17.0 mmol) and 4.5-dihydro-2- 
methyloxazole (1.45 g, 18.0 mmol) was stirred under N2 for 2.5 h at 120 °C. 
Cooling to r.t. gave a white precipitate which was recrystallised to afford sulfide 
85 (3.10 g, 76%) as white crystals, m.p. 109-110 °C (from EtOAc); Rf 0.44 
(EtOAc); v max (KBr) 3291 (N-H), 1638 (amide I), 1597, 1561 (amide II), 1497 
and 816 (para-disubstituted benzene) cm '1; §H (CDCI3) 7.36 (2 H, AA'BB', 3J= 
8 .8 , 4-H), 6.85 (2 H, AA’BB1, 3J= 8 .8 , 3-H), 6.05 (1 H, br s, N-H), 3.79 (3 H, s, 1- 
H), 3.39 (2 H, m, 7-H), 2.93 (2 H, t, 3J= 6.5, 6 -H) and 1.95 (3 H, s, 9-H); 6 C 
(CDCI3) 170.2 (C-8 ), 159.2 (C-2 ), 133.6 (C-4), 124.8 (C-5), 114.7 (C-3), 55.3 
(C-1), 38.4 (C-7), 35.5 (C-6 ) and 23.2 (C-9); m/z 225 {M+, 23.6), 166 (94.6), 
151 (34.2), 139 (31.9), 135 (25.3) and 8 6  (100%); (Found: C, 58.71; H, 6.73; N, 
6.11%. C h H 15N 02S requires C, 58.64; H, 6.71; N, 6 .2 2 %).
A/-[2-[(4-Methylphenyl)thio]ethyl]ethanamide (86)
A mixture of 4-methylthiophenol (3.72 g, 30.0 mmol) and 4.5-dihydro-2- 
methyloxazole (2.55 g, 30.0 mmol) was stirred under N2 for 2.5 h at 1 2 0  °C. 
Cooling to r.t. gave a white precipitate which was recrystallised to afford the title 
compound 8 6  (5.12 g, 82%) as white crystals, m.p. 76-78 °C (from EtOAc); 
(lit. , 107 73-75 °C).
New data: Rf 0.30 (EtOAc); vmax (KBr) 3289 (N-H), 1638 (amide I), 1561 (amide 
II), and 803 (para-disubstituted benzene) cm '1; 5h (C D C I3 )  7.28 (2 H, AA'BB',
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3J= 8.9, 4-H), 7.12 (2 H, AA'BB', 3J= 8.9, 3-H), 6.08 (1 H, br s, N-H), 3.41 (2 H, 
m, 7-H), 3.00 (2 H, t, 3J= 6.5, 6 -H), 2.32 (3 H, s, 1-H) and 1.94 (3 H, s, 9-H); 8 C 
(CDCI3) 170.2 (C-8 ), 136.9 (C-2 ), 131.0 (C-5), 130.6 (C-4), 129.9 (C-3), 38.6 
(C-7), 34.2 (C-6 ), 23.2 (C-9) and 21.0 (C-1); m/z 209 (M*, 16.1), 150 (100), 135 
(79.0), 123 (11.9) and 105 (11.3%); (Found: C, 63.23; H, 7.39; N, 6.49%. 
C n H 15NOS requires C, 63.12; H, 7.22; N, 6.69%).
A/-[2-[(4-Chlorophenyl)thio]ethyl]ethanamide (87)
A mixture of 4-chlorothiophenol (5.91 g, 40.9 mmol) and 4.5-dihydro-2- 
methyloxazole (3.40 g, 40.0 mmol) was stirred under N2 for 2 h at 120 °C. 
Cooling to r.t. gave a white precipitate which was recrystallised to afford sulfide 
87 (5.91 g, 64%) as white crystals, m.p. 95-97 °C (from EtOAc); Rf 0.36 
(EtOAc); Vmax (KBr) 3285 (N-H), 1638 (amide I), 1561 (amide II) and 812 (para- 
disubstituted benzene) c m 1; 8 h (D4-methanol) 7.36 (2 H, AA'BB', 3J= 6.1, 3-H), 
7.28 (2 H, AA'BB', 3J=6A , 2-H), 3.35 (2 H, t, 3J= 6 .8 , 6 -H), 3.03 (2 H, t, 3J = 6 .8 ,
5 -H) and 1.70 (3 H, s, 8 -H); 8 C (D4-methanol) 173.3 (C-7), 136.0 (C-4), 133.0 
(C-1), 131.7 (C-3), 130.1 (C-2 ), 40.0 (C-6 ), 33.5 (C-5) and 22.5 (C-8 ); m/z 229 
(M+, 12.0), 170 (79.4), 135 (83.9), 108 (26.9) and 30 (100%); (Found: C, 52.46; 
H, 5 .2 2 ; N, 6.02%. C 10H12CINOS requires C, 52.28; H, 5.27; N, 6 .1 0 %).
2-(Phenylthio)ethylamine hydrochloride (88)
© © 
6 'N H 3 Cl
The title compound was prepared in 65% yield on a 6  mmol scale by the 
general procedure of Padgette et al.74 and gave m.p. 105-108 °C (from EtOAc-
- 1 2 7 -
MeOH), (lit. , 103 106-110 °C). The 1H NMR103 and IR93  spectral data were in 
good agreement with those reported in the literature.
New data: 8 C (D20 ) 133.7 (C-4), 131.3 (C-2 ), 130.3 (C-3), 128.3 (C-1 ), 38.8 (C-
6 ) and 31.4 (C-5); m/z 153 [M+ (free base), 2.9], 124 (20.0), 109 (13.8), 91 
(7.3), 77 (24.3) and 30 (100%); (Found: C, 50.54; H, 6.54; N, 7.29%. 
C8H12CINS requires C, 50.65; H, 6.38; N, 7.38%).
2-[(4-Chlorophenyl)thio]ethylamine hydrochloride (89)
The title compound was prepared in 69% yield on a 6  mmol scale by the 
general procedure of Padgette et al.74 and gave m.p. 165-166 °C (from EtOH), 
(lit. ,204 1 70-172 °C).
New data: vmax(KBr) 3011 (N-H str.), 1593, 1574, 1506, 1482 (N-H bend) and 
818 (para-disubstituted benzene) cm4 ; 8h (D20 ) 7.26 (2 H, AA'BB', 3J=9.0, 3- 
H), 7.17 (2 H, AA'BB', 3J= 9.0, 2-H) and 3.08-2.91 (4 H, m, 5-H and 6 -H); 8 C 
(D20 ) 133.8 (C-4), 132.7 (C-2 ), 132.2 (C-1), 130.2 (C-3), 38.7 (C-6 ) and 31.6 
(C-5); m/z 187 [/W+(free base), 3.2], 158 (13.8), 143 (3.8), 108 (9.9), 75 (10.8) 
and 30 (100%); (Found: C, 42.79; H, 5.04; N, 6 .0 2 %. C8 H nC I2NS requires C, 
42.87; H, 4.95; N, 6.25%).
Cl
~ ©  ©  
6 NH3 Cl
A/-[2-[(4-Ethanoyloxyphenyl)thio]ethyl]ethanamide (90)
The general procedure of Furniss et a/.109 was employed as follows: Ice (10 g) 
was added to a solution of compound 47 (1.55 g, 7.30 mmol) in 3 mol dm -3 aq. 
NaOH (10 cm3). After 5 min, acetic anhydride (0.92 g, 0.85 cm3, 9.01 mmol) 
was added and the mixture swirled for 5 min. whereupon the crude precipitated 
product was collected by filtration and recrystallised to afford ester 90 (0.95 g, 
52%) as white crystals, m.p. 79-80 °C (from EtOAc); Rf 0.25 (EtOAc); v max (KBr) 
3291 (N-H), 1752 (C=0), 1638 (amide I), 1561 (amide II), and 843 (para- 
disubstituted benzene) cm '1; 5h (C D C I3 )  7.38 (2  H, AA’BB', 3J= 6 .6 , 5-H), 7.02 
(2 H, AA'BB', 3J= 6 .6 , 4-H), 6.08 (1 H, br s, N-H), 3.43 (2 H, m, 8 -H), 3.03 (2 H, 
t, 3J= 6.4, 7-H), 2.30 (3 H, s, 1-H) and 1.97 (3 H, s, 10-H); 5C ( C D C I3) 170.4 (C-
9), 169.4 (C-2 ), 149.4 (C-3), 132.3 (C-6 ), 131.1 (C-5), 122.4 (C-4), 38.7 (C-8 ),
34.0 (C-7), 23.2 (C-10) and 2 1 .1  (C-1); m/z 253 (M+, 5.1), 2 1 1  (5.9), 194(12.7), 
152 (59.0), 8 6  (36.4) and 43 (100%); (Found: C, 56.94; H, 5.98; N, 5.54%. 
C 1 2 H 1 5 N O 3 S  requires C, 56.90; H, 5.97; N, 5.53%).
A/-[2-[(4-Propanoyloxyphenyl)thio]ethyl]ethanamide (91)
The general procedure of Furniss et al, 109 was employed as follows: Ice (10 g) 
was added to a solution of compound 47 (1.50 g, 7.10 mmol) in 3 mol dm ' 3 aq. 
NaOH (10 cm3). After 5 min, propanoic anhydride (1.32 g, 1.30 cm3, 10 .1  mmol) 
was added and the mixture swirled for 5 min whereupon the crude precipitated 
product was collected by filtration and recrystallised to afford ester 91 (1.18 g, 
62%) as white crystals, m.p. 97-99 °C (from EtOAc); Rf 0.32 (EtOAc); v max (KBr) 
3291 (N-H), 1750 (C=0), 1638 (amide I), 1561 (amide II), and 806 (para- 
disubstituted benzene) cm-1; 5h (CDCI3) 7.40 (2 H, AA'BB', 3J= 8.7, 6 -H), 7.04 
(2 H, AA'BB', 3J= 8.7, 5-H), 6.02 (1 H, br s, N-H), 3.42 (2 H, m, 9-H), 3.03 (2 H, 
t, 3J= 6.5, 8 -H), 2.58 (2 H, q, 3J= 7.6, 2-H), 1.94 (3 H, s, 11 -H) and 1.26 (3 H, t, 
3J= 7.6, 1 -H); 5C (CDCI3) 172.9 (C-10), 170.3 (C-3), 149.6 (C-4), 132.1 (C-7),
131.2 (C-6 ), 122.4 (C-5), 38.7 (C-9), 34.1 (C-8 ), 27.7 (C-2 ), 23.2 (C-1 1 ) and 9.0 
(C-1); m /z  267 (M+, 1.8), 208 (2.3), 152 (34.4), 107 (8.4), 8 6  (36.4) and 29
o
H
-  129 -
(100%); (Found: C, 58.31; H, 6.29; N, 5.14%. C 13H17N 03S requires C, 58.41; 
H, 6.41; N, 5.24%).
A/-[2-[(4-Hydroxyphenyl)thio]-1,1 -dimethylethyl]ethanamide (92)
OH
A mixture of 4-hydroxythiophenol (5.35 g, 42.4 mmol) and 5,6-dihydro-2,4,4- 
trimethyloxazole (5.28 g, 46.7 mmol) was stirred under N2 for 4 h at 130 °C. 
Upon cooling to r.t., the oily reaction mixture was triturated using a glass rod to 
give a white precipitate which was crystallised to afford sulfide 92 (7.77 g, 77%) 
as white crystals, m.p. 98-99 °C (from EtOAc-hexane); Rf 0.31 (EtOAc); v max 
(KBr) 3358 (N-H), 1646 (amide I), 1582, 1542 (amide II), 1494 and 830 (para- 
disubstituted benzene) cm '1; 8 h (D6-acetone) 8.83 (1 H, br s, OH), 7.29 (2 H, 
AA'BB', 3J= 8.7, 3-H), 6.96 (1 H, br s, NH), 6.77 (2 H, AA'BB', 3J= 8.7, 2-H), 
3.38 (2  H, s, 5-H), 1.75 (3 H, s, 9-H) and 1.36 (6  H, s, 7-H); 8 C (D6-acetone)
170.7 (C-8 ), 157.7 (C-1), 134.1 (C-3), 126.9 (C-4), 116.8 (C-2 ), 54.7 (C-6 ), 45.8 
(C-5), 26.4 (C-7) and 23.7 (C-9); m/z 239 (M+, 4.6), 180 (39.8), 165 (3.7), 140
(5.1), 100 (14.4) and 59 (100%); (Found: M+, 239.0976; C, 60.28; H, 7.16; N, 
5.78%. C i2H17N 02S requires M, 239.0980; C, 60.22; H, 7.16; N, 5.85%).
2-Cyclohexyl-4,5-dihydro-4,4-dimethyloxazole (96)
The title compound 96 was prepared in 75% yield on a 80 mmol scale using 
general procedure 1 (2  d) and gave b.p. 122-123 °C/25 mmHg, (lit. , 113  95-97 
°C/14 mmHg). The IR spectral data were in good agreement with those 
reported in the literature. 113
6 -H, 7-H and 8 -H) and 1.18 (6  H, s, 1 -H); 6 C (CDCI3) 169.3 (C-4), 78.6 (C-3),
66.4 (C-2 ), 37.3 (C-5), 29.7 (C-6 ), 28.2 (C-1), 25.7 (C-8 ) and 25.5 (C-7).
2-Heptyl-4,5-dihydro-4,4-dimethyloxazole (97)
The title compound 97 was prepared in 84% yield on a 150 mmol scale using 
general procedure 1 ( 2  d) and gave b.p. 78 °C/2.0 mmHg, (lit. , 114 110 °C/12 
mmHg). The IR, 1H NMR and 13C NMR spectral data were in good agreement 
with those reported in the literature. 114 -115
New data: m/z 197 (M+, 0.7), 126 (33.7), 113 (100), 98 (20.7) and 58 (48.4%); 
(Found: M+, 197.1771; C12H23NO requires M, 197.1780).
2-(2-Cyclohexylethyl)-4,5-dihydro-4,4-dimethyloxazole (98)
The title compound 98 was prepared in 58% yield on a 40 mmol scale using 
general procedure 1 (2 d) and gave b.p. 107-110 °C/2.0 mmHg, (lit. , 116 96 
°C/0.8 mmHg). The 1H NMR and IR spectral data were in good agreement with 
those reported in the literature.116
New data: 6 C (CDCI3) 166.4 (C-4), 78.8 (C-3), 66.7 (C-2 ), 37.3 (C-7), 33.4 (C- 
5), 32.9 (C-8 ), 28.3 (C-1 ), 26.5 (CH2) 26.2 (C-9) and 25.7 (CH2); m/z 209 (M+,
7), 180 (17), 126 (93), 113 (100), 98 (13) and 83 (9%)
New data: 6 H (CDCI3) 3.80 (2  H, s, 3-H), 2.17 (1 H, m, 5-H), 1.92-0.95 (10 H, m
3
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2-(3-Cyclohexylpropyl)-4,5-dihydro-4,4-dimethyloxazole (99)
10
11
General procedure 1 was employed as follows: A m ixture of 4- 
cyclohexylbutanoic acid (8.90 g, 52.2 mmol), 2-amino-2-methyl-1 -propanol 
(9.30 g, 104 mmol) and boric acid (0.30 g, 4.9 mmol) was heated in refluxing 
xylene (150 cm3) for 3 d. On cooling to r.t. the reaction mixture was 
concentrated in vacuo and distilled to afford oxazoline99  (6.06 g, 52%) as a 
colourless oil, b.p. 115-117 °C/2.0 mmHg; vmax(neat) 2924 (C-H), 1669 (C=N), 
1449 and 996 cnrr1; 6 H (CDCI3) 3.85 (2  H, s, 3-H), 2.17 (2  H, t, 3J= 7.4, 5-H), 
1.68-1.50 (7 H, m, 7-H, 8 -Hand 9-H), 1.22 ( 6  H, s, 1-H) and 1.20-0.80 (8  H, m, 
6 -H, 10-H and 11-H); 6c (CDCI3) 166.2 (C-4), 78.8 (C-3), 66.7 (C-2), 37.2 (C-8 ),
36.9 (C-7), 33.2 (C-5 and C-9), 28.4 (C-1 ), 26.6 (C-6 ), 26.3 (C-1 0 ) and 23.4 (C- 
11); m /z  223 (M +, 2), 208 (8 ), 180 (9), 126 (24), 113 (100) and 98 (9%); 
(Found: M+, 223.1919; C14H25NO requires M, 223.1936).
2-(4-Cyclohexylbutyl)-4,5-dihydro-4,4-dimethyloxazole (100)
General procedure 1 was employed as follows: A m ixture of 4- 
cyclohexylpentanoic acid (9.92 g, 53.8 mmol), 2-amino-2-methyl-1-propanol 
(9.60 g, 108 mmol) and boric acid (0.30 g, 4.9 mmol) was heated in refluxing 
xylene (150 cm3) for 3 d. On cooling to r.t. the reaction mixture was 
concentrated in vacuo and distilled to afford oxazoline 100 (6.95 g, 54%) as a 
colourless oil, b.p. 125-127 °C/2.0 mmHg; vmax(neat) 2924 (C-H), 1669 (C=N), 
1449 and 996 cm-1; 6 H (CDCI3, 360 MHz) 3.89 (2 H, s, 3-H), 2.23 (2  H, t, 3J=
7.5, 5-H), 1.61-1.49 (7 H, m, 8 -H, 9-H and 10-H), 1.28-0.80 (10 H, m, 6 -H, 7-H, 
1 1 -H and 1 2 -H) and 1.18 (6  H, s, 1 -H); 6 C (CDCI3) 166.1 (C-4), 78.9 (C-3), 6 6 . 8  
(C-2 ), 37.4 (C-9), 37.0 (C-8 ), 33.4 (C-5 and C-10), 28.4 (C-1), 28.2 (CH2), 26.7 
(CH2), 26.4 (CH2) and 26.3 (CH2); m/z 237 (M+, 3), 2 2 2  (8 ), 184 (8 ), 126 (38), 
113 (100) and 58 (34%); (Found: M+, 237.2095; C i5H27NO requires M, 
237.2093).
3
- 132 -
2-Cyclopentyl-4,5-dihydro-4,4-dimethyloxazole (101)
4
5
6
7
General procedure 1 was employed as follows: A mixture of cyclopentane 
carboxylic acid (8.96 g, 8.51 cm3, 78.5 mmol), 2-amino-2-methyl-1 -propanol 
(14.0 g, 157 mmol) and boric acid (0.40 g, 6.5 mmol) was heated in refluxing 
xylene (150 cm3) for 3 d. On cooling to r.t. the reaction mixture was 
concentrated in vacuo and distilled to afford oxazoline 101 (8.14 g, 62%) as a 
colourless oil, b.p. 104-105 °C/20 mmHg; vmax(neat) 2964 (C-H), 1663 (C=N), 
1191, 1146 (C-O) and 998 cm '1; 6 H (CDCI3) 3.74 (2 H, s, 3-H), 2.54 (1 H, m, 5- 
H), 1.86-1.33 (8  H, m, 6 -Hand 7-H) and 1.10 ( 6  H, s, 1-H); 5C (CDCI3) 169.1 
(C-4), 78.7 (C-3), 38.1 (C-5), 30.3 (C-6 ), 28.2 (C-1) and 25.6 (C-7); m/z 167 
{M+, 13), 152 (49), 139 (46), 126 (100), 96 (23), 81 (10) and 69 (29%); (Found: 
M+, 167.1316; C i0H17NO requires M, 167.1310).
4,5-Dihydro-4,4-dimethyl-2-propyloxazole (102)
The title compound 102 was prepared in 60% yield on a 120 mmol scale using 
general procedure 2 (3 d) and gave b.p. 150-151 °C/760 mmHg, (lit. , 118 152 
°C/760 mmHg). The IR, 1H NMR and 13C NMR spectral data were in good 
agreement with those reported in the l i t e r a tu r e .1 15>118
New data: m/z 141 (M+, 1.0), 126 (80.3), 113 (94.0), 98 (51.9), 83 (69.6), 70
(70.2), 58 (29.1) and 41 (100%); (Found: M+, 141.1143; CsH^NO requires M, 
141.1154).
4
5 \ S / 7
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4,5-Dihydro-4,4-dimethyl-2-(1 -methylethyl)oxazole (103)
"V
6
The title compound 103 was prepared in 76% yield on a 98 mmol scale using 
general procedure 2  (3 d) and gave b.p. 136-137 °C/760 mmHg, (lit. ,205 137 
°C/760 mmHg). The IR, 1H NMR and 13C NMR spectral data were in good 
agreement with those reported in the literature. 115>116>119 
New data: m/z 141 (M+, 15.8), 126 (100), 111 (51.0), 96 (48.3), 70 (43.6) and 
43 (50.0%); (Found: M+, 141.1141; CsHi5NO requires M, 141.1154).
/V-[2-[(4-Hydroxyphenyl)thio]-1,1-dimethylethyl]cyclohexanecarboxamide
(104)
OH
N
H
A mixture of 4-hydroxythiophenol (0.85 g, 6.74 mmol) and oxazoline 96 (1.22 g, 
6.74 mmol) was stirred under N2 for 4 h at 130 °C. Upon cooling to r.t., the oily 
reaction mixture was triturated using a glass rod to give a white precipitate 
which was crystallised to afford sulfide 104 (1.55 g, 75%) as white crystals, m.p. 
153-154 °C (from hexane-EtOAc); Rf 0.65 (EtOAc); vmax(KBr) 3357 (N-H), 1638 
(amide I), 1600, 1583, 1541 (amide II), 1495 and 830 (para-disubstituted 
benzene) cm '1; 5h (D6-acetone) 9.18 (1 H, br s, OH), 7.05 (2 H, AA'BB1, 3J=
8.7, 3-H), 6.85 (1 H, br s, NH), 6.54 (2 H, AA'BB', 3J= 8.7, 2-H), 3.13 (2 H, s, 5- 
H), 1.85 (1 H, m, 9-H), 1.45 (2 H, m, 10-H), 1.11 ( 6  H, s, 7-H) and 1.05 (4 H, m, 
11-H and 1 2 -H); 6 C (D6-acetone) 176.1 (C-8 ), 157.5 (C-1), 133.4 (C-3), 126.1 
(C-4), 116.6 (C-2 ), 53.8 (C-6 ), 45.9 (C-9), 45.5 (C-5), 30.0 (C-10), 26.8 (C-7),
- 134-
26.3 (C-1 2 ) and 26.1 (C-11); m/z 307 (M +, 3.3), 180 (8 6 .8 ), 139 (7.2), 125
(31.9), 97 (12.2) and 58 (100%); (Found: M+, 307.1593; C, 66.58; H, 8.03; N, 
4.54%. C17H25NO2S requires M, 307.1606; C, 66.41; H, 8.20; N, 4.56%).
A/-[2-[(4-Hydroxyphenyl)thio]-1,1 -dimethylethyl]octanamide (105)
OH
N
H
A mixture of 4-hydroxythiophenol (1.70 g, 13.5 mmol) and oxazoline 97 (2.66 g,
13.5 mmol) was stirred under N2 for 4 h at 130 °C. Upon cooling to r.t., the oily 
reaction mixture was triturated using a glass rod to give a white precipitate 
which was crystallised to afford sulfide 105 (3.24 g, 74%) as white crystals, m.p. 
96-97 °C (from hexane-EtOAc); Rf 0.52 (2:1 hexane-EtOAc); vmax(KBr) 3322 
(N-H), 1630 (amide I), 1556 (amide II), 1494 and 822 (para-disubstituted 
benzene) cm '1; §h (CDCI3) 8.94 (1 H, br s, OH), 7.26 (2 H, AA'BB', 3J= 8 .6 , 3- 
H), 6.75 (2 H, AA'BB', 3J= 8 .6 , 2-H), 5.60 (1 H, br s, NH), 3.33 (2 H, s, 5-H),
2.00 (2 H, t, 3J= 7 .2, 9-H), 1.60-1.10 (10 H, m, 10-H, 11-H, 12-H, 13-H and 14- 
H), 1.38 (6  H, s, 7-H) and 0.84 (3 H, t, 3J= 5.6, 15-H); 6 C (CDCI3) 174.2 (C-8 ),
156.6 (C-1), 133.4 (C-3), 125.1 (C-4), 116.3 (C-2), 54.6 (C-6 ), 45.8 (C-5), 37.5 
(C-9), 31.6 (C-13), 29.0 (C- 1 0  or C-1 2 ), 28.9 (C- 1 2  or C -1 0 ), 26.9 (C-7), 25.7 
(C-11), 22.5 (C-14) and 14.1 (C-15); m/z 323 (M+, 2.6), 198 (3.3), 180 (67.4), 
125 (16.4), 97 (4.8) and 58 (100%); (Found: M+, 323.1892; C, 66.84; H, 9.04; N, 
4.25%. C18H29N02S requires M, 323.1919; C, 66.83; H, 9.04; N, 4.33%).
- 135-
A/-[2-[(4-Hydroxyphenyl)thio]-1,1-dimethylethyl]-3-cyclohexylpropanamide
(106)
6 N 8
A mixture of 4-hydroxythiophenol (1.25 g, 9.9 mmol) and oxazoline 98 (2.07 g,
9.9 mmol) was stirred under N2 for 7 h at 130 °C. Upon standing overnight at 
r.t., the oily reaction mixture solidified to give a white precipitate which was 
crystallised to afford sulfide 106 (2.41 g, 73%) as white crystals, m.p. 129-130 
°C (from EtOAc); Rf 0.43 (1:1 hexane-EtOAc); v max (KBr) 3342 (N-H), 1637 
(amide I), 1598, 1584, 1543 (amide II), 1495 and 832 (para-disubstituted 
benzene) crrr1; §h (D6-acetone) 8.74 (1 H, br s, OH), 7.29 (2  H, AA'BB1, 3J= 
8 .6 , 3-H), 6 . 8 6  (1 H, br s, NH), 6.78 (2 H, AA'BB', 3J= 8 .6 , 2-H), 3.39 (2 H, s, 5- 
H), 2.06 (2  H, t, 3J= 7 .5, 9-H), 1.75-0.90 (13 H, m, 10-H, 11-H, 13-H and 14-H) 
and 1.36 (6  H, s, 7-H); 6C (D6-acetone) 173.6 (C-8 ), 157.5 (C-1), 133.9 (C-3),
127.0 (C-4), 116.8 (C-2 ), 54.5 (C-6 ), 46.2 (C-5), 38.0 (C-11), 34.9 (C-9), 33.8 
(C-10), 33.8 (C-13), 27.0 (C-1 2 ), 27.0 (C-7) and 26.9 (C-14); m/z 335 (M+, 2 .2 ), 
210 (3.0), 180 (67.6), 125 (21.9), 95 (9.2) and 58 (100%); (Found: M+, 
335.1907; C, 68.20; H, 8.84; N, 4.18%. C19H29NO2S requires M, 335.1919; C, 
68.02; H, 8.71; N, 4.17%).
A/-[2-[(4-Hydroxyphenyl)thio]-1,1-dimethylethyl]-4-cyclohexylbutanamide
(107)
OH
N
H
- 136-
A mixture of 4-hydroxythiophenol (1.00 g, 7.93 mmol) and oxazoline 99 (1.77 g, 
7.93 mmol) was stirred under N2 for 7 h at 130 °C. Upon cooling to r.t., the 
crude product was purified by flash chromatography on silica gel eluting with 
hexane - EtOAc (3:2) followed by crystallisation to afford sulfide 107 (1.79 g, 
65%) as white crystals, m.p. 110 °C (from EtOAc-hexane); Rf 0.49 (1:1 EtOAc- 
hexane); v max(KBr) 3334 (N-H), 1632 (amide I), 1586, 1546 (amide II), 1496 
and 822 (para-disubstituted benzene) cm '1; §h (D6-acetone) 7.28 (2 H, AA'BB', 
3J= 8.5, 3-H), 6.93 (1 H, br s, NH), 6.78 (2  H, AA'BB', 3J= 8.5, 2 -H), 3.40 (2 H, 
s, 5-H), 2.04 (2 H, t, 3J= 7.7, 9-H), 1.80- 1.05 (15 H, m, 10-H, 11-H, 13-H, 14-H 
and 15-H) and 1.36 ( 6  H, s, 7-H); 8 C (D6-acetone) 173.8 (C-8 ), 157.7 (C-1),
133.9 (C-3), 126.8 (C-4), 116.8 (C-2 ), 54.7 (C-6 ), 46.1 (C-5), 38.2 (C-1 2 ), 37.7 
(CH2), 37.6 (CH2), 34.0 (CH2), 27.3 (CH2), 27.0 (CH2), 27.0 (C-7) and 23.9 
(CH2); m/z 349 (M+, 2.4), 224 (2.7), 210 (3.3), 180 (68.5), 125 (14.3), 107 (3.3) 
and 58 (100%); (Found: M+, 349.2051; C, 68.67; H, 8.75; N, 3.94%. 
C20H31NO2S requires M, 349.2075; C, 68.73; H, 8.94; N, 4.01%).
A/-[2-[(4-Hydroxyphenyl)thio]-1,1-dimethylethyl]-5-cyclohexylpentanamide
(108)
OH
N
H
A mixture of 4-hydroxythiophenol (1.44 g, 11.4 mmol) and oxazoline 100 (2.71 
g, 1 1 .4 mmol) was stirred under N2 for 4 h at 130 °C. Upon cooling to r.t., the 
oily reaction mixture was triturated using a glass rod to give a white precipitate 
which was crystallised to afford sulfide 108 (2.42 g, 58%) as white crystals, m.p. 
125-126 °C (from EtOAc-hexane); Rf 0.49 (1:1 EtOAc-hexane); v max (KBr) 3340 
(N-H), 1636 (amide I), 1584, 1550 (amide II), 1494 and 830 (para-disubstituted 
benzene) cm '1; 8 h (D^methanol) 7.05 (2 H, AA'BB', 3J= 8.7, 3-H), 6.50 (2 H, 
AA'BB', 3J= 8.7, 2-H), 3.12 (2 H, s, 5-H), 1.81 (2 H, t, 5J=7.1, 9-H), 1.50 - 0.70 
(17 H, m, 10-H, 11-H, 12-H, 13-H, 14-H, 15-H and 16-H) and 1.14 (6  H, s, 7-H); 
8C (D4-methanol) 175.9 (C-8 ), 157.9 (C-1), 134.5 (C-3), 127.2 (C-4), 116.9 (C-
2 ), 55.2 (C-6 ), 46.4 (C-5), 38.8 (C-12), 38.4 (CH2), 37.7 (CH2), 34.5 (CH2), 27.8 
(CH2), 27.5 (CH2), 27.5 (CH2), 27.3 (C-7) and 27.1 (CH2); m/z 363 (M+, 3.0),
- 137-
224 (3.7), 180 (82.4), 139 (3.6), 125 (14.4) and 58 (100%); (Found: M+, 
363.2230; C, 69.34; H, 9.21; N, 3.86%. C21H33NO2S requires M, 363.2232; C, 
69.38; H, 9.15; N, 3.85%).
A/-[2-[(4-Hydroxyphenyl)thio]-1,1-dimethylethyl]cyclopentanecarboxamide
(109)
OH
N
H
A mixture of 4-hydroxythiophenol (2.35 g, 18.6 mmol) and oxazoline 101 (3.12 
g, 18.6 mmol) was stirred under N2 for 4 h at 130 °C. Upon cooling to r.t., the 
oily reaction mixture was triturated using a glass rod to give a white precipitate 
which was crystallised to afford sulfide 109 (3.93 g, 72%) as white crystals, m.p. 
143-144 °C (from aq. EtOH); Rf 0.31 (1:1 hexane-EtOAc); v max(KBr) 3342 (N- 
H), 1639 (amide I), 1600, 1584, 1544 (amide II), 1495 and 830 (para- 
disubstituted benzene) cm-1; 5h (D6-acetone) 8.44 (1 H, br s, OH), 7.11 (2 H, 
AA'BB', 3J= 8.7, 3-H), 6.60 (2 H, AA'BB', 3 j=  8.7, 2-H), 6.56 (1 H, br s, NH), 
3.21 (2 H, s, 5-H), 2.36 (1 H, m, 9-H), 1.60-1.22 (8  H, m, 10-H and 11-H) and 
1.17 (6  H, s, 7-H); 5C (D6-acetone) 176.5 (C-8 ), 157.5 (C-1), 133.8 (C-3), 127.1 
(C-4), 116.8 (C-2 ), 54.5 (C-6 ), 46.2 (C-9), 46.2 (C-5), 31.0 (C-10), 27.0 (C-7) 
and 26.7 (C-1 1 ); m/z 293 (M+, 4.6), 180 (74.7), 168 (3.4), 154 (6.4), 125 (14.5) 
and 58 (100%); (Found: M+, 293.1451; C, 65.58; H, 8.02; N, 4.83%. 
C16H23N02S requires M, 293.1449; C, 65.49; H, 7.90; N, 4.77%).
A/-[2-[(4-Hydroxyphenyl)thio]-1,1 -dimethylethyl]butanamide (110)
OH
N
H
- 138-
A mixture of 4-hydroxythiophenol (2.49 g, 19.7 mmol) and oxazoline 102 (2.79 
g, 19.7 mmol) was stirred under N2 for 4 h at 130 °C. Upon cooling, the reaction 
mixture was dissolved in ethanol ( 1 0  cm3) and diluted by slow addition of water 
( 2 0  cm3) to give a fine precipitate which was filtered and washed with diethyl 
ether. Crystallisation afforded sulfide 110 (3.24 g, 61%) as white crystals, m.p. 
99-100 °C (from EtOAc); Rf 0.28 (2:1 hexane-EtOAc); v max (KBr) 3241 (N-H), 
1635 (amide I), 1599, 1585, 1546 (amide II), 1496 and 830 (para-disubstituted 
benzene) cm '1; 5H (C D C I3 )  8 . 8 6  (1 H, br s, OH), 7.27 (2  H, AA'BB', 3J= 8.5, 3- 
H), 6.77 (2 H, AA'BB', 3J= 8.5, 2-H), 5.57 (1 H, br s, NH), 3.34 (2 H, s, 5-H), 
1.97 (2 H, t, 3J= 7.2, 9-H), 1.53 (2 H, tq, 3J= 7.2 and 7.3, 1 0 -H), 1.39 ( 6  H, s, 7-
H) and 0 . 8 8  (3 H, t, 3J= 7.3, 1 1 -H); 5C (C D C I3 )  174.0 (C-8 ), 156.6 (C-1 ), 133.5 
(C-3), 125.1 (C-4), 116.3 (C-2), 54.6 (C-6 ), 45.8 (C-5), 39.3 (C-9), 26.9 (C-7),
19.1 (C-1 0 ) and 13.6 (C-1 1 ); m /z  267 (M+, 7.6), 180 (75.7), 165 (4.5), 142 
(4.2). 125 (10.5) and 58 (100%); (Found: M+, 267.1293; C, 62.86; H, 7.73; N, 
5.23%. C14H21NO2S requires M, 267.1293; C, 62.89; H, 7.92; N, 5.24%).
A/-[2-[(4-Hydroxyphenyl)thio]-1,1-dimethylethyl]-2-methylpropanamide
(111)
OH
N
H
A mixture of 4-hydroxythiophenol (1.64 g, 13.0 mmol) and oxazoline 103 (1.84 
g, 13.0 mmol) was stirred under N2 for 4 h at 130 °C. Upon standing overnight 
at r.t., the oily reaction mixture solidified to give a white precipitate which was 
crystallised to afford sulfide 111 (2.41 g, 69%) as white crystals, m.p. 139-140 
°C (from hexane-EtOAc); Rf 0.31 (2:1 hexane-EtOAc); vmax (KBr) 3329 (N-H), 
1642 (amide I), 1599, 1582, 1556 (amide II), 1497 and 831 (para-disubstituted 
benzene) cm '1; 6 H (CDCI3+D6-DMSO) 9.16 (1 H, br s, OH), 7.24 (2 H, AA'BB', 
3J= 8 .6 , 3-H), 6.74 (2 H, AA'BB', 3J= 8 .6 , 2-H), 6.38 (1 H, br s, NH), 3.29 (2  H, 
s, 5-H), 2.29 (1 H, septet, 3J= 6 .8 , 9-H), 1.36 (6  H, s, 7-H) and 1.05 (6  H, d, 3J=
6 .8 , 1 0 -H); 6 C (CDCI3+D6-DMSO) 176.7 (C-8 ), 156.4 (C-1), 132.8 (C-3), 125.1 
(C-4), 115.9 (C-2 ), 53.5 (C-6 ), 45.9 (C-5), 35.2 (C-9), 26.4 (C-7) and 19.4 (C-
-  139 -
10); m /z  267 (M+, 5.3), 180 (6 8 .6 ), 165 (4.9), 142 (4.3), 125 (13.4) and 58 
(100%); (Found: M+, 267.1282; C, 62.94; H, 7.94; N, 5.24%. C14H2 iN 0 2S 
requires M, 267.1293; C, 62.89; H, 7.92; N, 5.24%).
2,2'-(1,2-Ethanediyl)bis[4,5-dihydro-4,4-dimethyloxazole] (112)
Using the procedure of Furuta ef a/ .121 on a 50 mmol scale, the title compound 
was prepared in 70% yield as white crystals, m.p. 82-83 °C (from EtOAc). The 
1H NMR spectral data were in good agreement with those reported in the 
literature .121
New data: v max (KBr) 2970 (C-H), 1661 (C=N), 1464, 1366, 1148 (C-O) and 983 
c m 1; 6 C (CDCI3) 164.5 (C-4), 79.1 (C-3), 67.0 (C-2 ), 28.4 (C-1 ) and 24.7 (C-5); 
m/z 224 (M+, 6.4), 209 (49.1), 169 (21.9), 137 (100) and 110 (10.3%); (Found: 
M+, 224.1517; C-|2H20N2O2 requires M, 224.1525).
/V-b/s-[2-[(4-Hydroxyphenyl)thio]-1,1 -dimethylethyl]succinamide (113)
OH OH
H H
A mixture of 4-hydroxythiophenol (500 mg, 3.97 mmol) and bis-oxazoline 112 
(440 mg, 1.99 mmol) was stirred under N2 for 4 h at 130 °C. Cooling to r.t., 
followed by flash chromatography on silica gel eluting with EtOAc furnished, 
after crystallisation, title compound 113 (340 mg, 36%) as white crystals, m.p. 
179-180 °C (from EtOAc); Rf 0.6 (EtOAc); vmax(KBr) 3330 (N-H), 1643 (amide
I), 1600, 1583, 1551 (amide II) and 829 (para-disubstituted benzene) cm-1; 8 h 
(De-DMSO) 9.35 (2 H, br s, OH), 7.35 (2 H, br s, NH), 7.04 (4 H, AA'BB', 3J= 
8.0, 3-H), 6.54 (4 H, AA'BB', 3J= 8.0, 2-H), 3.10 (4 H, s, 5-H), 2.03 (4 H, s, 9-H) 
and 1.09 ( 1 2  H, s, 7-H); 6 C (D6-DMSO) 171.5 (C-8 ), 156.5 (C-1), 132.6 (C-3),
125.3 (C-4), 116.1 (C-2 ), 53.4 (C-6 ), 44.9 (C-5), 31.8 (C-9), and 26.5 (C-7); m/z
- 140-
476 {M+, 2.8), 337 (6.3), 297 (15.0), 280 (26.9) and 181 (100%); (Found: M+, 
476.1840. C24H32N2O4S2 requires M, 476.1803).
2,4-Diethyl-4,5-dihydro-oxazole (114)
General procedure 2  was employed as follows: A mixture of propanonitrile (3.15 
g, 57.2 mmol), (±)-2-amino-1 -butanol (5.10 g, 57.2 mmol) and cadmium 
diacetate dihydrate (0.380 g, 1.43 mmol) was stirred for 3 d at 130 °C. 
Distillation of the crude product gave oxazoline 114 (5.78 g, 79%) as a 
colourless oil, b.p. 62-66 °C/25 mmHg; vmax (neat) 2964 (C-H), 1670 (C=N), 
1215, 1183 (C-O) and 1015 cm-1; 5H (C D C I3 )  4.09 (1 H, dd, 2J = -8.4, 3J=7 .6 , 4- 
Ha), 3.83 (1 H, m, 3-H), 3.66 (1 H, dd, 2J = -7.6 , 3J=7 .6 , 4-H&), 2.10 (2  H, q, 3J=
7.5, 6 -H), 1.39 (2 H, m, 2-H), 1.00 (3 H, t, 3J= 7.5, 7-H) and 0.80 (3 H, t, 3J=7A ,
1 -H); 6 C (CDCI3 ) 168.2 (C-5), 71.6 (C-4), 67.1 (C-3), 28.4 (C-2 ), 21.3 (C-6 ),
1 0 .2  (C-7) and 9.6 (C-1); m/z 127 (M+, 7.0), 98 (89.2), 82 (57.4), 70 (100), 56
(33.1) and 43 (19.3%); (Found: M+, 127.0995; C7H13NO requires M, 127.0997).
2-Cyclohexyl-4-ethyl-4.5-dihydro-oxazole (115)
General procedure 2  was employed as follows: A mixture of cyclohexane 
carbonitrile (4.83 g, 44.2 mmol), (±)-2-amino-1 -butanol (3.94 g, 44.2 mmol) and 
cadmium diacetate dihydrate (0.392 g, 1 .47 mmol) was stirred for 3 d at 130 °C. 
Distillation of the crude product gave oxazoline 115 (4.37 g, 55%) as a 
colourless oil, b.p. 95-97 °C/15 mmHg; vmax(neat) 3380, 2932, 1664 (C=N),
-  141 -
1450 and 1 0 2 0  (C-O) c n r1; 8 H (CDCI3) 4.13 (1 H, dd, 2J = -7.6, 3J= 9.1, 4-Ha), 
3.91 (1 H, m, 3-H), 3.72 (1 H, dd, 2J= -7.6, 3J=7.6, 4-H&), 2.18 (1 H, m, 6 -H), 
1.84-1.11 (12 H, m, 2 -H, 7-H, 8 -H and 9-H) and 0.81 (3 H, t, 3J= 7.5, 1-H); 5C 
(CDCI3) 170.5 (C-5), 71.3 (C-4), 66.9 (C-3), 37.3 (C-6 ), 29.8 (C-7), 28.3 (C-2 ),
25.7 (C-9), 25.5 (C-8 ) and 9.5 (C-1); m/z 181 (M+, 1 2 ), 168 (32), 152 (26), 128 
(28), 126 (27), 83 (65) and 58 (1 0 0 %); (Found: M+, 181.1474; C n H 19NO 
requires M, 181.1467).
N-[ 1 -[[(4-Hydroxyphenyl)thio]methyl]propyl]propanamide (116)
OH
7
N
H
A mixture of 4-hydroxythiophenol (1.40 g, 11.1 mmol) and oxazoline 114 (1.41 
g, 11.1 mmol) was stirred under N2 for 4 h at 130 °C. Upon cooling to r.t., the 
oily reaction mixture was triturated using a glass rod to give a white precipitate 
which was crystallised to afford sulfide 116 (2.23 g, 79%) as white crystals, m.p. 
105-106 °C (from hexane-EtOAc); Rf 0.43 (EtOAc); vmax(KBr) 3340 (N-H), 1640 
(amide I), 1596, 1582, 1548 (amide II), 1496 and 828 (para-disubstituted 
benzene) cm '1; 5h (CDCI3 ) 8.79 (1 H, br s, OH), 7.14 (2 H, AA'BB', 3J= 8 .2 , 3- 
H), 6.63 (2 H, AA'BB', 3J= 8.2, 2-H), 5.43 (1 H, br d, 3J= 8.3, NH), 3.80 (1 H, m,
6 -H), 2.77 (1 H, dd,2J= -13.6, 3J=5.2, 5-Ha), 2.65 (1 H, dd, 2J = -13.6, 3J= 6.7, 5- 
Hb), 1.99 (2 H, q, 3J= 7.4, 10-H), 1.50 (1 H, m, 7-Ha), 1.26 (1 H, m, 7-H/,), 0.94 
(3 H, t, 3J= 7.4, 11-H) and 0.69 (3 H, t, 3J= 7 .2, 8 -H); 5C (CDCI3) 175.0 (C-9),
157.0 (C-1), 134.1 (C-3), 123.3 (C-4), 116.3 (C-2 ), 50.3 (C-6 ), 40.4 (C-5), 29.8 
(C-10), 26.6 (C-7), 1 0 . 2  (C-11) and 10.0 (C-8 ); m/z 253 (M+, 7.4), 180 (58.5), 
165 (4.9), 139 (5.9), 125 (11.1) and 58 (100); (Found: M+, 253.1155; C, 61.69; 
H, 7.47; N, 5.55%. C13H 19N 02S requires M, 253.1136; C, 61.63; H, 7.56; N, 
5.53%).
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A/-[1-Ethyl-2-[(4-hydroxyphenyl)thio]ethyl]cyclohexanecarboxamide
(117)
OH
4
S .  5
O
6 N 9
H
11
10 12
13
A mixture of 4-hydroxythiophenol (0.52 g, 4.2 mmol) and oxazoline 115 (0.75 g,
4.2 mmol) was stirred under N2 for 4 h at 130 °C. Upon standing overnight at 
r.t., the oily reaction mixture solidified to give a white precipitate which was 
crystallised to afford sulfide 117 (0.83 g, 65%) as white crystals, m.p. 124-125 
°C (from EtOAc); Rf 0.26 (EtOAc); vmax(KBr) 3325 (N-H), 1640 (amide I), 1600, 
1579, 1543 (amide II), 1496 and 828 (para-disubstituted benzene) cm '1; 6 h 
(CDCI3 ) 8.59 (1 H, br s, OH), 7.26 (2 H, AA'BB', 3J= 8.7, 3-H), 6.74 (2 H, 
AA'BB', 3J= 8.7, 2-H), 5.45 (1 H, br d, 3J= 8.7, NH), 3.91 (1 H, m, 6 -H), 2.87 (1 
H, 66,2J= -14.0, 3J= 5.4, 5-Ha), 2.75 (1 H, dd, 2J = -14.0, 3J= 6.9, 5-Hb), 1.98 (1 
H, m, 10-H), 1.85-1.05 (12 H, m, 7-H, 11-H, 12-H and 13-H) and 0.80 (3 H, t, 
3J= 7.4, 8 -H); 6 C (CDCI3 ) 177.3 (C-9), 157.2 (C-1), 134.5 (C-3), 123.3 (C-4),
116.3 (C-2 ), 49.6 (C-6 ), 46.0 (C-10), 40.6 (C-5), 29.7 (C-11), 26.7 (C-7), 25.5 
(C- 1 2  and C-13) and 10.3 (C-8 ); m/z 307 {M+, 7.0), 180 (100), 139 (9.6), 125
(17.3) and 97 (7.5); (Found: M+, 307.1590; C, 66.51; H, 8.37; N, 4.56%. 
C 17H25NO2S requires M, 307.1606; C, 66.41; H, 8.20; N, 4.56%).
2-Ethyl-4,5-dihydro-4-hydroxymethyl-4-methyloxazole (118)
.OH
7 \
N^ °
- 143-
Using the procedure of Wehrmeister122 on a 59 mmol scale, the title compound 
was prepared in 89% yield as a colourless oil, b.p. 115-117 °C/25 mmHg, 
(lit. , 122 82-83 °C/10 mmHg).
New data: vmax(neat) 1662 (C=N), 1462, 1454, 1378, 1 2 2 2 , 1186, 1152, 1060 
and 1002 cm '1; 5h (D4-methanol) 4.13 (1 H, d, 2J= -8.4, 1-Ha), 3.70 (1 H, d, 2J= 
-8.4, 1 -Hjb), 3.23 (2 H, m, 4-H), 2.10 (2 H, q, 3J=7.6, 6 -H), 1.04 (3 H, s, 2-H) and 
0.98 (3 H, t, 3J= 7.6, 7-H); 8 C (D4-methanol) 171.6 (C-5), 76.2 (C-4), 71.9 (C-3),
68.5 (C-1 ), 23.7 (C-2 ), 22.4 (C-6 ) and 10.7 (C-7); m/z 143 (M+, 0.1), 1 1 2  (100), 
84 (42.1), 56 (56.9) and 41 (9.1%); (Found: M+, 143.0946; C7 H-13NO2 requires 
M, 143.0946).
2-Ethyl-4,5-dihydro-4,4-di(hydroxymethyl)oxazole (119)
Using the procedure of Wehrmeister on a 50 mmol scale, the title compound 
was prepared in 6 6 % yield as white crystals, m.p. 82-83 °C (from EtOAc), 
(lit. , 122 82-83 °C). The 1H NMR spectral data were in good agreement with 
those reported by Meyers and Yamamoto. 123
New data: v max (KBr) 3420 (O-H), 1665 (C=N) and 1032 (C-O) cm '1; 5C (CDCI3)
171.6 (C-4), 75.7 (C-2 ), 71.9 (C-3), 64.8 (C-1), 21.7 (C-5) and 10.4 (C-6 ); m/z 
160 0.4), 128 (27.5), 98 (41.6), 82 (7.4), 72 (9.2), 56 (38.9) and 29
(100%); (Found: (MH)+, 160.0972; C7H13N 0 3 requires MH, 160.0974).
A/-[1-Hydroxymethyl-2-[(4-hydroxyphenyl)thio]-1-methylethyl]propanamide
(120)
A solution of 4-hydroxythiophenol (1.00 g, 7.93 mmol) and oxazoline 118 (1.19 
g, 8.33 mmol) in anhydrous DMF (2  cm3) was stirred under N2 for 7 h at 120 °C. 
After cooling to r.t., the reaction mixture was dissolved in EtOAc (50 cm3), 
washed with water ( 1 0  x 10 cm3) and brine (10 cm3). The organic portion was 
dried (MgS0 4 ) and concentrated in vacuo to give an oil which was purified by 
flash chromatography on silica gel eluting with EtOAc. Crystallisation of the 
resulting oil afforded sulfide 120 (0.63 g, 30%) as white crystals, m.p. 98-100 °C 
(from EtOAc); Rf 0.42 (EtOAc); vmax(KBr) 3424, 3342 (N-H), 1640 (amide I), 
1600, 1585, 1542 (amide II), 1497 and 830 (para-disubstituted benzene) cm '1; 
5h (D6-acetone) 8.59 (1 H, brs, 1-OH), 7.30 (2 H, AA'BB', 3J= 8.7, 3-H), 6 . 8 6  (1 
H, brs , NH), 6.78 (2 H, AA'BB', 3J= 8.7, 2-H), 4.85 (1 H, dd,3J=6.7 and 5.3, 8 - 
OH), 3.68 (1 H, dd, *J=-11.1, 3J= 6 .8 , 8 -Ha), 3.60 (1 H, dd, 2J = ^ A A ,  3J= 5.3, 
8 -Hfc), 3.52 (1 H, d, 2J= -13.1, 5-Ha), 3.20 (1 H, d, 2J=-13.1, 5-Hb), 2.08 (2 H, q, 
3J= 7.6, 10-H), 1.28 (3 H, s, 7-H) and 1.00 (3 H, t, 3J= 7.6, 11-H); 6 C (De­
acetone) 175.1 (C-9), 157.5 (C-1 ), 134.0 (C-3), 126.8 (C-4), 116.8 (C-2 ), 68.4 
(C-8 ), 59.2 (C-6 ), 42.4 (C-5), 30.2 (C-10), 22.3 (C-7) and 10.1 (C-11 ); m/z 269 
(M+, 3.9), 196 (59.3), 182 (8.4), 139 (9.3), 126 (64.3) and 74 (100%); (Found: 
M+, 269.1082; C, 57.97; H, 7.08; N, 5.20%. C13H19N 03S requires M, 269.1086; 
C, 57.97; H, 7.11; N, 5.20%).
/V-[1,1-Di(hydroxymethyl)-2-[(4-hydroxyphenyl)thio]ethyl]propanamide
(121)
A solution of 4-hydroxythiophenol (1.50 g, 11.9 mmol) and oxazoline 119 (2.08 
g, 13.1 mmol) in anhydrous DMF (5 cm3) was stirred under N2 for 7 h at 120 °C. 
After cooling to r.t., the reaction mixture was dissolved in EtOAc (100 cm3), 
washed with water (10 x 15 cm3) and brine (15 cm3). The organic portion was 
dried (MgS0 4 ) and concentrated in vacuo to give an oil which was purified by 
flash chromatography on silica gel eluting with EtOAc. Crystallisation of the 
resulting oil afforded sulfide 121 (0.72 g, 21%) as white crystals, m.p. 117-118 
°C (from EtOAc); Rf 0.3 (EtOAc); vmax(KBr) 3273 (O-H), 1652 (amide I), 1601, 
1585, 1564 (amide II), 1495 and 829 (para-disubstituted benzene) cm '1; §h (D4- 
methanol) 7.10 (2 H, AA'BB', 3J= 6.7, 3-H), 6.52 (2 H, AA'BB', 3J= 6.7, 2-H),
I 7 I o
OH OH
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3.62 ( 2  H, d, 2J=-11.1, 7-Ha), 3.54 (2 H, d, 2J=-11.1, 7-Hb), 3.13 (2 H, s, 5-H), 
1.87 (2 H, q, 3J= 7.6, 9-H) and 0.82 (3 H, t, 3J= 7.6, 10-H); 5C (D4-methanol)
177,5 (C-8 ), 158.0 (C-1), 134.7 (C-3), 126.7 (C-4), 116.9 (C-2), 63.4 (C-7), 62.8 
(C-6 ), 38.3 (C-5), 30.3 (C-9) and 1 0 .1  (C-1 0 ); m/z 285 (M+, 4.6), 234 (6.5), 2 1 2
(49.9), 139 (19.8), 126 (70.3) and 57 (1 0 0 %); (Found: M+, 285.1030; C, 54.76; 
H, 6.60; N, 4.88%. C 13H 19N 04S requires M, 285.1035; C, 54.72; H, 6.71; N, 
4.91%).
A/-[2-[(4-Hydroxyphenyl)thio]-1,1-(propamethylene)ethyl]propanamide
(126)
H C L 1
A mixture of 1-amino-1-(hydroxymethyl)cyclopentane (0.43 g, 3.7 mmol), 
propanonitrile (0.21 g, 0.27 cm3, 3.7 mmol) and cadmium diacetate dihydrate 
(25 mg, 94 pmol) was stirred under gentle reflux (oil bath 120 °C) for 3 d. Upon 
cooling to r.t., the crude intermediate was transferred to a flask containing 4- 
hydroxythiophenol (0.47 g, 3.73 mmol) and stirred under N2 for 5 h at 130 °C to 
give a viscous yellow oil. Purification by flash chromatoraphy on silica gel 
eluting with EtOAc-hexane (1:2 then 1:1) followed by crystallisation of the 
resulting oil furnished title compound 126 (0.49 g, 47%), as white crystals, m.p. 
140-142 °C (from hexane-EtOAc); Rf 0.27 (1:1 hexane-EtOAc); v max (KBr) 3345 
(N-H), 1636 (amide I), 1599, 1585, 1546 (amide II) and 831 (para-disubstituted 
benzene) cm’1; 6 H (D6-DMSO) 9.34 (1 H, br s, OH), 7.38 (1 H, br s, NH), 7.06 
(2 H, AA'BB1, 3J= 8 .6 , 3-H), 6.54 (2 H, AA'BB', 3J= 8 .6 , 2-H), 3.19 (2 H, s, 5-H), 
1.95 - 1.75 (4 H, m, 7-Ha and 10-H), 1.62 - 1.25 (6  H, m, 7-Hb and 8 -H) and 
0.76 (3 H, t, 3J= 7.6, 1 1 -H); 5C (D6-DMSO) 173.1 (C-9), 156.4 (C-1), 132.5 (C-
3), 125.3 (C-4), 116.0 (C-2 ), 63.9 (C-6 ), 42.7 (C-5), 36.9 (C-7), 28.9 (C-1 0 ),
23.4 (C-8 ) and 10.0 (C-11); m /z  279 (M+, 4.6), 206 (47.7), 140 (19.0), 125
(16.4) and 84 (100%); (Found: M+, 279.1285; C, 64.22; H, 7.67; N, 5.04%. 
C i5H2 iN 0 2S requires M, 279.1293; C, 64.48; H, 7.58; N, 5.01%).
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/V-[2-[(4-Ethanoyloxyphenyl)thio]-1,1 -dimethylethyl]ethanamide (127)
O
O
3
The general procedure of Furniss et a/.109 was employed as follows: Ice (10 g) 
was added to a solution of compound 92 (0.860 g, 3.59 mmol) in 3 mol dm ' 3 aq. 
NaOH (10 cm3). After 5 min, acetic anhydride (0.54 g, 0.50 cm3, 5.29 mmol) 
was added and the mixture swirled for 5 min. whereupon the crude precipitated 
product was collected by filtration and recrystallised to afford ester 127 (0.92 g, 
92%) as white crystals, m.p. 71 °C (from EtOAc-hexane); Rf 0.43 (EtOAc); v max 
(KBr) 3395 (N-H), 1741 (C=0), 1633 (amide I), 1550 (amide II) and 838 (para- 
disubstituted benzene) cm '1; 8 h (D6-acetone) 7.27 (2 H, AA'BB', 3J= 8 .8 , 5-H), 
6.90 (2 H, AA'BB', 3J= 8 .8 , 4-H), 6.80 (1 H, br s, NH), 3.37 (2 H, s, 7-H), 2.08 (3 
H, s, 1-H), 1.59 (3 H, s, 11-H) and 1.23 (6  H, s, 9-H); 5C (D6-acetone) 170.2 (C-
1 0 ), 169.6 (C-2 ), 150.1 (C-3), 135.5 (C-6 ), 131.2 (C-5), 123.1 (C-4), 54.4 (C-8 ),
43.8 (C-7), 27.1 (C-9), 23.8 (C-11) and 21.0 (C-1); m /z  281 (M+, 2.3), 2 2 2
(14.9), 180 (23.7), 100 (19.1) and 59 (100%); (Found: M+, 281.1076; C, 59.89; 
H, 6.79; N, 4.92%. C i4 H 19N 03S requires M, 281.1086; C, 59.76; H, 6.81; N, 
4.97%).
2-Ethyl-4,5-dihydro-oxazole (130)
1 2
r r
V°13
The title compound 130 was prepared in 65% yield on a 120 mmol scale using 
general procedure 2  (3 d) and gave b.p. 128-129 °C/760 mmHg, (lit. , 126  124- 
126 °C/760 mmHg). The IR, 1H NMR and MS spectral data were in good 
agreement with those reported in the literature. 127
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New data: 5C (CDCI3) 169.3 (C-3), 67.0 (C-2 ), 54.1 (C-1), 2 1 . 1  (C-4) and 10.0 
(C-5).
4,5-Dihydro-2-(1 -methylethyl)oxazole (131)
1 2 
V°T 3
The title compound 131 was prepared in 67% yield on a 120 mmol scale using 
general procedure 2  (3 d) and gave b.p. 136-137 °C/760 mmHg, (lit. , 128 64 
°C/50 mmHg). The IR, 1H NMR and MS spectral data were in good agreement 
with those reported in the literature. 127-128
New data: 5C (CDCI3) 172.4 (C-3), 67.0 (C-2 ), 54.1 (C-1 ), 27.9 (C-4) and 19.5 
(C-5).
4,5-Dihydro-2-propyloxazole (132)
1 2
r ^ \
N ^ °  
3
. 4
The title compound 132 was prepared in 50% yield on a 120 mmol scale using 
general procedure 2  (3 d) and gave b.p. 148-150 °C/760 mmHg, (lit. , 129 148- 
149 °C/760 mmHg). The IR, 1H NMR and MS spectral data were in good 
agreement with those reported in the literature. 127
New data: 6 C (CDCI3) 168.0 (C-3), 66.7 (C-2 ), 54.1 (C-1 ), 29.5 (C-4), 19.1 (C-5) 
and 13.4 (C-6 ).
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2-Butyl-4,5-dihydro-oxazole (133)
1 2
r ^ \
N ^ °  
3
vsV s\ 7
The title compound 133 was prepared in 65% yield on a 60 mmol scale using 
general procedure 2  (3 d) and gave b.p. 173-174 °C/760 mmHg, (lit. , 130  174- 
175 °C/760 mmHg). The IR spectral data were in good agreement with those 
reported in the literature. 130
New data: 5H (CDCI3) 4.01 (2  H, t, 3J= 8.5, 2 -H), 3.52 (2  H, t, 3J= 8.5, 1 -H), 2.08 
(2 H, t, 3J= 7.9, 4-H), 1.41 (2 H, m, 5-H), 1.25 (2 H, m, 6 -H) and 0.83 (3 H, t, 3J= 
7.3, 7-H); 6 C (CDCI3) 168.4 (C-3), 6 6 . 8  (C-2 ), 54.1 (C-1), 27.8 (C-4), 27.4 (C-5),
2 2 .1  (C-6 ) and 13.5 (C-7); m/z 127 (M+, 5), 98 (31), 85 (100), 57 (31) and 41 
(35%).
4,5-Dihydro-2-(1,1 -dimethylethyl)oxazole (134)
N ^ °  
3
The title compound 134 was prepared in 43% yield on a 25 mmol scale using 
general procedure 2  (3 d) and gave b.p. 138-141 °C/760 mmHg, (lit. , 131 142- 
143 °C/760 mmHg). The IR, 1H NMR and MS spectral data were in good 
agreement with those reported in the literature. 127
New data: 8C (CDCI3) 174.7 (C-3), 67.2 (C-2), 63.4 (C-4), 54.0 (C-1) and 27.5 
(C-5).
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2-Cyclohexyl-4,5-dihydro-oxazole (129)
1 2
The title compound 129 was prepared in 43% yield on a 60 mmol scale using 
general procedure 2 (3 d) and gave b.p. 130-132 °C/25 mmHg, (lit.,125 120 
°C/15 mmHg). The IR spectral data were in good agreement with those 
reported by Witte and Seeliger.117
New data: 5H (CDCI3) 4.08 (2 H, t, 3J=8A , 2-H), 3.69 (2 H, t, 3J= 8.4, 1-H), 2.15 
(1 H, m, 4-H) and 1.84-1.06 (10 H, m, 5-H, 6-H and 7-H); 6C (CDCI3) 171.5 (C-
3), 66.8 (C-2), 54.1 (C-1), 37.2 (C-4), 29.7 (C-5), 25.7 (C-7) and 25.5 (C-6).
/V-[2-[(4-Hydroxyphenyl)thio]ethyl]propanamide (136)
OH
S
6 N 
H
A mixture of 4-hydroxythiophenol (3.10 g, 24.6 mmol) and oxazoline 130 (2.43 
g, 2.48 cm3, 24.6 mmol) was stirred under N2 for 3 h at 130 °C. Upon cooling to 
r.t., the oily reaction mixture was triturated using a glass rod to give a white 
precipitate which was crystallised to afford sulfide 136 (4.82 g, 87%) as white 
crystals, m.p. 81-82 °C (from hexane-EtOAc); Rf 0.34 (EtOAc); v max (KBr) 3290 
(N-H), 1641 (amide I), 1601, 1591, 1562 (amide II), 1496 and 820 (para- 
disubstituted benzene) cm '1; 8h (D6-DMSO) 9.82 (1 H, br s, OH), 8.14 (1 H, br 
m, NH), 7.46 (2 H, AA'BB1, 3J= 8.1, 3-H), 6.94 (2 H, AA'BB', 3J= 8.1, 2-H), 3.36 
(2 H, m, 6-H), 3.01 (2 H, t, 3J= 6.9, 5-H), 2.25 (2 H, q, 3J= 7.3, 8-H) and 1.16 (3 
H, t, 3J= 7.3, 9-H); 6C (De-DMSO) 173.2 (C-7), 157.1 (C-1), 133.4 (C-3), 123.3 
(C-4), 116.4 (C-2), 38.6 (C-6), 34.6 (C-5), 28.7 (C-8) and 10.1 (C-9); m/z 225 
(M+, 19), 152 (100), 125 (12), 100 (30). and 57 (17%); (Found: M+, 225.0825;
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C, 58.62; H, 6.63; N, 6.14%. C n H 15N 02S requires M, 225.0823; C, 58.64; H, 
6.71; N, 6 .2 2 %).
/V-[2-[(4-Hydroxyphenyl)thio]ethyl]-2-methylpropanamide (137)
A mixture of 4-hydroxythiophenol (2.31 g, 18.3 mmol) and oxazoline 131 (2.07 
g, 18.3 mmol) was stirred under N2 for 3 h at 130 °C. Cooling to r.t., followed by 
dry-column flash chromatography on silica gel eluting with EtOAc furnished, 
after crystallisation, sulfide 137 (3.14 g, 72%) as white crystals, m.p. 115-116 
°C (from hexane-EtOAc); Rf 0.52 (EtOAc); vmax(KBr) 3331 (N-H), 1641 (amide
I), 1602, 1580, 1549 (amide II), 1495 and 835 (para-disubstituted benzene) cnr 
1; 8 h (De-DMSO) 9.65 (1 H, b rs , OH), 7.95 (1 H, br t, 3J=b. 4, NH), 7.31 (2  H, 
AA'BB', 3J= 8 .6 , 3-H), 6.79 (2 H, AA'BB', 3J= 8 .6 , 2-H), 3.21 (2 H, m, 6 -H), 2.86 
(2 H, m, 5-H), 2.36 (1 H, sept, 3J= 6.9, 8 -H) and 1.02 (6  H, d, 3J= 6.9, 9-H); 8C 
(De-DMSO) 176.3 (C-7), 157.0 (C-1), 133.3 (C-3), 123.2 (C-4), 116.2 (C-2 ),
38.4 (C-6 ), 34.4 (C-5), 34.1 (C-8 ) and 19.6 (C-9); m/z 239 (M+, 17), 152 (100), 
125 (13) and 114 (30%); (Found: M+, 239.0984; C, 60.41; H, 7.27; N, 5.86%. 
C 12H17N 02S requires M, 239.0980; C, 60.22; H, 7.16; N, 5.85%).
A/-[2-[(4-Hydroxyphenyl)thio]ethyl]butanamide (138)
A mixture of 4-hydroxythiophenol (2.17 g, 17.2 mmol) and oxazoline 132 (1.95 
g, 17.2 mmol) was stirred under N2 for 3 h at 130 °C. Upon cooling to r.t., the
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oily reaction mixture was triturated using a glass rod to give a white precipitate 
which was crystallised to afford sulfide 138 (3.24 g, 79%) as white crystals, m.p. 
85-86 °C (from hexane-EtOAc); Rf 0.45 (EtOAc); vmax (KBr) 3284 (N-H), 1636 
(amide I), 1602, 1590, 1560 (amide II), 1496 and 820 (para-disubstituted 
benzene) cm’1; 8 h (D6-DMSO) 9.65 (1 H, br s, OH), 8.00 (1 H, br t, 3J= 5.4, 
NH), 7.30 (2 H, AA'BB1, 3J= 8 .6 , 3-H), 6.79 (2 H, AA'BB', 3J= 8 .6 , 2-H), 3.20 (2 
H, m, 6 -H), 2.85 (2 H, t, 3J= 5.9, 5-H), 2.06 (2 H, t, 3J= 7.2, 8 -H), 1.53 (2 H, m, 
9-H) and 0.88 (3 H, t, 3J= 7.3, 1 0 -H); 8C (D6-DMSO) 172.2 (C-7), 157.0 (C-1),
133.3 (C-3), 123.1 (C-4), 116.2 (C-2 ), 38.4 (C-6 ), 37.4 (C-8 ), 34.5 (C-5 ), 18.8 
(C-9) and 13.7 (C-1 0 ); m/z 239 (M+, 16), 152 (1 0 0 ), 125 (1 2 ) and 114 (29%); 
(Found: M+, 239.0989; C, 59.94; H, 7.10; N, 5.76%. C12H17N 0 2S requires M, 
239.0980; C, 60.22; H, 7.16; N, 5.85%).
AF[2-[(4-Hydroxyphenyl)thio]ethyl]pentanamide (139)
A mixture of 4-hydroxythiophenol (2.00 g, 15.9 mmol) and oxazoline 133 (2.02 
g, 15.9 mmol) was stirred under N2 for 3 h at 130 °C. Upon cooling to r.t., the 
oily reaction mixture was triturated using a glass rod to give a white precipitate 
which was crystallised to afford sulfide 139 (2.99 g, 74%) as white crystals, m.p. 
91-92 °C (from hexane-EtOAc); Rf 0.52 (EtOAc); vmax (KBr) 3286 (N-H), 1636 
(amide I), 1602, 1591, 1563 (amide II), 1497 and 820 (para-disubstituted 
benzene) cm '1; 8 h (D6 -DMSO) 9.60 (1 H, br s, OH), 7.94 (1 H, br t, 3J= 5 .2 , 
NH), 7.26 (2 H, AA'BB', 3J= 8 .6 , 3-H), 6.74 (2 H, AA'BB', 3J= 8 .6 , 2-H), 3.16 (2 
H, m, 6 -H), 2.80 (2  H, t, 3J= 7 .5, 5-H), 2.03 (2 H, t, 3J=7.1, 8 -H), 1.45 (2  H, m, 
9-H), 1.25 (2 H, m, 10-H) and 0.83 (3 H, t, 3J= 7.1, 11-H); 8c (D6-DMSO) 172.6 
(C-7), 157.2 (C-1), 133.4 (C-3), 123.3 (C-4), 116.4 (C-2 ), 38.6 (C-6 ), 35.4 (C-8 ),
34.6 (C-5), 27.6 (C-9), 2 2 .1  (C-10) and 14.0 (C-11); m/z 253 {M+, 14), 152 
(100), 128 (27), 125 (11) and 107 (5%); (Found: M+, 253.1130; C, 61.52; H, 
7.47; N, 5.35%. C i3 H19N 02S requires M, 253.1136; C, 61.63; H, 7.56; N,
OH
H
5.35%).
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/V-[2-[(4-Hydroxyphenyl)thio]ethyl]-2,2-dimethylpropanamide (140)
OH
A mixture of 4-hydroxythiophenol (1.70 g, 13.5 mmol) and oxazoline 134 (1.71 
g, 13.5 mmol) was stirred under N2 for 3 h at 130 °C. Cooling to r.t., followed by 
flash chromatography on silica gel eluting with hexane-EtOAc (3:2) afforded, 
after crystallisation, sulfide 140 (2.20 g, 64%) as white crystals, m.p. 93-94 °C 
(from hexane-EtOAc); Rf 0.60 (EtOAc); vmax(KBr) 3380 (N-H), 1626 (amide I), 
1602, 1578, 1539 (amide II), 1495 and 824 (para-disubstituted benzene) cm '1; 
5h (D6 -DMSO) 9.62 (1 H, br s, OH), 7.65 (1 H, br t, 3J= 5.5, NH), 7.30 (2 H, 
AA'BB', 3J= 8 .6 , 3-H), 6.79 (2 H, AA'BB1, 3J= 8 .6 , 2-H), 3.21 (2 H, m, 6 -H), 2.85 
(2  H, m, 5-H) and 1 . 1 0  (9 H, s, 9-H); 5C (D6-DMSO) 177.6 (C-7), 157.0 (C-1),
133.1 (C-3), 123.3 (C-4), 116.2 (C-2), 39.0 (C-6 ), 38.1 (C-8 ), 34.1 (C-5) and
27.5 (C-9); m/z 253 (M+, 17), 152 (100), 128 (34), 125 (17). and 57 (26%); 
(Found: M+, 253.1139; C, 61.61; H, 7.74; N, 5.34%. C13H i9N 02S requires M, 
253.1136; C, 61.63; H, 7.56; N, 5.53%).
A/-[2-[(4-Hydroxyphenyl)thio]ethyl]cyclohexanecarboxamide (141)
OH
A mixture of 4-hydroxythiophenol (2.00 g, 15.9 mmol) and oxazoline 129 (2.43 
g, 15.9 mmol) was stirred under N2 for 3 h at 130 °C. Upon cooling to r.t., the 
oily reaction mixture was triturated using a glass rod to give a white precipitate 
which was crystallised to afford the sulfide 141 (3.58 g, 81%) as white crystals,
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m.p. 94-95 °C (from hexane-EtOAc); R f 0.58 (EtOAc); vmax (KBr) 3227 (N-H), 
1647 (amide I), 1602, 1581, 1547 (amide II), 1495 and 832 (para-disubstituted 
benzene) cm’1; 8 h (Dg-DMSO) 9.65 (1 H, br s, OH), 7.89 (1 H, br t, 3J= 5.6, 
NH), 7.28 (2 H, AA'BB', 3J= 8.7, 3-H), 6.78 (2 H, AA'BB', 3J= 8.7, 2-H), 3.19 (2
H, m, 6 -H), 2.83 (2 H, m, 5-H), 2.09 (1 H, m, 8 -H), 1.70 (4 H, m, 9-H) and 1.42 -
I.09 ( 6  H, m, 10-H and 11-H); 8 C (D6-DMSO) 175.4 (C-7), 157.0 (C-1), 133.3 
(C-3), 123.2 (C-4), 116.2 (C-2 ), 44.1 (C-8 ), 38.4 (C-6 ), 34.5 (C-5), 29.3 (C-9),
25.6 (C-11) and 25.4 (C-1 0 ); m /z 279 (M+, 1 1 ), 152 (1 0 0 ), 125 (1 1 ) and 83 
(18%); (Found: M+, 279.1298; C, 64.56; H, 7.75; N, 4.95%. C15H2 iN 0 2S 
requires M, 279.1293; C, 64.48; H, 7.58; N, 5.01%).
A/-[2-[(4-Hydroxyphenyl)thio]ethyl]methanamide (143)
OH
H
A solution of 2-[(4-hydroxyphenyl)thio]ethylamine 42 (1.00 g, 18.3 mmol) in 
ethanol (5 cm3) and ethyl formate (20 cm3) was heated under reflux for 12 h. 
On cooling to r.t., the reaction mixture was concentrated in vacuo to give a 
colourless oil which was purified by dry-column flash chromatography on silica 
gel, eluting with EtOAc, to afford carboxamide 143 (0.75 g, 64%) as a white 
powder, m.p. 91-92 °C (from hexane-EtOAc); Rf 0.24 (EtOAc); vmax(KBr) 3323 
(N-H), 1642 (amide I), 1601, 1582, 1562 (amide II), 1496, 1270, 1223 and 819 
(para-disubstituted benzene) cm-1; 8 h (D6-DMSO) 8.21 (1 H, brs, NH), 8.06 (1- 
H, s, 7-H), 7.31 (2  H, AA'BB', 3J= 8.5, 3-H), 6.79 ( 2  H, AA'BB', 3J= 8.5, 2-H), 
3.25 (2 H, m, 6 -H) and 2.87 (2 H, t, 3J= 6.7, 5-H); 8 C (D6-DMSO) 161.4 and
161.3 (C-7), 157.2 (C-1 ), 133.5 (C-3), 122.7 (C-4), 116.3 (C-2 ), 36.9 (C-6 ) and
34.5 (C-5); m /z  197 (M+, 34), 152 (100), 139 (20), 125 (14), 95 (13) and 72 
(27%); (Found: M +, 197.0517; C, 54.77; H, 5.68; N, 6.98%. C g H n N O ^  
requires M, 197.0510; C, 54.80; H, 5.62; N, 7.10%).
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A/-[2-[(4-Benzoyloxyphenyl)thio]ethyl]benzamide (145)
O
H
To a cooled (0 °C) solution of 2-[(4-hydroxyphenyl)th io]ethylam ine 
hydrochloride 42 (0.42 g, 2.0 mmol) in aq. NaOH ( 2  mol dm '3, 10 cm3) was 
added benzoyl chloride (0.69 g, 0.57 cm3, 4.9 mmol). The reaction mixture was 
shaken vigorously for 5 min before collection of the precipitated crude product 
by filtration. Recrystallisation furnished benzamide 145 (0.60 g, 78%) as white 
crystals, m.p. 127-128 °C (from hexane-EtOAc); Rf 0.70 (EtOAc); vmax (KBr) 
3318 (N-H), 1734 and 1728 (ester C=0), 1644 (amide I), 1602, 1579, 1542 
(amide II), 1492, 1313, 1287, 703 and 695 cm '1; 6 H (CDCI3) 8.19 (2  H, m, 3-H), 
7.76 (2 H, m, 14-H), 7.66 (1 H, m, 1-H), 7.58 - 7.32 (7 H, m, 2-H, 8 -H, 15-H and 
16-H), 7.16 - 6.95 (3 H, m, 7-H and N-H), 3.60 (2 H, m, 11-H) and 3.12 (2 H, t, 
3J= 6.3, 1 0 -H); 6 C (CDCI3) 167.7 (C-12), 165.1 (C-5), 149.6 (C-6 ), 134.1 (aryl 
quat. C), 133.8 (aryl quat. C), 132.4 (aryl quat. C), 131.6 (aryl quat. C), 131.1 
(aryl C-H), 130.2 (aryl C-H), 129.2 (aryl quat. C), 128.6 (aryl C-H), 128.5 (aryl 
C-H), 127.0 (aryl C-H), 122.5 (C-7), 39.2 (C-11) and 33.8 (C-10); m/z 377 (M+, 
8 ), 256 (45), 148 (12), 105 (100) and 77 (32%); (Found: M+, 377.1086;. 
C22H19NO3S requires M, 377.1086).
A/-[2-[(4-Hydroxyphenyl)thio]ethyl]benzamide (146)
OH
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A solution of amide 145 (1.00 g, 2.74 mmol) and 1-butylamine (2.00 g, 2.70 
cm3, 27.3 mmol) in anhydrous THF (20 cm3) was stirred at r.t. for 20 h. The 
reaction mixture was concentrated in vacuo and the residue partitioned 
between EtOAc (60 cm3) and 2 mol dn r3 aq. NaOH (40 cm3). The aqueous 
layer was adjusted to pH 2 using 5 mol dm -3 hydrochloric acid and extracted by 
ethyl acetate (2 x 30 cm3). The two organic extracts from this stage were 
combined and washed with brine (30 cm3), dried over MgS0 4  and concentrated 
in vacuo before purification by dry-column flash chromatography on silica gel 
using hexane-ethyl acetate (1:1) as eluent to afford benzamide 146 (0.49 g, 
65%) as white crystals, m.p. 83-84 °C (from hexane-EtOAc); Rf 0.63 (EtOAc); 
Vmax (KBr) 3372 (N-H), 1633 (amide I), 1600, 1578, 1545 (amide II), 1494, 829 
(para-disubstituted benzene) and 710 (monosubstituted benzene) cm-1; 5h 
( C D C I3) 7.92 (1 H, br s, OH), 7.69 (2 H, m, 9-H), 7.46 - 7.36 (3 H, m, 10-H and
11-H), 7.29 (2 H, AA'BB1, 3J=8.4, 3-H), 6.78 (2 H, AA'BB', 3J=QA, 2-H), 6.70 (1 
H, br s, NH), 3.58 (2 H, m, 6 -H) and 3.00 (2 H, t, 3J= 6.2, 5-H); 6 C (C D C I3 )
168.3 (C-7), 156.7 (C-1 ), 134.3 (C-3), 133.7 (C-8 ), 131.9 (C-1 1 ), 128.7 (C-9),
126.9 (C-10), 123.2 (C-4), 116.5 (C-2), 39.2 (C-6 ) and 35.5 (C-5); m/z 273 (M+, 
15), 152 (100), 148 (27), 105 (57) and 77 (35%); (Found: M+, 273.0818; C, 
65.92; H, 5.56; N, 5.04%. C i5H15N 02S requires M, 273.0823; C, 65.91; H, 5.53; 
N, 5.12%).
5,6-Dihydro-2-methyl-4H-1,3-oxazine (147)
The title compound 147 was prepared in 59% yield on a 120 mmol scale using 
general procedure 2  (2  d) and gave b.p. 135-137 °C/760 mmHg, (lit. ,206  132- 
133 °C/760 mmHg). The IR, 1H NMR and 13C NMR spectral data were in good 
agreement with those reported in the literature.206 
New data: m/z 99 {M+, 64), 72 (15), 56 (6 6 ), 42 (100) and 31 (32%)
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2-Cyclohexyl-5,6-dihydro-4H-1,3-oxazine (148)
General procedure 2 was employed as follows: A mixture of cyclohexane 
carbonitrile (2.83 g, 25.9 mmol), 3-amino-1 -propanol (1.95 g, 26.0 mmol) and 
cadmium diacetate dihydrate (0.189 g, 0 . 8 6  mmol) was stirred for 3 d at 130 °C. 
Distillation of the crude product gave dihydrooxazine 148 (1.39 g, 32%) as a 
colourless oil, b.p. 74-76 °C/ 2  mmHg; v max(neat) 2930, 1671 (C=N), 1245 and 
1 1 2 2  (C-O) cm-1; 5h (CDCI3) 3.94 (2  H, m, 3-H), 3.16 (2  H, m, 1 -H), 1.82 (1 H, 
m, 5-H) and 1.75-0.80 (12 H, m, 2-H, 6 -H, 7-H and 8 -H); 6 C (CDCI3) 163.3 (C-
4), 64.5 (C-3), 43.9 (C-5), 41.9 (C-1 ), 29.8 (C-6 ), 25.8 (C-2 ), 25.8 (C-7) and
21.7 (C-8 ); m/z 167 (M+, 6 8 ), 138 (62), 112 (100) and 83 (17%); (Found: M+, 
167.1317; C i0H17NO requires M, 167.1310).
A/-[3-[(4-Hydroxyphenyl)thio]propyl]ethanamide (150)
OH
O
A mixture of 4-hydroxythiophenol (1.92 g, 15.2 mmol) and 5,6-dihydro-2-methyl- 
4H-1,3-oxazine 147 (1.51 g, 15.2 mmol) was stirred under N2 for 4 h at 130 °C. 
Upon cooling to r.t., the oily reaction mixture was purified by dry-column suction 
flash chromatography on silica gel eluting with hexane-EtOAc (1:1) then EtOAc 
to furnish sulfide 150 (2.17 g, 63%) as white crystals, m.p. 76-77 °C (from 
hexane-EtOAc); Rf 0.26 (EtOAc); vmax(KBr) 1620 (amide I), 1597, 1584, 1569 
(amide II), 1494, 1263, 1226 and 838 (para-disubstituted benzene) cm '1; 8 h
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(D6-DMSO) 9.64 (1 H, br s, OH), 7.93 (1 H, br m, NH), 7.26 (2 H, AA'BB', 3J=
8.5, 3 -H), 6.78 (2 H, AA'BB', 3J= 8.5, 2 -H), 3.14 ( 2  H, m, 7-H), 2.81 (2 H, t, 3J=-
7.5, 5-H), 1.83 (3 H, s, 9-H) and 1.63 (2 H, m, 6 -H); 8 C (D6-DMSO) 169.3 (C-8 ),
156.8 (C-1 ), 133.0 (C-3), 123.5 (C-4), 116.2 (C-2 ), 37.6 (C-7), 32.4 (C-5), 29.0 
(C-6 ) and 22.7 (C-9); m/z 225 (M+, 32), 125 (23), 100 (100), 79 (19), 58 (24) 
and 43 (24%); (Found: M+, 225.0824; C, 58.74; H, 6.81; N, 6.14%. C11H15N 02S 
requires M, 225.0823; C, 58.64; H, 6.71; N, 6 .2 2 %).
A/-[3-[(4-Hydroxyphenyl)thio]propyl]-1 -cyclohexylmethanamide (151)
OH
12
O
A mixture of 4-hydroxythiophenol (1.73 g, 13.7 mmol) and 2-cyclohexyl-5,6- 
dihydro-4H-1,3-oxazine 148 (2.29 g, 13.7 mmol) was stirred under N2 for 4 h at 
130 °C. Upon cooling to r.t., the oily reaction mixture was purified by flash 
chromatography on silica gel eluting with hexane-EtOAc (2 :1 ) to furnish sulfide 
151 (2.33 g, 58%) as white crystals, m.p. 84-85 °C (from hexane-EtOAc); Rf 
0.58 (EtOAc); vmax(KBr) 3321 (N-H), 1620 (amide I), 1597, 1578, 1546 (amide
II), 1268, 1223 and 842 (para-disubstituted benzene) c m 1; 8 h (CDCI3) 8.80 (1 
H, br s, OH), 7.23 (2 H, AA'BB', 3J= 8 .6 , 3 -H), 6.63 (2  H, AA'BB', 3J= 8 .6 , 2-H), 
6.15 (1 H, b rt, 3J= 5.6, NH), 3.32 (2 H, m, 7-H), 2.77 (2 H, t, 3J=-7.0, 5 -H), 2.07 
(1 H, m, 9-H), 1.74 ( 6  H, m, 6 -H and 10-H) and 1.50-1.10 (6  H, m, 11-H and 12- 
H); 8 C (CDCI3) 177.5 (C-8 ), 156.6 (C-1), 133.7 (C-3), 124.4 (C-4), 116.2 (C-2 ),
45.5 (C-8 ), 38.5 (C-7), 33.6 (C-5), 29.6 (C-10), 28.9 (C-6 ) and 25.6 (C-1 1 and 
C-1 2 ); m/z 293 {M+, 18), 168 (100), 125 (13), 83 (29) and 55 (15%); (Found: 
M+, 293.1440; C, 65.29; H, 7.92; N, 4.66%. C i6 H23N 02S requires M, 293.1449; 
C, 65.50; H, 7.90; N, 4.47%).
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A/-[3-[(4-Hydroxyphenyl)thio]-1,1 -dimethylbutyljethanamide (152)
OH
A mixture of 4-hydroxythiophenol (1.72 g, 13.6 mmol) and 5,6-dihydro-2,4,4,6- 
tetramethyl-4/-/-1,3-oxazine (1.93 g, 13.6 mmol) was stirred under N2 for 4 h at 
130 °C. Upon cooling to r.t., the oily reaction mixture was triturated using a 
glass rod to give a white precipitate which was crystallised to afford sulfide 152 
(2.72 g, 75%) as white crystals, m.p. 171-172 °C (from acetone); Rf 0 . 2 0  (1:1 
EtOAc-hexane); vmax (KBr) 3098 (N-H), 1628 (amide I), 1598, 1579, 1541 
(amide II) and 830 (para-disubstituted benzene) cm-1; 8 h (D6-DMSO) 9.70 (1 H, 
br s, OH), 7.47 (1 H, br s, NH), 7.30 (2 H, AA'BB', 3J= 8.4, 3-H), 6.80 (2 H, 
AA'BB', 3J= 8.4, 2-H), 3.08 (1 H, m, 5-H), 2.07 (1 H, dd, 2J=- 14.2, 3J= 6.4, 7- 
Ha), 1.85 (4 H, m, 7-Hf, and 12-H), 1.27 (3 H, s, 9-H), 1.25 (3 H, s, 10-H) and 
1.18 (3 H, d, 3J= 6 .6 , 6 -H); 8 C (De-DMSO) 169.1 (C-11), 157.5 (C-1), 135.7 (C- 
3), 122.8 (C-4), 116.1 (C-2), 52.6 (C-8 ), 44.6 (C-7), 40.4 (C-5), 27.9 (C-9), 27.4 
(C-10), 23.8 (C-12) and 2 2 . 8  (C-6 ); m/z 267 (M \  2.5), 142 (50.3), 125 (17.8), 
100 (30.4), 83 (30.2) and 59 (100%); (Found: M+, 267.1281; C, 62.95; H, 7.93; 
N, 5.16%. C i4 H21N 02S requires M, 267.1293; C, 62.89; H, 7.92; N, 5.24%).
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7.3 Experimental to Chapter 5
4,5-Dihydro-4,4-dimethyl-2-[(E)-1 -propenyl]oxazole (154)
4
7
The title compound 154 was prepared in 26% yield on a 40 mmol scale using 
general procedure 2  (2  d) and gave b.p. 72-74 °C/25 mmHg, (lit. , 1 15  62-65 
°C/18 mmHg). The 1H NMR and IR spectral data were in good agreement with 
those reported in the literature. 115
New data: 5C (CDCb) 161.2 (C-4), 138.6 (C-5), 119.1 (C-6 ), 78.4 (C-3), 66.7 
(C-2 ), 28.1 (C-1 ) and 18.1; m/z 139 (M+, 15.7), 124 (1 0 0 ), 96 (47.3), 6 8  (99.8) 
and 41 (90.6%).
4,5-Dihydro-4,4-dimethyl-2-[2-(4-hydroxyphenyl)thio]propyloxazole (155)
OH
A mixture of 4-hydroxythiophenol (0.85 g, 6.7 mmol) and oxazoline 154 (0.94 g, 
6.7 mmol) was stirred under N2 for 2 h at 120 °C. Upon cooling to r.t., the oily 
reaction mixture was subjected to flash chromatography on silica gel using 
EtOAc-light petroleum (1:1) as eluent to afford sulfide 155 (1.25 g, 70%) as a 
white powder, m.p. 115-116 °C (from EtOAc-hexane); Rf 0.44 (EtOAc); vmax 
(KBr) 1654 (C=N), 1594, 1576, 1494 and 834 (para-disubstituted benzene) crrr 
1; SH (C D C I3 )  10.26 (1 H, br s, OH), 7.24 (2  H, AA'BB1, 3j=  8 .6 , 3-H), 6.67 (2  H, 
AA'BB1, 3 j=  8 .6 , 2-H), 3.97 (2 H, m, 9-H), 3.32 (1 H, m, 5-H), 2.60 (1 H, dd, 2J=
9
-  160 -
-14.7, 3J= 6 .1 , 7-Ha), 2.34 (1 H, dd, 2J= -14.7, 3J= 8.8, 7-Hto), 1.31 (3 H, s, 11- 
H), 1.28 (3 H, s, 1 2 -H) and 1.25 (3 H, d, 3J= 7.0, 6 -H); 8 C (CDCI3) 166.0 (C-8 ),
157.9 (C-1 ), 136.8 (C-3), 1 2 0 . 8  (C-4), 116.1 (C-2 ), 79.4 (C-9), 66.7 (C-1 0 ), 40.9 
(C-5), 35.4 (C-9), 28.2 (CH3), 28.1 (CH3) and 20.4 (C-6 ); m/z 265 (M+, 19.1), 
232 (21.1), 153 (19.2), 140 (47.2) and 113 (100%); (Found: M+, 265.1129; C, 
63.23; H, 7.12; N, 5.26%. C i4H19N 02S requires M, 265.1136; C, 63.37; H, 7.22; 
N, 5.28%).
A/-[1,1 -Dimethyl-2-[(4-hydroxyphenyl)thio]ethyl]-3-[(4- 
hydroxyphenyl)thio]butanamide (157)
OH
A mixture of 4-hydroxythiophenol (1.35 g, 10.7 mmol) and oxazoline 154 (0.745 
g, 5.35 mmol) was stirred under N2 for 6  h at 120 °C. Upon cooling to r.t., the 
oily reaction mixture was subjected to flash chromatography on silica gel using 
light petroleum-EtOAc (3:1) as eluent to afford sulfide 157 (1.38 g, 6 6 %) as 
white crystals, m.p. 116-117 °C (from EtOAc-hexane); Rf 0.66 (EtOAc); v max 
(KBr) 3350 (N-H), 1650 (amide I), 1598, 1580, 1536 (amide II) and 830 (para- 
disubstituted benzene) cm-1; 8 h (D6-acetone) 8.73 (2 H, brs, 1-OH and 16-OH), 
7.30 (4 H, m, 3-H and 14-H), 7.11 (1 H, br s, N-H), 6.80 (4 H, m, 2-H and 15-H), 
3.40 (2 H, m, 12-H), 2.39 (1 H, dd, 2J= -14.1, 3J= 5.5, 7-Ha), 2.13 (1 H, dd, 2J= 
-14.1, 3J= 9.2, 7-Hb), 1.37 (3 H, s, 10-H), 1.36 (3 H, s, 11-H) and 1.22 (3 H, d, 
3J= 6.7, 6 -H); 8 C (De-acetone) 171.5 (C-8 ), 158.6 (aryl C-OH), 157.5 (aryl C- 
OH), 137.1 (aryl CH), 134.0 (aryl CH), 126.9 (aryl C-S), 123.4 (aryl C-S), 116.9 
(aryl CH), 116.8 (aryl CH), 55.0 (C-9), 46.1 (C-12), 44.7 (C-7), 41.6 (C-5), 27.0 
(C-10 and C-11) and 21.0 (C-6 ); m/z 391 (M+, 5.5), 252 (7.1), 180 (78.1), 153 
(23.7) and 12.5 (39.3%); (Found: M+, 391.1261. C i4HigN0 2S requires M, 
391.1276).
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A/-[2-[(4-Hydroxyphenyl)thio]-1,1 -dimethylethyl]thioethanamide (164)
OH
2
3 7
8*. - s
6 N  8
H
CAUTION! All experiments involving the use of HMPA must be confined to a 
well-ventilated fume hood.
A solution of amide 92 (2.39 g, 10.0 mmol) and Lawesson Reagent (2.43 g,
6.01 mmol) in HMPA (10 cm3) was stirred under N2 for 2 h at 100 °C. Upon 
cooling to r.t., the mixture was poured into water (50 cm3) and extracted using 
EtOAc (3 x 50 cm3). The combined extracts were washed with brine (50 cm3), 
concentrated in vacuo and the residue flash chromatographed on silica gel with 
hexane-EtOAc (7:3) as eluent to give thioamide 164 (0.79 g, 31%) as a white 
powder, m.p. 95-96 °C; Rf 0.65 (EtOAc); v max(KBr) 3290 (N-H), 1598, 1582, 
1543 (amide II), 1494, 1269 (amide I) and 830 (para-disubstituted benzene) crrr 
1; 5h (CDCI3) 7.28 (2  H, AA'BB', 3J= 8.7, 3-H), 7.05 (1 H, br s, OH), 6.72 (2  H, 
AA'BB', 3J= 8.7, 2-H), 5.87 (1 H, br s, NH), 3.50 (2 H, s, 5-H), 2.29 (3 H, s, 9-H) 
and 1.54 ( 6  H, s, 7-H); 6 C (CDCI3) 200.4 (C-8 ), 155.5 (C-1 ), 133.9 (C-3), 125.9 
(C-4), 116.3 (C-2 ), 59.0 (C-6 ), 44.4 (C-5), 26.7 (C-9) and 25.9 (C-7); m/z 255 
(M+, 10.3), 180 (100), 165 (12.6), 125 (31.0) and 59 (51.7%); (Found: M+, 
255.0755; C, 56.25; H, 6.92; N, 5.29%. C12H17NOS2 requires M, 255.0752; C, 
56.43; H, 6.71; N, 5.48%).
A/-[2-[(4-Hydroxyphenyl)thio]ethyl]thioethanamide (165)
A solution of amide 47 (1.16 g, 5.49 mmol) and Lawesson Reagent (1.93 g, 
2.80 mmol) in DME (30 cm3) was stirred under N2 for 18 h at r.t. The reaction
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mixture was concentrated in vacuo, dissolved in EtOAc (50 cm3) and washed 
with saturated aq. NaHCOs (30 cm3), water (30 cm3) and brine (30 cm3). The 
organic portion was then dried (MgS0 4 ), and concentrated to give an oil which 
was purified by dry-column flash chromatography on silica gel eluting with 
hexane-EtOAc (1:1) to give thioamide 165 (0.720 g, 58%) as a white powder, 
m.p. 118-119 °C; Rf 0.63 (EtOAc); vmax(KBr) 3286 (N-H), 1602, 1581, 1566 
(amide II), 1492, 1224 (amide I) and 827 (para-disubstituted benzene) cm-1; 6 h 
(CDCI3-D4 -methanol) 7.23 (2 H, AA’BB1, 3J= 8.7, 3-H), 6.70 (2 H, AA'BB', 3J= 
8.7, 2-H), 3.66 (2 H, t, 3J= 6.5, 6 -H), 2.96 (2 H, t, 3J= 6.45, 5-H) and 2.39 (3 H, 
s, 8 -H); 6 C (CDCI3-D4-methanol)) 200.9 (C-7), 156.6 (C-1), 134.1 (C-3), 123.1 
(C-4), 116.1 (C-2 ), 45.1 (C-6 ), 33.4 (C-5) and 33.0 (C-8 ); m/z 227 (M+, 36), 152 
(100), 1 0 2  (71), 81 (8 ) and 59 (43%); (Found: M+, 227.0435; C, 52.79; H, 5.94; 
N, 6.03%. C 10H13NOS2 requires M, 227.0439; C, 52.83; H, 5.76; N, 6.16%).
A stirred mixture of 4-hydroxythiophenol (1.76 g, 13.9 mmol), anhydrous K2C 03 
(3.85 g, 27.9 mmol) and de-oxygenated 50% (v/v) aq. 2-propanol (20 cm3) was 
cooled to 0 °C under N2 before addition of 6 -butyrolactone (1.19 g, 1.13 cm3,
13.9 mmol) over 10 min. After stirring for 2 h at r.t., the reaction mixture was 
concentrated to ca. 10 cm3 in vacuo, diluted with saturated aq. NaHCO3 (150 
cm3) and washed with EtOAc (3 x 25 cm3). The aq. portion was acidified to pH 
1 with 5 mol drrr3 hydrochloric acid, extracted using EtOAc (3 x 70 cm3), dried 
(M gS04) and concentrated in vacuo to give a colourless oil which was 
crystallised to furnish carboxylic acid 168 (2.15 g, 73%) as white crystals, m.p. 
92 °C (from CHCI3); Rf 0.54 (5:1 EtOAc-MeOH); v max (KBr) 3360 (O-H), 1714 
(C=0), 1600, 1586, 1494 and 836 (para-disubstituted benzene) cm-1; 6 h (De­
acetone) 8.47 (1 H, br s, 1-OH), 7.20 (2 H, AA'BB', 3J= 8 .6 , 3-H), 6.69 (2 H, 
AA'BB', 3J= 8 .6 , 2-H), 3.22 (1 H, m, 5-H), 2.42 (1 H, m, 7-Ha), 2.22 (1 H, m, 7- 
Hb) and 1.08 (3 H, m, 6 -H); 6c (D6-acetone) 172.7 (C-8 ), 158.7 (C-1), 137.5 (C- 
3 ), 123.0 (C-4), 116.8 (C-2 ), 41.8 (C-7), 41.1 (C-5) and 2 1 .1  (C-6 ); m/z 2 1 2
3-[(4-Hydroxyphenyl)thio]butanoic acid (168)
OH
6 O
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(M+, 29.3), 153 (12.2), 126 (100) and 97 (68.3%); (Found: M+, 212.0510; C, 
56.34; H, 5.97%. C 10H12O3S requires M, 212.0507; C, 56.32; H, 6.14%).
2,3-Dihydro-6-hydroxy-2-methyl-(4H)-1 -benzothiopyran-4-one (169)
O
HO
A solution of carboxylic acid 168 (1.50 g, 7.06 mmol) in conc. aq. sulfuric acid 
(25 cm3) was stirred at r.t. for 0.5 h whereupon the reaction mixture was poured 
onto ice (200 g). The precipitated product was collected by filtration, dissolved 
in EtOAc (20 cm3) and filtered through a short column of silica gel. 
Concentration of the filtrate in vacuo afforded title compound 169 (0.87 g, 64%) 
as a yellow powder, m.p. 133-134 °C; Rf 0.62 (EtOAc); vmax(KBr) 3394 (O-H), 
1662 (0=0), 1596, 1474, 1430 and 1214 cm-1; 8 H (D6-acetone) 8.67 (1 H, brs, 
OH), 7.51 (1 H, d, 4J= 2.7, 2-H), 7.15 (1 H, d, 3J=8.5, 9-H), 7.01 (1 H, dd, 3J=
8.5, 4J= 2.7, 1 0 -H), 3.63 (1 H, m, 6 -H), 2.97 (1 H, dd, 2J = -16.6, 3J=ZA, 5-Ha), 
2.65 (1 H, dd, 2J= -16.6, 3J= 11.4, 5-Hb) and 1.37 (3 H, d, 3J= 6 .8 , 7-H); 5C (De­
acetone) 194.6 (C-4), 155.9 (C-1), 129.7 (C-9), 122.8 (C-10), 114.8 (C-2 ), 41.6 
(C-5), 37.2 (C-6 ) and 20.6 (C-7); m/z 194 (M \ 58.2), 179 (13.1), 152 (100), 124 
(47.4) and 95 (11.5%); (Found: M+, 194.0386; C, 61.88; H, 5 .2 2 %. C 10H10O2S 
requires M, 194.0401; C, 61.83; H, 5.19%).
(E)-Oxime of 2,3-Dihydro-6-hydroxy-2-methyl-(4H)-1 -benzothiopyran-4-one 
(170)
HO
A mixture of 169 (1.49 g, 7.67 mmol), sodium acetate (6.0 g, 82 mmol) and 
hydroxylamine hydrochloride (3.0 g, 43 mmol) was heated in refluxing EtOH (30 
cm3) for 3 h. On cooling to r.t., the reaction mixture was concentrated in vacuo, 
diluted with water (50 cm3) and extracted using CH2 CI2 (3 x 50 cm3). The 
combined organic extracts were washed with water (50cm3), dried (Na2S0 4 )
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and evaporated in vacuo to afford oxime 170 (1.27 g, 79%) as tan crystals, m.p. 
137 °C (from EtOH); Rf 0.60 (EtOAc); vmax (KBr) 1598, 1566, 1470, 1438, 1316 
and 1224 cm '1; 5h (D6-acetone) 10.49 (1 H, br s, N-OH), 8.33 (1 H, br s, 1 -OH), 
7.48 (1 H, d, 4J= 2.6, 2-H), 7.04 (1 H, d, 3J= 8.5, 9-H), 6.78 (1 H, dd, 3J= 8.5, 
4J= 2.6, 10-H), 3.37 (1 H, dd, 2J=-M .3 , 3J= 3.5, 5-Ha), 3.25 (1 H, m, 6 -H), 2.53 
(1 H, dd, 2J= -17.3, 3J= 10.7, 5-H/,) and 1.35 (3 H, d, 3J= 6 .6 , 7-H); 8C (De­
acetone) 155.8 (C-4), 153.0 (C-1), 132.2 (C-3), 129.9 (C-9), 126.0 (C-8 ), 118.0 
(C-1 0 ), 1 1 2 . 6  (C-2 ), 36.2 (C-6 ), 34.9 (C-5) and 20.7 (C-7); m/z 209 (M*, 100), 
192 (41.3), 176 (13.7), 165 (12.4) and 150 (39.2%); (Found: M+, 209.0495; C, 
57.26; H, 5.31; N, 6.61%. C i0H hNO 2S requires M, 209.0510; C, 57.40; H, 5.30; 
N, 6.69%).
Schmidt Reaction of Thiochroman-4-one 169
HO
177
H
N
S
167
HO NH
166
Azidotrimethylsilane (1.21 g, 1.40 cm3, 10.50 mmol) was added dropwise to a 
stirred solution of thiochroman-4-one 169 (1.36 g, 7.00 mmol) in trifluoroacetic 
acid (15 cm3) under N2 at r.t. After stirring for 3 d, the reaction mixture was 
concentrated in vacuo, taken into EtOAc (400 cm3) and washed with saturated 
aq. NaHCOa (400 cm3) and 1 mol dm ' 3 hydrochloric acid (100 cm3) before 
extraction using cold 2 mol drrr3 aq. NaOH (100 cm3). The aqueous layer was 
acidified to pH 1 using iced 2 mol dm "3 hydrochloric acid and extracted with 
EtOAc (2 x 100 cm3). The combined organic extracts were washed with brine 
(50 cm3) and evaporated to give a pale purple oil which was purified by flash 
chromatography on silica gel, eluting with hexane-EtOAc (3:1 to 1:1) to afford 
the following three compounds.
5,6-Dihydro-10-hydroxy-6-methyltetrazolo[1,5-c/|[1,4]benzothiazepine (177)
( 2 1 0  mg, 13%) as pale pink crystals, m.p. 179-180 °C; Rf 0.3 (1:1 EtOAc- 
hexane); vmax (KBr) 1595, 1479, 1423, 1400, 1291 and 1232 cm’ 1; 8 H (D6- 
DMSO) 10.38 (1 H, br s, OH), 7.56 (1 H, d, 3J= 8.5, 9-H), 7.34 (1 H, d, 4J= 2.7,
2 -H), 7.02 (1 H, dd, 3J= 8.5, 4J=2.1, 1 0 -H), 4.83 (1 H, dd, 2J=-14.5, 3J= 5.4, 5- 
Ha), 4.38 (1 H, dd, 2J = -14.5, 3J= 7.6, 5-H/,), 4.01 (1 H, m, 6 -H) and 1.36 (3 H, d, 
3J= 6 .6 , 7-H); 8 C (De-DMSO) 158.4 (C-1), 154.4 (C-4), 136.4 (C-9), 130.0 (C-3),
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120.5 (C-8 ), 119.1 (aryl CH), 117.3 (aryl CH), 52.3 (C-5), 46.3 (C-6 ) and 20.0 
(C-7); m/z 234 (M+, 100), 191 (54.6), 164 (54.7), 150 (39.0), 123 (12.1), 106 
(13.2) and 56 (50.4%); (Found: M+, 234.0567; C, 51.31; H, 4.18; N, 23.94%. 
C 10H 10N4OS requires M, 234.0575; C, 51.27; H, 4.30; N, 23.91%).
2.3-Dihydro-7-hydroxy-2-methyl-1,5-benzothiazepin-4(5H)-one (167)
(139 mg, 9%) as white crystals, m.p. 197 °C (dec.); Rf 0.45 (EtOAc); vmax (KBr) 
3100, 1653 (amide I), 1605, 1576, 1500, 1472 and 1305 cm-1; 8 H (D6-DMSO) 
7.35 (1 H, d, 3J= 8.1, 9-H), 6.64-6.56 (2 H, m, 2-H and 1 0 -H), 3.75 (1 H, m, 6 -
H), 2.50 (1 H, dd, 2J = -12.3, 3J= 6.0, 5 -Ha), 2.15 (1 H, dd, 2J = -12.3, 3J=8.5, 5- 
Hb) and 1.28 (3 H, d, 3J= 6 .6 , 7-H); 8C (D6-DMSO) 179.4 (C-4), 158.9 (C-1 ),
143.8 (C-3), 136.5 (C-9), 114.4 (C-8 ), 112.9 (aryl CH), 110.0 (aryl CH), 44.7 (C-
6 ), 41.6 (C-5) and 23.2 (C-7); m/z 209 (M+, 46.7), 166 (11.5), 141 (16.4) and 70 
(100%); (Found: M+, 209.0509; C, 57.36; H, 5.27; N, 6.61%. CfoHnNK^S 
requires M, 209.0510; C, 57.40; H, 5.30; N, 6.69%).
2.3-Dihydro-7-hydroxy-2-methyl-1,4-benzothiazepin-5(4H)-one (166)
(142 mg, 10%) as white crystals, m.p. 193 °C (dec.); Rf 0.31 (EtOAc); vmax (KBr) 
3200, 1647 (amide I), 1563, 1460, 1410, 1294 and 1 2 2 1  cm '1; 8 H (D6-DMSO)
10.00 (1 H, br s, OH), 8.42 (1 H, br m, NH), 7.28 (1 H, d, 3J= 8.3, 9-H), 6.96 (1 
H, d, 4J= 2.7, 2-H), 6.84 (1 H, dd, 3J= 8.3, 4J= 2.7, 10-H), 3.47 (1 H, m, 6 -H), 
3.17 (1 H, m, 5 -Ha), 2.73 (1 H, m, 5-Hb) and 1.17 (3 H, d, 3J= 6 .6 , 7-H); 8 C (D6- 
DMSO) 170.6 (C-4), 158.3 (C-1), 142.4 (C-8 ), 135.6 (C-9), 117.8 (aryl CH),
117.6 (C-3), 116.1 (aryl CH), 46.3 (C-6 ), 45.9 (C-5) and 19.5 (C-7); m /z  209 
(M+, 100), 180 (73.2), 165 (50.2), 151 (28.5), 137 (17.6) and 124 (18.9%); 
(Found: M+, 209.0510; C, 57.36; H, 5.19; N, 6.55%. C10H11NO2S requires M, 
209.0510; C, 57.40; H, 5.30; N, 6.69%).
A/-Methyl-3-(4-hydroxyphenyl)propanamide (184)
OH
N
DCC (1.96 g, 9.50 mmol) was added, with stirring, to a cooled ( 0  °C) solution of 
3-(4-hydroxyphenyl)propanoic acid (1.75 g, 10.5 mmol) and 4-nitrophenol (1.32
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g, 9.50 mmol) in EtOAc (40 cm3). After stirring for 1 h at 0 °C, the pale yellow 
reaction mixture was filtered through Celite® and to the filtrate was added 8.03 
mol dm ' 3 ethanolic methylamine (3.50 cm3, 28.1 mmol) and DBU (1.45 g, 1.42 
cm3, 9.52 mmol). Stirring for 14 h at r.t. gave a bright yellow solution which was 
diluted with EtOAc (40 cm3) and washed with 1 mol dnr3 hydrochloric acid (2 x 
30 cm3), saturated aq. sodium bicarbonate solution (30 cm3) and brine (30 
cm3). The organic phase was dried (MgS0 4 ) and concentrated in vacuo to give 
a yellow oil which was subjected to flash chromatography on silica gel using 
EtOAc then EtOAc-MeOH (19:1) as eluent. Crystallisation of the resulting 
colourless oil afforded amide 184 (0.83 g, 49%) as white crystals, m.p. 99-100 
°C (from hexane-EtOAc); Rf 0.25 (EtOAc); vmax(KBr) 3364 (N-H), 1652 (amide
I), 1612, 1595, 1560 (amide II), 1516, 1226 and 832 (para-d isubstitu ted 
benzene) cm-1; 6 H (CDCI3+D6-DMSO) 8.57 (1 H, br s, OH), 6.82 (2 H, AA'BB1, 
3J= 8.5, 3-H), 6.57 (2 H, AA'BB', 3J= 8.5, 2-H), 6.50 (1 H, br s, NH), 2.67 (2 H, t, 
3J= 8.4, 5-H), 2.54 (3 H, d, 3J= 4.7, 8 -H) and 2.23 (2 H, t, 3J= 8.4, 6 -H); 6 C 
(CDCI3+D6 -DMSO) 173.3 (C-7), 155.3 (C-1), 131.6 (C-4), 129.1 (C-3), 115.3 
(C-2 ), 38.5 (C-5), 30.9 (C-6 ) and 26.0 (C-8 ); m/z 179 (M+, 97), 147 (6 ), 120 
(62), 107 (100). 91 (11) and 77 (17%); (Found: M+, 179.0950; C, 67.02; H, 7.36; 
N, 7.91%. C 10H13NO2 requires M, 179.0946; C, 67.02; H, 7.31; N, 7.82%).
DCC (2.06 g, 9.98 mmol) was added, with stirring, to a cooled (0  °C) solution of 
3-(4-hydroxyphenyl)propanoic acid (1.87 g, 11.3 mmol) and 4-nitrophenol (1.39 
g, 9.99 mmol) in EtOAc (50 cm3). After stirring for 1 h at 0 °C, the pale yellow 
reaction mixture was filtered through Celite® and to the filtrate was added 
propylamine (1.18 g, 1.66 cm3, 20.0 mmol) and DBU (1.52 g, 1.49 cm3, 9.98 
mmol). Stirring for 14 h at r.t. gave a bright yellow solution which was diluted 
with EtOAc (100 cm3) and washed with 1 mol drrr3 hydrochloric acid (2  x 50 
cm3), saturated aq. sodium bicarbonate solution (50 cm3) and brine (50 cm3). 
The organic phase was dried (MgSO^ and concentrated in vacuo to give a 
yellow oil which was subjected to flash chromatography on silica gel using
A/-Propyl-3-(4-hydroxyphenyl)propanamide (185)
OH
H
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EtOAc-hexane (2:1) as eluent. Crystallisation of the resulting colourless oil 
afforded amide 185 (0.81 g, 43%) as white crystals, m.p. 71-72 °C (from 
hexane-EtOAc); Rf 0.44 (EtOAc); v max(KBr) 3302 (N-H), 1642 (amide I), 1613, 
1595, 1566 (amide II), 1514, 1458, 1246 and 829 (para-disubstituted benzene) 
cm-1; 5h (CDCI3+D6-DMSO) 8.69 (1 H, br s, OH), 6.89 (2 H, AA'BB1, 3J= 8.3, 3- 
H), 6.77 (2 H, AA'BB', 3J= 8.3, 2-H), 6.30 (1 H, br m, NH), 3.04 (2 H, m, 8 -H), 
2.75 (2 H, t, 3J= 7.9, 5-H), 2.33 (2 H, t, 3J= 7.9, 6 -H), 1.35 (2 H, m, 9-H) and 
0.74 (3 H, t, 3J= 7.3, 10-H); 6 C (CDCI3+D6-DMSO) 173.0 (C-7), 155.3 (C-1), 
131.4 (C-4), 129.1 (C-3), 115.4 (C-2 ), 41.2 (C-8 ), 39.7 (C-5), 31.0 (C-6 ), 22.6 
(C-9) and 11.3 (C-10); m/z 207 (M+, 95), 149 (10), 120 (63), 107 (100). 77 (14) 
and 60 (17%); (Found: M+, 207.1263; C, 69.34; H, 8 .1 1 ; N, 6.67%. C12H17N 02 
requires M, 207.1259; C, 69.54; H, 8.27; N, 6.76%).
/V-[3-(4-Hydroxyphenyl)propanoyl]piperidine (186)
OH
DCC (2.09 g, 10.1 mmol) was added, with stirring, to a solution of 3-(4- 
hydroxyphenyl)propanoic acid (1.85 g, 11.1 mmol) and 4-nitrophenol (1.41 g,
10.1 mmol) in EtOAc (60 cm3). After stirring for 1 h at r.t., the pale yellow 
reaction mixture was filtered through Celite® and to the filtrate was added 
piperidine (1.72 g, 2 0 . 2  mmol) and DBU (1.54 g, 1.51 cm3, 10.1 mmol). Stirring 
for 14 h at r.t. gave a bright yellow solution which was diluted with EtOAc (40 
cm3) and washed with 1 mol dm -3 hydrochloric acid (2 x 30 cm3), saturated aq. 
sodium bicarbonate solution (30 cm3) and brine (30 cm3). The organic phase 
was dried (MgS0 4 ) and concentrated in vacuo to give a yellow oil which was 
subjected to flash chromatography on silica gel using EtOAc then EtOAc-MeOH 
(15:1) as eluent. Crystallisation of the resulting colourless oil afforded amide 
186 (1.52 g, 65%) as white crystals, m.p. 117-118 °C (from hexane-CHCI3); Rf 
0.45 (EtOAc); vmax (KBr) 1603 (C=0), 1515, 1264, 1244, 1096 and 828 (para- 
disubstituted benzene) cm-1; 8 h (CDCI3) 8.27 (1 H, br s, OH), 6.99 (2  H, AA'BB', 
3J= 8.4, 3-H), 6.78 (2 H, AA'BB', 3J= 8.4, 2-H), 3.54 (2 H, m, 8 -H), 3.30 (2 H, m,
11
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1 2 - H ) ,  2 .8 4  (2  H , m , 5 - H ) ,  2 .5 8  (2  H , m , 6 -H )  a n d  1 .6 8 - 1 .2 2  ( 6  H , m , 9 - H ,  1 0 -H  
a n d  1 1 - H ) ;  6 C ( C D C I3) 1 7 1 .4  (C -7 ) ,  1 5 5 .2  ( C - 1 ), 1 3 1 .8  ( C - 4 ) ,  1 2 9 .3  ( C - 3 ) ,  1 1 5 .5  
( C - 2 ) , 4 6 .7  ( C - 1 2 ), 4 3 .0  ( C - 5 ) ,  3 5 .5  ( C - 8 ), 3 0 .9  ( C - 6 ), 2 6 .3  ( C H 2), 2 5 .5  ( C H 2) 
a n d  2 4 .3  ( C - 1 0 ) ;  m/z 2 3 3  (M+, 7 8 ) ,  1 2 6  ( 1 0 0 ) ,  1 2 0  (2 9 ) ,  1 0 7  (4 4 ) .  8 4  (3 4 )  a n d  
7 7  ( 1 2 % ) ;  ( F o u n d :  M+, 2 3 3 .1 4 0 9 ;  C , 7 1 .9 7 ;  H , 8 .0 7 ;  N , 5 .9 0 % .  C i 4 H 19N 0 2 
r e q u i r e s  M, 2 3 3 .1 4 1 6 ;  C , 7 2 .0 7 ;  H , 8 .2 1 ;  N , 6 .0 0 % ) .
A/-[3-(4-Hydroxyphenyl)propanoyl]morpholine (187)
OH
10
D C C  ( 2 .2 7  g , 1 1 . 0  m m o l)  w a s  a d d e d ,  w ith  s t i r r in g ,  to  a  c o o le d  ( 0  ° C )  s o lu t io n  o f  
3 - ( 4 - h y d r o x y p h e n y l ) p r o p a n o ic  a c id  ( 1 2 .0  g , 1 2 .3  m m o l)  a n d  4 - n i t r o p h e n o l  ( 1 .5 3  
g , 1 1 .0  m m o l)  in  E tO A c  (4 0  c m 3). A f t e r  s t i r r in g  f o r  1 h  a t  0  ° C , th e  p a le  y e l lo w  
r e a c t io n  m ix tu r e  w a s  f i l t e r e d  t h r o u g h  C e l i t e ®  a n d  t o  t h e  f i l t r a t e  w a s  a d d e d  
m o r p h o l in e  ( 2 . 8 7  g , 2 .8 7  c m 3 , 3 3 .0  m m o l)  a n d  D B U  ( 1 . 6 7  g , 1 .6 5  c m 3 , 1 1 .0  
m m o l) .  S t i r r in g  f o r  1 4  h  a t  r . t .  g a v e  a  b r ig h t  y e l lo w  s o lu t io n  w h ic h  w a s  d i lu t e d  
w ith  E tO A c  ( 4 0  c m 3 ) a n d  w a s h e d  w it h  1 m o l d r r r 3 h y d r o c h lo r i c  a c id  (2  x  3 0  
c m 3 ), s a tu r a te d  a q .  s o d iu m  b ic a r b o n a te  s o lu t io n  (3 0  c m 3 ) a n d  b r in e  (3 0  c m 3). 
T h e  o r g a n ic  p h a s e  w a s  d r ie d  ( M g S 0 4) a n d  c o n c e n t r a t e d  in vacuo to  g iv e  a  
y e l lo w  o i l  w h ic h  w a s  s u b je c te d  to  f la s h  c h r o m a t o g r a p h y  o n  s i l i c a  g e l  u s in g  
E tO A c  a s  e lu a n t .  C r y s ta l l i s a t io n  o f  th e  r e s u l t in g  c o lo u r le s s  o i l  a f f o r d e d  amide 
187 ( 1 . 0 2  g , 3 9 % )  a s  w h it e  c r y s ta ls ,  m .p .  1 3 2 - 1 3 3  ° C  ( f r o m  h e x a n e - C H C y ;  Rf 
0 .3 4  ( E tO A c ) ;  v m a x (K B r )  1 6 0 7  ( C = 0 ) ,  1 5 1 2 , 1 2 6 2 , 1 2 4 3 ,  1 1 1 3  a n d  8 2 7  (,para- 
d is u b s t i t u te d  b e n z e n e )  c m '1; 8 h ( C D C I3 ) 8 .0 2  (1 H , b r  s , O H ) ,  7 .0 0  ( 2  H , A A 'B B ',  
3J= 7 .9 ,  3 - H ) ,  6 .7 7  (2  H , A A 'B B ’ , 3J= 7 .9 ,  2 - H ) ,  3 .5 9  (4  H , b r  s , 9 - H  a n d  1 0 -H ) ,  
3 .4 5  (2  H , m , 8 -H ) ,  3 .3 2  (2  H , m , 1 1 -H ) ,  2 .8 6  (2  H , t, 3J= 7 .1, 5 - H )  a n d  2 .5 7  (2  
H , t ,  3J= 7 .1 ,  6 - H ) ;  5 C ( C D C I3 ) 1 7 1 .6  (C - 7 ) ,  1 5 5 .2  ( C - 1 ) ,  1 3 1 .6  ( C - 4 ) ,  1 2 9 .4  (C -  
3 ) ,  1 1 5 .5  ( C - 2 ), 6 6 .7  ( C H 2), 6 6 .3  ( C H 2 ), 4 6 .1  ( C - 1 1 ), 4 2 .1  ( C - 5 ) ,  3 5 .0  ( C - 8 ) a n d
3 0 .8  ( C - 6 ) ; m/z  2 3 5  {M+, 1 0 0 ) ,  1 2 8  (2 4 ) ,  1 2 0  ( 5 6 ) ,  1 0 7  ( 7 1 ) .  8 8  ( 2 5 )  a n d  5 7  
(2 2 % ) ; ( F o u n d :  M+, 2 3 5 .1 2 0 1 ;  C , 6 6 .1 4 ;  H , 7 .1 9 ;  N , 5 .7 7 % .  C 13H 17N O 3 r e q u ir e s  
M, 2 3 5 .1 2 0 8 ;  C , 6 6 .3 6 ;  H , 7 .2 8 ;  N , 5 .9 5 % ) .
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3-[(4-Hydroxyphenyl)thio]propanonitrile (188)
OH
The procedure of Ito and co-workers179 was adapted as follows.
A mixture of 4-hydroxythiophenol (2.05 g, 16.2 mmol), anhydrous sodium 
bicarbonate (1.36 g, 16.2 mmol) and acrylonitrile (1.03 g, 1.28 cm3, 19.4 mmol) 
was stirred under N2 in refluxing ethanol (4 cm3) for 6  h. Upon cooling to r.t., the 
mixture was diluted with water ( 1 0 0  cm3) and extracted using chloroform (2  x 
100 cm3). The combined extracts were washed with brine (50 cm3), dried 
(MgS0 4 ) and concentrated in vacuo to give a white solid. Purification by flash 
chromatography on silica gel [hexane-EtOAc (1:1)] gave, after crystallisation, 
the title compound 188 (1.96 g, 6 8 %) as white crystals, m.p. 70-71 °C (from 
benzene-hexane), (lit., 72-73 °C) . 179
New data: Rf 0.88 (EtOAc); vmax (KBr) 2266 (CN), 1598, 1580, 1493, 1272, 
1 2 2 2  and 830 (para-disubstituted benzene) cm-1; 5h (CDCI3) 7.33 (2 H, AA'BB1, 
3J= 8 .6 , 3-H), 6.80 (2 H, AA'BB', 3J= 8 .6 , 2-H), 6.39 (1 H, br s, OH), 2.96 (2 H, t, 
3J= 7.3, 5-H) and 2.54 (2  H, t, 3J= 7.3, 6 -H); 6C (CDCI3) 156.5 (C-1), 135.4 (C- 
3), 122.7 (C-4), 118.3 (C-7), 116.6 (C-2 ), 31.7 (C-5) and 18.2 (C-6 ); m/z 179 
(M+, 100), 139 (97), 125 (36) 95 (14) and 81 (8 %); (Found: M+, 179.0408; C, 
60.38; H, 5.06; N, 7.68%. C9H9NOS requires M, 179.0405; C, 60.31; H, 5.06; N, 
7.81%).
3-[(4-Hydroxyphenyl)thio]propanoic acid (180)
A mixture of 4-hydroxythiophenol (6.85 g, 54.3 mmol) and acrylic acid (3.91 g,
54.3 mmol) was stirred at 100 °C under N2 for 1 2  h. On cooling to r.t., the 
reaction mixture precipitated to give a white plug of solid which was taken into 
acetone (50 cm3) and loaded onto silica gel by evaporation of the solution in 
vacuo. Flash chromatography on silica gel, eluting with hexane-diethyl ether 
afforded the title compound 180 (5.72 g, 53%), m.p. 117-119 °C (from hexane- 
diethyl ether).
New data: Rf 0.31 (EtOAc); v max(KBr) 1715, 1694 (C=0), 1598, 1587, 1494, 
1426, 1241 and 818 (para-disubstituted benzene) cm-1; 5h (D6-acetone) 7.32 (2  
H, AA'BB', 3J= 6 .8 , 3-H), 6.84 (2 H, AA'BB', 3J= 6 .8 , 2-H), 3.03 (2 H, t, 3J=7 .2, 
5-H) and 2.56 (2  H, t, 3J = 7 .2, 6 -H); 5C (D6-acetone) 173.3 (C-7), 158.1 (C-1),
135.0 (C-3), 117.0 (C-2 ), 34.6 (C-6 ) and 31.7 (C-5); m/z 198 (M+, 100), 139 
(47), 125 (42) 97 (15) and 45 (2 1 %); (Found: IW, 198.0353; C, 54.53; H, 5.19%. 
C9H10O3S requires M, 198.0351; C, 54.53; H, 5.08%).
DCC (1.79 g, 8 . 6 8  mmol) was added, with stirring, to a solution of 3-[(4- 
hydroxyphenyl)thio]propanoic acid (1.72 g, 8 . 6 8  mmol) and 4-nitrophenol (1.32 
g, 9.49 mmol) in EtOAc (50 cm3). After stirring for 1 h at r.t., the pale yellow 
reaction mixture was filtered through Celite® and to the filtrate was added 8.03 
mol dm -3 ethanolic methylamine (2.16 cm3, 17.36 mmol) and DBU (1.32 g, 1.30 
cm3, 8 . 6 8  mmol). Stirring for 14 h at r.t. gave a bright yellow solution which was 
diluted with EtOAc (70 cm3) and washed with 1 mol dm-3 hydrochloric acid (2  x 
30 cm3), saturated aq. sodium bicarbonate solution (30 cm3) and brine (30 
cm3). The organic phase was dried (MgS0 4 ) and concentrated in vacuo to give 
a yellow solid which was dry-column flash chromatographed on silica gel 
[hexane:EtOAc (1:1) then EtOAc] to furnish amide 179 (1.12 g, 61%) as white 
crystals, m.p. 86-87 °C (from CHCl3 -MeOH); Rf 0.27 (EtOAc); vmax(KBr) 3384 
(N-H), 1644 (amide I), 1601, 1587, 1570 (amide II), 1496, 1254 and 820 (para- 
disubstituted benzene) cm-1; 5h (D6-acetone) 9.82 (1 H, br s, OH), 7.28 (3 H, m,
3-H and N-H), 6.81 (2 H, AA'BB', 3J=7 .9, 2-H), 3.04 (2 H, t, 3J= 7 .2, 5-H), 2.70
AFMethyl-3-[(4-hydroxyphenyl)thio]propanamide (179)
OH
O
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(3 H, d, 3J= 4.7, 8 -H) and 2.42 (2 H, t, 3J= 7.2, 6 -H); 5C (D6-acetone) 172.4 (C-
7), 158.1 (C-1), 134.6 (C-3), 125.0 (C-4), 117.0 (C-2 ), 36.7 (C-6 ), 32.3 (C-5) 
and 26.2 (C-8 ); m/z 2 1 1  (M+, 100), 152 (1 1 ), 139 (13), 125 (14) and 8 6  (54%); 
(Found: M+, 211.0666; C, 56.64; H, 6.17; N, 6.42%. C i0 H13SNO2 requires M, 
211.0667; C, 56.85; H, 6.20; N, 6.63%).
/V-Propyl-3-[(4-hydroxyphenyl)thio]propanamide (189)
OH
O
DCC (1.24 g, 6.00 mmol) was added, with stirring, to a solution of 3-[(4- 
hydroxyphenyl)thio]propanoic acid (1.16 g, 5.85 mmol) and 4-nitrophenol (0.85 
g, 6.14 mmol) in EtOAc (50 cm3). After stirring for 1 h at r.t., the pale yellow 
reaction mixture was filtered through Celite® and to the filtrate was added 
propylamine (0.60 g, 0.97 cm3, 11.7 mmol) and DBU (0.89 g, 0.87 cm3, 5.85 
mmol). Stirring for 14 h at r.t. gave a bright yellow solution which was diluted 
with EtOAc (50 cm3) and washed with 1 mol dm -3 hydrochloric acid (2 x 20 
cm3), saturated aq. sodium bicarbonate solution ( 2 0  cm3) and brine ( 2 0  cm3). 
The organic phase was dried (MgS0 4 ) and concentrated in vacuo to give a 
yellow solid which was flash chromatographed on silica gel [hexane:EtOAc 
(1:1)] to furnish amide 189 (0.84 g, 60%) as white crystals, m.p. 95-96 °C (from 
hexane-EtOAc); Rf 0.42 (EtOAc); v max(KBr) 3382 (N-H), 1639 (amide I), 1604, 
1590, 1558 (amide II), 1496, 1434, 1255 and 820 (para-disubstituted benzene) 
cm '1; 8 h (D6 -acetone) 9.91 (1 H, br s, OH), 7.38 (1 H, br s, NH), 7.27 (2 H, 
AA'BB', 3J= 8 .6 , 3-H), 6.81 (2 H, AA'BB', 3J= 8 .6 , 2-H), 3.14 (2  H, m, 8 -H), 3.04 
(2 H, t, 3J= 7.5, 5-H), 2.42 (2 H, t, 3J= 7.5, 6 -H), 1.51 (2 H, m, 9-H) and 0.88 (3 
H, t, 3J= 7.4, 10-H); 5C (De-acetone) 171.7 (C-7), 158.1 (C-1), 134.6 (C-3),
124.9 (C-4), 117.0 (C-3), 41.7 (C-8 ), 36.8 (C-6 ), 32.4 (C-5), 23.5 (C-9) and 11.7 
(C-10); m/z 239 (/l^, 1 0 0 ), 152 (14), 125 (24), 114 (6 8 ) and 97 (7%); (Found: 
M+, 239.0989; C, 60.17; H, 7.18; N, 5.89%. C12H17SN 02 requires M, 239.0980; 
C, 60.22; H, 7.16; N, 5.85%).
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/V-[3-[(4-hydroxyphenyl)thio]propanoyl]piperidine (190)
OH
O
DCC (1.12 g, 5.45 mmol) was added, with stirring, to a solution of 3-[(4- 
hydroxyphenyl)thio]propanoic acid (1.08 g, 5.45 mmol) and 4-nitrophenol (0.86 
g, 6.2 mmol) in EtOAc (40 cm3). After stirring for 1 h at r.t., the pale yellow 
reaction mixture was filtered through Celite® and to the filtrate was added 
piperidine (0.928 g, 1.08 cm3, 10.9 mmol) and DBU (0.83 g, 0.82 cm3, 5.5 
mmol). Stirring for 14 h at r.t. gave a bright yellow solution which was diluted 
with EtOAc (50 cm3) and washed with 1 mol dm ' 3 hydrochloric acid (2 x 25 
cm3), saturated aq. sodium bicarbonate solution (25 cm3) and brine (25 cm3). 
The organic phase was dried (MgS0 4 ) and concentrated in vacuo to give a 
yellow solid which was flash chromatographed on silica gel [hexane-EtOAc 
(1:1) then EtOAc] to furnish amide 190 (0.94 g, 65%) as white crystals, m.p. 
101-102 °C (from hexane-CHCy; Rf 0-47 (EtOAc); v max(KBr) 1620 (C=0), 
1601, 1583, 1497, 1444, 1264, 1219 and 829 (para-disubstituted benzene) cnr 
1; 5H (CDCI3) 8.32 (1 H, br s, OH), 7.00 (2  H, AA'BB', 3j=  8 .6 , 3-H), 6.57 (2  H, 
AA'BB', 3J= 8.4, 2-H), 3.30 (2 H, m, 12-H), 3.08 (2 H, m, 8 -H), 2.86 (2 H, t, 3j=
7.6, 5-H), 2.37 (2 H, t, 5J= 7.6, 6 -H) and 1.31 (6  H, m, 9-H, 10-H and 11-H); 6C 
(CDCI3 ) 170.1 (C-7), 156.6 (C-1), 133.5 (C-3), 124.1 (C-4), 116.3 (C-2), 46.8 
(C-8 ), 43.1 (C-1 2 ), 33.2 (C-6 ), 31.5 (C-5), 26.3 (CH2), 25.4 (CH2) and 24.2 
(CH2); m/z 265 {M+, 72), 152 (11), 140 (100), 125 (17) and 1 1 2  (22%); (Found: 
M+, 265.1135; C, 63.27; H, 7.12; N, 5.22%. C14H i9SN 02 requires M, 265.1136; 
C, 63.37; H, 7.22; N, 5.28%).
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A/-[3-[(4-hydroxyphenyl)thio]propanoyl]morpholine (191)
OH
O
DCC (1.56 g, 7.57 mmol) was added, with stirring, to a solution of 3-[(4- 
hydroxyphenyl)thio]propanoic acid (1.50 g, 7.57 mmol) and 4-nitrophenol (1.16 
g, 8.32 mmol) in EtOAc (50 cm3). After stirring for 1 h at r.t., the pale yellow 
reaction mixture was filtered through Celite® and to the filtrate was added 
morpholine (1.65 g, 1.65 cm3, 18.9 mmol) and DBU (1.15 g, 1.13 cm3, 7.57 
mmol). Stirring for 14 h at r.t. gave a bright yellow solution which was diluted 
with EtOAc (70 cm3) and washed with 1 mol dn r3 hydrochloric acid (2  x 30 
cm3), saturated aq. sodium bicarbonate solution (30 cm3) and brine (30 cm3). 
The organic phase was dried (MgS0 4 ) and concentrated in vacuo to give a 
yellow solid which was dry-column flash chromatographed on silica gel [EtOAc 
then EtOAc-MeOH (9:1)] to furnish amide 191 (0.96 g, 47%) as white crystals, 
m.p. 137-138 °C (from EtOAc); Rf 0.30 (EtOAc); vmax(KBr) 1625 (C=0), 1601, 
1583, 1497, 1428, 1267, 1219, 1114 (ether C-O), 1030 and 823 (para- 
disubstituted benzene) cm-1; 5h (CDCl3+D4-methanol) 7.18 (2 H, AA'BB', 3J=
8.7, 3-H), 6.69 (2 H, AA'BB', 3J= 8.7, 2-H), 3.55 (6  H, m, 9-H, 10-H and 11-H), 
3.28 (2  H, m, 8 -H), 2.98 (2 H, t, 3J=7.6, 5-H) and 2.48 (2 H, t, 3J=7 .6 , 6 -H); 6 C 
(CDCI3+D4-methanol) 170.4 (C-7), 156.6 (C-1), 133.7 (C-3), 123.7 (C-4), 116.0 
(C-2 ), 66.5 (CH2), 66.3 (CH2), 45.7 (C-8 ), 41.7 (C-1 1 ), 32.7 (C-6 ) and 31.2 (C-
5); m/z 267 [(MH)+, 100], 152 (17), 142 (97), 125 (25) and 114 (24%); (Found: 
M+, 267.0922; C, 58.35; H, 6.52; N, 5.03%. C13H i7S N 03 requires M, 267.0929; 
C, 58.41; H, 6.41; N, 5.24%).
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7.4 Experimental to Chapter 6
A/-[2-[(4-Hydroxyphenyl)sulfinyl]ethyl]ethanamide (192)
©O ©
A solution of Nal0 4  (1.67 g, 7.81 mmol) in water (15 cm3) was added over 5 
min to a stirred, cooled (0 °C), solution of sulfide 47 (1.50 g, 7.10 mmol) in EtOH 
(100 cm3). Allowing the reaction mixture to warm to r.t., stirring was continued 
for a further 15 h. Removal of precipitated sodium iodate by filtration through 
Celite® before concentration in vacuo gave a yellow solid which was purified by 
flash chromatography on silica gel eluting with EtOAc-methanol (6:1). 
Crystallisation afforded sulfoxide 192 (1.12 g, 69%) as pale yellow crystals, m.p. 
137-138 °C (from EtOAc-MeOH); Rf 0.41 (5:1 EtOAc-MeOH); vmax (KBr) 1657 
(amide I), 1563 (amide II), 1497, 1278, 1024 (S=0) and 828 (para-disubstituted 
benzene) cm '1; 5h (CDCl3+D4-methanol) 7.48 (2 H, AA'BB1, 3J= 8.7, 3-H), 6.95 
(2 H, AA'BB', 3J= 8.7, 2-H), 3.43 (2 H, m, 6 -H), 2.89 (2 H, m, 5-H) and 1.82 (3 
H, s, 8 -H); 6 C (CDCI3+D4 -methanol) 171.8 (C-7), 160.5 (C-1), 130.7 (C-4),
126.2 (C-3), 116.4 (C-2 ), 55.6 (C-5), 33.5 (C-6 ) and 2 2 . 2  (C-8 ); m/z (Cl) 228 
100], 212 (6 ) and 8 6  (45%); (Found: (Mhf)+, 228.0694; C, 52.93; H, 
5.79; N, 6.16%. C i0 H 13NO3S requires MH, 228.0694; C, 52.85; H, 5.77; N, 
6.16%).
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A/-[2-[(4-Hydroxyphenyl)sulfinyl]-1,1 -dimethylethyl]ethanamide (199)
OH
A solution of NalCU (1.33 g, 6.20 mmol) in water (15 cm3) was added over 5 
min to a stirred, cooled ( 0  °C), solution of sulfide 92 (1.35 g, 5.64 mmol) in 
EtOH (120 cm3). Using the same procedure as for 192 gave a yellow solid 
which was crystallised to afford sulfoxide 199 (1.03 g, 72%) as pale yellow 
crystals, m.p. 198-199 °C (from EtOAc); Rf 0.3 (8:1 EtOAc-MeOH); v max (KBr) 
3243 (N-H), 1641 (amide I), 1586, 1498, 1034 (S=0) and 827 (para- 
disubstituted benzene) cm-1; 8 h (D6-DMSO) 10.13 (1 H, brs, OH), 8.00 (1 H, br 
s, NH), 7.45 (2 H, AA'BB', 3J=8.6, 3-H), 6.97 (2 H, AA'BB', 3J= 8 .6 , 2-H), 3.46 
(1 H, d, 2J= 13.3, 5-Ha), 2.96 (1 H, d, 2J= 13.3, 5-H*), 1.86 (3 H, s, 1 0 -H), 1.45 
(3 H, s, 7-H) and 1.36 (3 H, s, 8 -H); 5C (De-DMSO) 169.7 (C-9), 159.8 (C-1),
134.3 (C-4), 125.8 (C-3), 116.1 (C-2 ), 6 6 . 8  (C-5), 52.2 (C-6 ), 27.6 (C-7 and C-8 ) 
and 23.5 (C-10); m/z 239 (M+ - O, 0.8), 180 (7.9), 141 (11.8), 114 (69.1) and 72 
(100%); (Found: C, 56.18; H, 6 .8 8 ; N, 5.34%. C i2H17N 03S requires C, 56.45; 
H, 6.71; N, 5.49%).
A/-[2-[(4-Hydroxyphenyl)sulfinyl]-1,1 -dimethylethyljoctanamide (200)
OH
A solution of Nal0 4  (0.32 g, 1.5 mmol) in water (3 cm3) was added over 5 min. 
to a stirred, cooled (0 °C), solution of sulfide 105 (0.46 g, 1.4 mmol) in EtOH (20 
cm3). Using the same procedure as for 192 gave a yellow solid which was 
purified by flash chromatography on silica gel eluting with EtOAc. Crystallisation 
afforded sulfoxide 200 (0.35 g, 73%) as pale yellow crystals, m.p. 139 °C (from
2
6 N  9 
H
16
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EtOAc); Rf 0.35 (EtOAc); v max (KBr) 3251 (N-H), 1638 (amide I), 1585, 1561 
(amide II), 1500, 1029 (S=0) and 835 (para-disubstituted benzene) cm '1; 8 h 
(CDCI3) 9.75 (1 H, br s, OH), 7.43 (2 H, AA'BB', 3J= 8 .6 , 3-H), 6.95 (2 H, 
AA'BB', 3J= 8 .6 , 2-H), 6.59 (1 H, br s, NH), 3.47 (1 H, d, 2J= 13.6, 5-Ha), 2.99 (1 
H, d, 2J= 13.6, 5-H/,), 2.23 (2 H, t, 3J= 7.2, 10-H), 1.75 - 1.10 (10 H, m, 11-H, 
1 2 -H, 13-H, 14-H and 15-H) and 0.82 (3 H, t, 3J= 6 .6 , 16-H); 8 C (CDCI3) 174.8 
(C-9), 160.5 (C-1), 132.8 (C-4), 125.8 (C-3), 116.1 (C-2 ), 66.9 (C-5), 53.4 (C-6 ),
37.3 (C-1 0 ), 31.6 (C-14), 29.1 (C- 1 1 or C-13), 28.9 (C-13 or C-1 1 ), 28.4 (C-7),
27.5 (C-8 ), 25.8 (C-1 2 ), 22.5 (C-15) and 14.0 (C-16); m/z 322 (M+ - O, 0.7), 
198 (100), 180 (8.4) and 141 (20.8%); (Found: C, 63.72; H, 8.74; N, 4.10%. 
C 18H29NO3S requires C, 63.68; H, 8.61; N, 4.13%).
A/-[2-[(4-Hydroxyphenyl)sulfonyl]ethyl]ethanamide (193)
O H
5O
o
N 7 
H
To a cooled (0 °C) solution of sulfoxide 200 (0.85 g, 3.74 mmol) in methanol (40 
cm3) was added a solution of potassium peroxymonosulfate (Oxone® 
monopersulfate compound, 3.45 g, 5.61 mmol) in water (10 cm3). The resulting 
cloudy slurry was stirred for 2 h at r.t., concentrated to ca. 25 cm3 in vacuo then 
diluted with water (50 cm3) and extracted with EtOAc (4 x 50 cm3). The 
combined organic extracts were washed with water (50 cm3) and brine (50 cm3) 
dried (MgSO^ and evaporated to give a white solid which was purified by flash 
chromatography on silica gel using ethyl acetate-methanol (1 0 :1 ) as eluent to 
afford, after crystallisation, sulfone 193 (0.63 g, 69%) as white crystals, m.p. 
152-153 °C (from EtOAc-MeOH); Rf 0.19 (EtOAc); vmax(KBr) 3329 (N-H), 1636 
(amide I), 1553 (amide II), 1304 (SO2), 1140 (SO2) and 840 (para-disubstituted 
benzene) cm"1; 8 h (D6 -acetone) 9.80 (1 H, br s, OH), 7.77 (2 H, AA'BB1, 3J=
8 .8 , 3-H), 7.34 (1 H, br s, NH), 7.03 (2 H, AA'BB', 3J= 8 .8 , 2-H), 3.50 (2 H, m, 6 - 
H), 3.34 (2 H, m, 5-H) and 1.82 (3 H, s, 8 -H); 8 C (D6-acetone) 171.2 (C-7),
163.2 (C-1 ), 131.2 (C-3), 130.8 (C-4), 116.7 (C-2 ), 55.6 (C-5), 30.7 (C-6 ) and
22.7 (C-8 ); m /z  243 {M+, 44), 201 (12), 184 (12), 157 (17), 141 (2 2 ) and 8 6  
(100%); (Found: M+, 243.0544; C, 49.28; H, 5.24; N, 5.73%. C10H13NO4S 
requires M, 243.0565; C, 49.37; H, 5.39; N, 5.76%).
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/V-[2-(Phenyloxy)ethyl]ethanamide (201)
6 N 7
A mixture of phenol (1.10 g, 11.7 mmol) and 4,5-dihydro-2-methyloxazole (0.99 
g, 0.99 cm3, 11.7 mmol) was stirred under reflux (oil bath temperature 135 °C) 
for 24 h. On cooling to r.t., the resulting brown mixture was dissolved in EtOAc 
(40 cm3) and washed with 1 mol dm ' 3 hydrochloric acid (2 x 20 cm3), 1 mol dnr 
3 aq. NaOH (2 x 20 cm3), saturated aq. NaHC0 3  (20 cm3) and brine (20 cm3). 
The organic layer was dried (MgS0 4 ) and concentrated in vacuo to afford, after 
crystallisation, the title compound 201 (0.63 g, 30%) as white crystals, m.p. 83- 
84 °C (from hexane-EtOAc), [lit. , 187 88-89 °C (from cyclohexane)]. The 1H NMR 
spectral data were in good agreement with those reported by Funahashi. 187 
New data: Rf 0.35 (EtOAc); vmax (KBr) 3316 (N-H), 1652 (amide I), 1554 (amide 
II), 1249, 764 and 891 (monosubstituted benzene) cm '1; 8 c  (C D C I3 )  170.5 (C- 
7), 158.4 (C-4), 129.5 (C-2 ), 1 2 1 .1  (C-1), 114.3 (C-3), 66.5 (C-5), 39.0 (C-6 ) 
and 23.1 (C-8 ); m /z  179 (M+, 2 ), 1 2 0  (14), 94 (1 2 ), 8 6  (1 0 0 ) and 77 (28%); 
(Found: M+, 179.0946. CioH13N 0 2 requires M, 179.0946).
/V-[2-[(4-Hydroxyphenyl)oxy]ethyl]ethanamide (194)
A mixture of hydroquinone (1.80 g, 11.7 mmol) and 4,5-dihydro-2- 
methyloxazole (1.81 g, 1.81 cm3, 21.3 mmol) was stirred under reflux (oil bath 
temperature 135 °C) for 24 h. On cooling to r.t., the resulting brown mixture was 
dissolved in EtOAc (100 cm3) and extracted using 2 mol dm ' 3 aq. NaOH (50 
cm3). The aq. portion was washed with EtOAc (100 cm3), acidified (conc.
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hydrochloric acid) and then extracted with EtOAc (3 x 80 cm3). The combined 
organic extracts were washed [saturated aq. NaHC0 3  (80 cm3) and brine (80 
cm3)], dried (MgS0 4 ) and concentrated in vacuo before purification by flash 
chromatography on silica gel using hexane-EtOAc (3:1) as eluent to afford the 
title compound 194 (0.81 g, 24%) as white crystals, m.p. 133-134 °C (from 
hexane-EtOAc), (lit. , 188 132-134 °C).
New data: Rf 0 . 2  (EtOAc); vmax(KBr) 3355 (N-H), 1624 (amide I), 1550 (amide 
II), 1514, 1478, 1223 and 834 (para-disubstituted benzene) cm '1; 8 h (De­
acetone) 8.38 (1 H, br s, OH), 7.68 (1 H, br s, NH), 6.77 (4 H, s, 2-H and 3-H), 
3.95 (2  H, t, 3 j=  5 .6 , 5-H), 3.56 (2  H, m, 6 -H) and 1.96 (3 H, s, 8 -H); 5C (De­
acetone) 170.6 (C-7), 152.1 and 151.8 (C-1 and C-4), 115.9 and 115.6 (C-2  and 
C-3), 67.2 (C-5), 39.1 (C-6 ) and 2 2 .1  (C-8 ); m/z 195 (M+, 4), 136 (4), 110 (23), 
8 6  (100), 81 (9) and 65 (14%); (Found: M+, 195.0905. C10H13NO3 requires M, 
195.0895).
3-(Ethanoylamino)propanoic acid (204)
O O
H
The title compound was prepared in 77% yield by the general method of Black 
and Boscacci190 and gave m.p. 77-79 °C (from acetone), (lit. , 191 78-80 °C). The 
1H NMR, 13C NMR and IR spectral data were in good agreement with those 
reported . 191 ’ 192
New data: m/z 131 (M+, 3.6), 8 8  (22.3), 70 (9.8), 55 (4.8) and 43 (100%). 
Phenyl 3-(ethanoylamino)propanoate (205)
O O
N
H
v
1
A stirred solution of carboxylic acid 204 (5.00 g, 38.1 mmol), phenol (3.60 g,
38.1 mmol) and pyridine (10 cm3) in EtOAc (50 cm3) was cooled to 0  °C before 
addition of DCC (7.86 g, 31.0 mmol) in one portion. The mixture was stirred
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under N2 at 0  °C for 4 h, filtered through Celite® and then heated under N2 at 
reflux for a further 2  h whereupon the mixture was concentrated in vacuo to give 
a pale yellow oil. This was taken into EtOAc (150 cm3), washed with cold 1 mol 
dm 3 hydrochloric acid (2 x 30 cm3) and brine (30 cm3), dried (MgS0 4 ) and then 
concentrated in vacuo. Purification by flash chromatography on silica gel eluting 
with EtOAc-hexane (3:1) afforded ester 205 (5.87 g, 74%) as a white powder, 
m.p. 57-58 °C; Rf 0.26 (EtOAc); v max (KBr) 3281 (N-H), 1756 (ester C=0), 1643 
(amide I), 1561 (amide II), 1195, 1166, 1156, 765 and 714 (monosubstituted 
benzene) c n r1; 6 H (CDCI3) 7.34 (2  H, m, 2 -H), 7.20 (1 H, m, 1-H), 7.04 (2  H, m, 
3-H), 6.55 (1 H, br s, N-H), 3.53 (2 H, m, 7-H), 2.74 (2 H, t, 3J= 6.0, 6 -H) and
1.89 (3 H, s, 9-H); 6 C (CDCI3) 171.2 (C=0), 170.5 (C=0), 150.3 (C-4), 129.4 (C-
2 ), 126.0 (C-1 ), 121.4 (C-3), 34.9 (CH2), 33.4 (CH2) and 23.1 (C-9); m/z (Cl) 
195 [(M+NH4)+, 100], 208 30], 114 (4) and 52 (3%); (Found: (MH)+,
208.0974; C, 63.74; H, 6.29; N, 6.75%. C n H 13N 0 3 requires MH, 208.1003; C, 
63.76; H, 6.32; N, 6.76%).
Ethyl 3-acetylamino-3-methylbutanoate (208)
N O
The title compound 208 was prepared in 48% yield on a 50 mmol scale using 
the method of Eugster ef a/ .193 and gave IR and 1H NMR spectral data in good 
agreement with those reported in the literature. 193 -207
New data: 5C (CDCI3) 171.2 (C=0), 170.2 (C=0), 60.0 (C-7), 51.8 (C-3 ), 43.5 
(C-5), 26.8 (C-4), 23.8 (C-1 ) and 14.0 (C-8 ); m/z 187 (M+, 6.4), 142 (13.6), 130 
(37.1), 100 (29.8) and 59 (100%).
3-Acetylamino-3-methylbutanoic acid (209)
N
H
The title compound 209 was prepared in 71% yield on a 50 mmol scale using 
the method of Eugster et a / . 193 and gave m.p. 135-136 °C (from acetone), (lit., 
135-136 °C). The IR and 1H NMR spectral data were in good agreement with 
those reported in the literature.190 -193
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New data: Rf 0 . 2  (EtOAc); 5C (CDCI3) 172.6 (C=0), 170.3 (C=0), 52.1 (C-3),
4 3 . 5  (C-5 ), 27.3 (C-4) and 23.8 (C-1); m/z 159 (M+, 10.6), 1 0 2  (47.6), 84 (30.0), 
72 (12.5) and 59 (100%).
Phenyl 3-ethanoylamino-3-methylbutanoate (210)
O N
H
1
A stirred solution of carboxylic acid 209 (0.800 g, 5.03 mmol), phenol (0.472 g, 
5.02 mmol) and pyridine (1 cm3) in EtOAc (9 cm3) was cooled to 0 °C before 
addition of DCC (1.04 g, 5.03 mmol) in one portion. The mixture was stirred 
under N2 at 0  °C for 4 h, filtered through Celite® and then heated under N2 at 
reflux for a further 2  h whereupon the mixture was concentrated in vacuo to give 
a pale yellow oil. This was taken into EtOAc (100 cm3), washed with cold 1 mol 
dm -3 hydrochloric acid (2  x 20 cm3) and brine ( 2 0  cm3), dried (MgSOzf) and then 
concentrated in vacuo. Purification by flash chromatography on silica gel eluting 
with EtOAc-hexane (1:1) afforded ester 210 (0.77 g, 65%) as a white powder, 
m.p. 65-66 °C; Rf 0.50 (EtOAc); vmax (KBr) 1749 (ester C=0), 1644 (amide I), 
1554 (amide II), 1495, 1435, 758 and 692 (monosubstituted benzene) cm '1; 5h 
(CDCI3) 7.31 (2 H, m, 2-H), 7.15 (1 H, m, 1-H), 7.00 (2 H, m, 3-H), 5.74 (1 H, br 
s, N-H), 2.98 (2 H, s, 6 -H), 1.86 (3 H, s, 10-H) and 1.44 (3 H, s, 8 -H); 6 C 
(CDCI3) 170.0 (C=0), 170.0 (C=0), 150.3 (C-4), 129.4 (C-2 ), 125.9 (C-1), 121.5 
(C-3), 52.1 (C-7), 43.2 (C-6 ), 27.3 (C-8 ) and 24.3 (C-1 0 ); m/z  178 [(M-57)+,
1.9], 142 (39.6), 100 (22.1), 92 (23.6), 83 (89.4) and 58 (100%); (Found: C, 
66.27; H, 7.41; N, 6.17%. C i3 H17N 0 3 requires C, 66.36; H, 7.28; N, 5.95%).
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A/-[3-(4-Hydroxyphenyl)-3-oxopropyl]acetamide (197)
OH
N
H
CAUTION! Nitromethane is known to explode when heated; the use of a blast 
shield throughout this experiment is recommended.
The general procedure of Harwood and co-workers195 was adapted as follows. 
Ester 205 (1.08 g, 5.20 mmol) was dissolved in nitromethane (15 cm3) and 
cooled to -10 °C with stirring under N2 . A solution of anhydrous aluminium 
chloride (3.50 g, 26.1 mmol) in nitromethane (15 cm3) was added dropwise over 
5 min and the mixture allowed to warm to r.t. over 20 min before being heated 
at 40 °C for 24 h. The mixture was then warmed to r.t., quenched with ice-cold 5 
mol dm*3 hydrochloric acid (70 cm3) and extracted with EtOAc (2 x 80 cm3). The 
combined organic portions were washed with brine (50 cm3), dried (MgS0 4 ) 
and concentrated in vacuo. Purification by flash chromatography on silica gel 
eluting with EtOAc-hexane (1:1) afforded ketone 197 (0.35 g, 32%) as white 
crystals, m.p. 161-162 °C (from hexane-EtOAc); Rf 0.49 (acetone); v max (KBr) 
3371 (N-H), 1655 (ketone C=0 and amide I), 1608, 1545 (amide II), 1218 and 
843 (para-disubstituted benzene) cm*1; 8 h (D6-acetone) 9.46 (1 H, br s, OH), 
7.69 (2 H, AA'BB', 3J= 8 .8 , 3-H), 7.24 (1 H, br s, N-H), 6.92 (2 H, AA'BB', 3J=
8 .8 , 2-H), 3.53 (2 H, m, 7-H), 3.15 (2 H, t, 3J= 6.2, 6 -H) and 1.88 (3 H, s, 9-H); 
8 C (De-acetone) 197.3 (C-5), 170.4 (C-8 ), 162.9 (C-1), 131.3 (C-3), 130.0 (C-4),
116.1 (C-2 ), 38.5 (C-7), 35.4 (C-6 ) and 22.9 (C-9); m/z 207 (M+, 29), 164 (6 ), 
148 (10), 121 (100), 8 6  (22) and 65 (16%); (Found: M+, 207.0908; C, 63.53; H, 
6.27; N, 6.62%. C n H 13N 0 3 requires M, 207.0895; C, 63.76; H, 6.32; N, 6.76%).
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A/-[3-(4-Hydroxyphenyl)-1,1 -dimethyl-3-oxopropyl]ethanamide (211)
OH
CAUTION! Nitromethane is known to explode when heated; the use of a blast 
shield throughout this experiment is recommended.
The general procedure of Harwood and co-workers195 was adapted as follows. 
Ester 210 (0.56 g, 2.38 mmol) was dissolved in nitromethane (7.5 cm3) and 
cooled to -10 °C with stirring under N2. A solution of anhydrous aluminium 
chloride (1.59 g, 11.9 mmol) in nitromethane (7.5 cm3) was added dropwise 
over 5 min and the mixture allowed to warm to r.t. over 20 min before being 
heated at 40 °C for 4 h. The mixture was then warmed to r.t., quenched with 
ice-cold 5 mol dnrv3 hydrochloric acid (40 cm3) and extracted with EtOAc (3 x 50 
cm3). The combined organic portions were concentrated in vacuo, taken into 2  
mol dm_3 aq. NaOH (50 cm3), washed with diethyl ether (2 x 20 cm3), acidified 
to pH 1 and then extracted using EtOAc (3 x 50 cm3). The combined extracts 
were washed with saturated aq. NaHCOa (3 x 50 cm3) and brine (3 x 30 cm3), 
dried (MgSO^ and concentrated in vacuo. Purification by flash chromatography 
on silica gel eluting with EtOAc-hexane (1:1) afforded /cefone211 (0.24 g, 42%) 
as white crystals, m.p. 177-178 °C (from hexane-EtOAc); Rf 0.31 (EtOAc); vmax 
(KBr) 3364 (N-H), 1688 (ketone C=0), 1653 (amide I), 1600, 1577, 1552 (amide 
II) and 1516 cm-1; 8 h (D6-acetone) 9.30 (1 H, br s, OH), 7.78 (2 H, AA'BB', 3J=
8 .8 , 3-H), 6.87 (1 H, br s, N-H), 6.77 (2 H, AA'BB', 3J= 8 .8 , 2-H), 3.30 (2 H, s, 6 - 
H), 1.66 (3 H, s, 10-H) and 1.29 ( 6  H, s, 8 -H); 8 C (D6-acetone) 197.7 (C-5),
170.3 (C-9), 162.7 (C-1), 131.5 (C-3), 131.3 (C-4), 115.9 (C-2 ), 53.1 (C-7), 45.7 
(C-6 ), 27.8 (C-8 ) and 23.9 (C-1 0 ); m/z 235 (M+, 6.0), 176 (20.8), 161 (12.4), 
136 (13.1) and 121 (100%); (Found: M+, 235.1199; C, 66.20; H, 7.22; N, 5.95%. 
C 13H17N 0 3 requires M, 235.1208; C, 66.36; H, 7.28; N, 5.95%).
8
H
- 1 8 3 -
A/-[3-(4-Hydroxyphenyl)propyl]acetamide (196)
OH
N
H
A mixture of ketone 197 (100 mg, 0.48 mmol), 10% palladium on activated 
carbon (25 mg) and MeOH (20 cm3) was stirred under a slight positive pressure 
of hydrogen gas for 3 h at r.t. The catalyst was then removed by filtration over 
Celite® and washed with MeOH ( 1 0  cm3); evaporation of the combined filtrates 
gave the title compound 196 (95 mg, 8 8 %) as white crystals, m.p. 93-95 °C 
(from hexane-EtOAc) (lit. , 197 93-95 °C).
New data: Rf 0.54 (acetone); vmax (KBr) 3316 (N-H), 1638 (amide I), 1596, 1570 
(amide II), 1514, 1249 and 856 (para-disubstituted benzene) cm '1; 5h (De­
acetone) 8.04 (1 H, br s, OH), 7.00 (1 H, br s, N-H), 6.89 (2 H, AA'BB', 3J= 8.6,
3-H), 6.60 (2 H, AA'BB', 3J= 8 .6 , 2-H), 3.04 (2 H, m, 7-H), 2.40 (2 H, t, 3J= 7.3, 
5-H), 1.72 (3 H, s, 9-H) and 1.60 (2 H, m, 6 -H); 6 C (D6-acetone) 170.0 (C-8 ),
156.4 (C-1), 133.4 (C-4), 130.0 (C-3), 115.9 (C-2 ), 39.4 (C-7), 32.9 (CH2), 32.6 
(CH2) and 22.9 (C-9); m/z 193 {M+, 56), 134 (48), 107 (37), 73 (1 0 0 ) and 4 3  
(27%); (Found: M+, 193.1108; C n H 15N 02 requires M, 193.1103).
4-Bromo-0-(ferf-butyldimethylsilyl)phenol (218)
OTBS
Br
The title compound 218 was prepared in 93% yield on a 70 mmol scale by the 
procedure of Riley et al.69  and gave b.p. 122-124 °C/1.0 mmHg (lit., 67-68 
°C/0.01 mmHg). The IR, MS, 1H NMR and 13C NMR spectral data were in good 
agreement with those reported.6 9 >2 0 8 >209
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E/s[4-[(ferf-butyldimethylsilyl)oxy]phenyl] diselenide (219)
The procedure of Riley et a l,6 9  on a 40 mmol scale, followed by flash 
chromatography on silica gel with hexane as eluent, afforded a -3:1 mixture of 
diselenide 219 (-20%  yield) and selenide 220 (-61%  yield) as an orange oil. 
The mixture was used in the following step without further purification.
A/-[2-[[4-[(ferf-Butyldimethylsilyl)oxy]phenyl]seleno]ethyl]ethanamide (222)
3
Sodium borohydride (0.200 g, 5.2 mmol) was added over 15 min to a solution of 
crude diselenide 219 (1.8 g mixture, 2.1 mmol diselenide) in ethanol (6  cm3) at 
0  °C under a stream of N2. Allowing the mixture to warm to r.t., stirring was 
continued for a further 30 min to give a colourless solution which was quenched 
by addition of 0.5 mol dm ' 3 hydrochloric acid (20 cm3) and extracted with 1:1 
diethyl ether-hexane ( 3 x 1 5  cm3). The combined extracts were dried (CaCI2) 
and concentrated in vacuo to give an oil which was immediately treated with
4,5-dihydro-2-methyloxazole (1.00 g, 11.7 mmol) and stirred under N2 for 4 h at 
130 °C. Flash chromatography of the crude product on silica gel, eluting with 
EtOAc-hexane (1:1), gave selenide 222 (0.75 g, 48%) as a clear oil, Rf 0.40 
(EtOAc); vmax (neat) 3386 (N-H), 1653 (amide I), 1586, 1553 (amide II), 1489 
and 840 (para-disubstituted benzene) cm '1; §h (CDCI3) 7.26 (2  H, AA'BB1, 3J= 
8 .6 , 6 -H), 6.70 (2 H, AA'BB', 3J= 8 .6 , 5-H), 6.24 (1 H, br s, NH), 3.42 (2 H, m, 9- 
H), 2.88 (2 H, t, 3J= 6 .6 , 8 -H), 1.87 (3 H, s, 11-H), 0.93 (9 H, s, 1-H) and 0.15 (6
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H, s, 3-H); 8 C (CDCI3 ) 170.1 (C-10), 155.6 (C-4), 135.5 (C-6 ), 121.0 (C-5),
119.5 (C-7), 39.4 (C-9), 28.1 (C-8 ), 25.6 (C-1), 23.1 (C-1 1 ), 18.1 (C-2 ) and -4.5 
(C-3); m/z 373 (M+ 10), 257 (3), 215 (4), 116 (24) and 8 6  (100%); (Found: M+, 
373.0986. C i6H27N0 2 SeSi requires M, 373.0976).
/V-[2-[[4-[(ferf-Butyldimethylsilyl)oxy]phenyl]seleno]ethyl]-2,2- 
dimethylpropanamide (223)
3
\  /
Sodium borohydride (0.460 g, 12.2 mmol) was added over 15 min to a solution 
of crude diselenide 219 (3.0 g mixture, 3.5 mmol diselenide) in ethanol (20 cm3) 
at 0 °C under a stream of N2. Allowing the mixture to warm to r.t., stirring was 
continued for a further 0.5 h to give a colourless solution which was quenched 
by addition of 0.5 mol dm"3 hydrochloric acid (40 cm3) and extracted with 1:1 
diethyl ether-hexane (3 x 20 cm3). The combined extracts were dried (CaCI2) 
and concentrated in vacuo to give an oil which was immediately treated with
4,5-dihydro-2-(1,1-dimethylethyl)oxazole (1.00 g, 7.9 mmol) and stirred under 
N2 for 4 h at 130 °C. Flash chromatography of the crude product on silica gel, 
eluting with hexane-EtOAc (4:1), gave selenide 223 (1.52 g, 52%) as a white 
solid, m.p. 75-76 °C; Rf 0.75 (EtOAc); v max (KBr) 3330 (N-H), 1638 (amide I), 
1584, 1534 (amide II), 1487 and 841 (para-disubstituted benzene) cm '1; 8 h 
(CDCI3) 7.38 (2 H, AA'BB', 3J= 8 .6 , 6 -H), 6.73 (2 H, AA'BB', 3J= 8 .6 , 5-H), 6.09 
(1 H, br s, NH), 3.45 (2 H, m, 9-H), 2.92 (2 H, t, 3J= 6.4, 8 -H), 1.14 (9 H, s, 12- 
H), 0.96 (9 H, s, 1 -H) and 0.17 (6  H, s, 3-H); 8 C (CDCI3) 178.3 (C-10), 155.6 (C-
4), 135.4 (C-6 ), 1 2 1 .1  (C-5), 119.3 (C-7), 39.0 (C-9), 38.6 (C-11), 28.4 (C-8 ),
27.5 (C-1 2 ), 25.6 (C-1), 18.1 (C-2 ) and -4.5 (C-3); m/z (Cl) 416 [{MH)+, 7], 276 
(3), 227 (6 ), 164 (42), 147 (100) and 130 (6 %); [Found: (MH)+, 416.1542; C, 
55.13; H, 7.98; N, 3.29%. C19H33N 02SeSi requires MH, 416.1523; C, 55.05; H, 
8.02; N, 3.38%].
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A/-[2-[(4-Hydroxyphenyl)seleno]ethy!]ethanamide (197)
OH
2
o
5
6 N ' 7 ^ 8
H
A solution of silyl ether 222 (2.30 g, 6.18 mmol) in anhydrous THF (60 cm3) was 
treated with TBAF (1 mol dm ' 3 solution in TFIF, 15.5 cm3, 15.5 mmol). After 
being stirred for 2.5 h at r.t., the mixture was diluted with saturated aq. NH4CI 
(30 cm3) and extracted using EtOAc (3 x 50 cm3). The combined extracts were 
washed with brine (50 cm3), dried (MgSO^ and concentrated in vacuo to give a 
colourless oil. Dry-column flash chromatography on silica gel, eluting with 
EtOAc, gave selenide 197 (1.39 g, 87%) as a white solid, m.p. 110-111 °C; Rf
0.28 (EtOAc); vmax (KBr) 3330 (N-H), 1635 (amide I), 1678, 1493, 1448 and 838 
(para-disubstituted benzene) cm '1; 5h (D6-acetone) 9.88 (1 H, brs, OH), 7.47 (1 
H, br s, NH), 7.41 (2 H, AA'BB1, 3J= 8.7, 3-H), 6.77 (2 H, AA'BB', 3J= 8.7, 2-H), 
3.40 (2 H, m, 6 -H), 2.88 (2 H, t, 3J= 6 .6 , 5-H) and 1.86 (3 H, s, 8 -H); 6C (De­
acetone) 171.1 (C-7), 158.4 (C-1), 136.7 (C-3), 118.3 (C-4), 117.2 (C-2 ), 40.5 
(C-6 ), 28.3 (C-5) and 2 2 . 8  (C-8 ); m/z 259 {M+, 11), 200 (8 ), 173 (9), 1 2 0  (23), 
107 (16) and 8 6  (100%); (Found: M+, 259.0093; C, 46.52; H, 5.06; N, 5.27%. 
C 10H13NO2Se requires M, 259.0111; C, 46.52; H, 5.08; N, 5.43%).
A/-[2-[(4-Hydroxyphenyl)seleno]ethyl]-2,2-dimethylpropanamide (224)
OH
A solution of silyl ether 223 (0.600 g, 1.45 mmol) in anhydrous THF (30 cm3) 
was treated with TBAF (1 mol dm-3 solution in THF, 2.89 cm3, 2.89 mmol). After 
being stirred for 2.5 h at r.t., the mixture was diluted with saturated aq. NH4CI
(30 cm3) and extracted using EtOAc (3 x 30 cm3). The combined extracts were 
washed with brine (30 cm3), dried (MgS0 4 ) and concentrated in vacuo to give a 
colourless oil. Dry-column flash chromatography on silica gel, eluting with 
EtOAc-hexane (1:1), gave selenide 224 (0.37 g, 8 6 %) as a white solid, m.p. 98- 
99 °C; Rf 0.50 (1:1 EtOAc-hexane); vmax(KBr) 3374 (N-H), 1626 (amide I), 
1600, 1576, 1539 (amide II), 1278 and 825 (para-disubstituted benzene) cm '1; 
§H (CDCI3) 8.52 (1 H, br s, OH), 7.36 (2 H, AA'BB', 8 .6 , 3-H), 6.77 (2 H, 
AA'BB', 3J= 8 .6 , 2-H), 6.28 (1 H, br m, NH), 3.44 (2 H, m, 6 -H), 2.87 (2 H, t, 3J= 
6.5, 5-H) and 1.48 (9 H, s, 9-H); 6C (C D C I3 )  179.5 (C-7), 157.1 (C-1 ), 136.1 (C-
3), 116.7 (C- 2  and C-4), 39.3 (C-6 ), 38.7 (C-8 ), 28.0 (C-5) and 27.4 (C-9); m/z 
(Cl) 302 [(Mhf)+, 45], 227 (9), 164 (12), 147 (96) and 130 (100%); [Found: 
(.MH)+, 302.0656; C, 52.09; H, 6.38; N, 4.74%. C13H19N 02Se requires MH, 
302.0659; C, 52.00; H, 6.38; N, 4.66%].
A/-2-Hydroxyethyl-/V-(4-hydroxyphenyl)ethanimamide hydrochloride. (Two 
isomers of 227 - 230).
To a solution of 4-hydroxyaniline hydrochloride 225 (1.90 g, 13.1 mmol) in EtOH 
(50 cm3) was added 2-methyl-2-oxazoline (1.11 g, 13.0 mmol) before the 
mixture was stirred for 14 h at r.t.. The product (1.67 g, 55%) was then filtered 
from the product mixtures as white crystals, m.p. 155-156 °C; vmax(KBr) 1646 
(C=N), 1518, 1269, 1 2 2 2 , 1060 and 844 (para-disubstituted benzene) cm '1; 8 h 
(D20 ) 6.93 (4 H, m, 3-H), 6.70 (4 H, m, 2-H), 3.63 (2 H, t, 8 -H), 3.42 (2 H, t, 8 - 
H), 3.32 (2 H, t, 7-H), 3.24 (2 H, t, 7-H), 2.20 (3 H, s, 6 -H) and 1.84 (3 H, s, 8 - 
H); 5C (D20) 166.4 (C-5), 165.9 (C-5), 157.1 (C-3), 156.7 (C-3), 129.1 (C-1),
128.7 (C-1), 128.1 (C-4), 125.8 (C-4), 117.7 (C-2 ), 117.0 (C-2 ), 60.6 (C-8 ), 59.5 
(C-8 ), 46.5 (C-7), 45.4 (C-7), 18.4 (C-6 ) and 17.8 (C-6 ); m/z  194 [M+ (free 
base), 10], 134 (9), 122 (28), 109 (100) and 80 (42%); [Found: M+ (free base), 
194.1059. CioH15N20 2CI requires M (free base), 194.1055].
6
Mixture of two of the four isomers
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4-[(ferf-Butyldimethylsilyl)oxy]aniline (233)
3
\  /
The procedure of Swenton et a / .199 was employed on a 20 mmol scale to give 
the crude product as a brown oil. Purification by flash chromatography on silica 
gel, eluting with hexane-ethyl acetate (3:1) afforded the title compound 223 in 
8 8 % yield as a yellow oil. The IR, MS and 1H NMR spectral data were in good 
agreement with those reported in the literature. 199
New data: 6 C (CDCI3) 148.1 (C-7), 140.3 (C-4), 1 2 0 . 6  (C-5), 116.3 (C-6 ), 25.7 
(C-1 ), 16.1 (C-2 ) and -4.5 (C-3).
A/-[2-[[4-(ferf-Butyldimethylsilyl)oxyphenyl]amino]ethyl]acetamide (234)
3
\  /
H
To a solution of 4-[(fe/?-butyldimethylsilyl)oxy]aniline 233 (4.00 g, 17.9 mmol 
and A/-(2-chloroethyl)ethanamide (2.18 g, 1.81 cm3, 17.9 mmol) in acetonitrile 
(15 cm3) was added sodium carbonate (3.78 g, 35.8 mmol). The mixture was 
stirred under N2 at reflux for 1 0  h to give a brown mixture which was filtered, 
concentrated in vacuo and flash chromatographed on silica gel using EtOAc 
then EtOAc-MeOH (9:1) as eluent to furnish amine 234 (2.25 g, 41%) as a 
cream solid, m.p. 62-63 °C; Rf 0.34 (EtOAc); v max(KBr) 3323 (N-H), 1626 
(amide I), 1521 (amide II), 1255, 920 and 841 (para-disubstituted benzene) crrr
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1; 5H (CDCI3) 6.70 (2 H, AA'BB', 3J= 8 .8 , 5-H), 6.57 (2 H, AA'BB', 3J= 8 .8 , 6 -H), 
6.13 (1 H, br s, amide NH), 3.47 (3 H, m, amine N-H and 9-H), 3.22 (2 H, m, 8 - 
H), 1.98 (3 H, s, 11-H), 0.97 (9 H, s, 1-H) and 0.15 (6  H, s, 3-H); 6C (CDCI3) 
170.9 (C-10), 148.2 (C-7), 141.6 (C-4), 1 2 0 . 8  (C-5), 114.5 (C-6 ), 45.1 (C-9),
39.1 (C-8 ), 25.7 (C-1 ), 23.2 (C-1 1 ), 16.1 (C-2 ) and -4.5 (C-3); m /z  (Cl) 309 
[{Mhf)+, 100], 241 (7), 224 (3), 148 (7) and 141 (6 %).
A/-[2-[(4-Hydroxyphenyl)amino]ethyl]acetamide hydrochloride (198)
OH
N
H
To a solution of conc. hydrochloric acid (1.0 g) in EtOH (30 cm3) was added 
amine 234 (0.900 g, 2.91 mmol) before the mixture was stirred for 14 h at r.t.. 
The resulting pale brown solution was evaporated to dryness in vacuo to give a 
brown solid which was recrystallised to afford the title compound 198 (0.520 g, 
77%) as white needles, m.p. 197-198 °C (from EtOAc-MeOH); vmax(KBr) 3248 
(N-H), 1646 (amide I), 1629, 1571, 1535 (amide II), 1516 and 842 (para - 
disubstituted benzene) cm '1; 5h (D20 ) 7.11 (2 H, AA'BB', 3J= 9.0, 3-H), 6.75 (2 
H, AA'BB', 3J= 9.0, 2-H), 3.31 (4 H, m, 5-H and 6 -H) and 1.74 (3 H, s, 8 -H); 6C 
(D20) 175.5 (C-7), 157.5 (C-1), 127.2 (C-4), 124.8 (C-3), 117.6 (C-2 ), 51.3 (C-
5), 36.3 (C-6 ) and 22.7 (C-8 ); m/z 194 [M+(free base), 20], 135 (19), 1 2 2  (100), 
94 (1 2 ) and 65 (5%); [Found: M+{free base), 194.1056; C, 51.68; H, 6.78; N,
11.94%. C 1oH15N20 2CI requires M (free base), 194.1055; C, 52.06; H, 6.55; N, 
12.14%).
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